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ABSTRACT
In the United States, at least 50% of breastfeeding mothers are vitamin D
deficient, increasing risk for vitamin D deficiency in exclusively breastfed infants. A gap
in knowledge exists regarding best practices in maternal vitamin D supplementation
during pregnancy and lactation that will yield adequate infant vitamin D levels. The
objective of this study was to identify the combined effect of maternal prenatal and
postnatal vitamin D supplementation on vitamin D transfer to exclusively breastfed
infants. Additionally, due to the immune modulating effects of vitamin D, maternal proand anti-inflammatory cytokines were measured across pregnancy and the postpartum. A
double-blind, randomized controlled trial design was used. A total of 16 pregnant
women were enrolled in the study at 24-28 weeks gestation. The control group (N= 6)
received a prenatal vitamin containing vitamin D 400 IU daily plus a placebo void of
vitamin D. The experimental group (N=7) received the same prenatal vitamin plus a
capsule containing 3400 IU vitamin D, for a total of 3800 IU daily. Participants
continued their assigned supplements through 4-6 weeks of lactation. Pertinent
pregnancy, delivery, and postnatal health data were collected on maternal and infant
participants. Serum levels of 25-hydroxyvitamin D were measured in maternal
participants at enrollment and in both maternal and infant participants at delivery and
after 4-6 weeks of lactation. Maternal plasma TNF-alpha, IL-6, and IL-10 were
measured at enrollment, delivery and 4-6 weeks of lactation. There was a significant
xii

effect of maternal vitamin D supplementation on maternal 25-hydroxyvitamin D at
delivery (p=0.044) and at 4-6 weeks of lactation (p=0.002). A significant difference in
the infant participant groups at delivery was also found (p=0.017), however this was not
significant at 4-6 weeks of lactation (p=0.256). Controlling for maternal baseline using
repeated measures techniques, the overall effect of maternal vitamin D supplementation
on infant 25-hydroxyvitamin D approached significance (p=0.065). There was no impact
of vitamin D supplementation on maternal cytokine production. This study adds novel
information regarding the impact of continuous prenatal to postpartum maternal vitamin
D supplementation on the vitamin D status of exclusively breastfed infants.
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CHAPTER I
INTRODUCTION
Background
The rapidly increasing incidence of vitamin D deficiency is now considered by
most experts to be a global epidemic (Holick, 2005; Lappe, 2011; Saadi et al., 2009).
Simultaneously, vitamin D deficiency is being linked with more diseases including
cardiovascular disease (Barnard & Colon-Emeric, 2010; Feneis & Arora, 2010), diabetes
(Eliades & Pittas, 2009), autoimmune disorders (Arnson & Amital, 2011; Kamen et al.,
2006), as well as the general functioning of the innate immune system (Akbar &
Zacharek, 2011; Di Rosa et al., 2012; Lagishetty, Liu, & Hewison, 2011; Thota, Farmer,
Garfield, Menon, & Al-Hendy, 2013). Certain pregnancy specific diseases are connected
with vitamin D deficiency as well, including gestational diabetes (Baker, Haeri,
Camargo, Stuebe, & Boggess, 2012; Clifton-Bligh, McElduff, & McElduff, 2008;
Maghbooli, Hossein-Nezhad, Karimi, Shafaei, & Larijani, 2008; Senti, Thiele, &
Anderson, 2012; Soheilykhah, Mojibian, Rashidi, Rahimi-Saghand, & Jafari, 2010;
Zhang et al., 2008) and preeclampsia (Baker, Haeri, Camargo, Espinola, & Stuebe, 2010;
Bodnar, Catov et al., 2007; Bodnar & Simhan, 2010; Haugen et al., 2009; Robinson,
Alanis, Wagner, Hollis, & Johnson, 2010). Manufactured in human skin when exposed
to adequate sunlight, vitamin D is responsible for calcium homeostasis, plays a role in the
functioning of almost all body tissues, and has receptors on at least 200 genes
1

(Mulligan, Felton, Riek, & Bernal-Mizrachi, 2010). When blood levels of vitamin D are
being tested, it is the circulating 25-hydroxyvitamin D (25[OH]D) form that is being
analyzed and this is what determines a person’s vitamin D status as sufficient,
insufficient, or deficient (Hollis, 2005; Hollis, 2008; Hollis, 2012). Although everyone is
susceptible to vitamin D deficiency if they lack sunlight on the skin, pregnant women are
at increased risk due to the calcium and vitamin D demands of the fetus. Additionally,
the exclusively breastfed infant continues to be at risk of vitamin D deficiency similar to
their mothers, compounding the risk of disease in these infants (Balasubramanian, 2011;
Salama & El-Sakka, 2010; Thandrayen & Pettifor, 2012).
Vitamin D deficiency is not a new or novel health problem in the United States.
During the Industrial Revolution in the 18th and 19th centuries, there was a rapid rise in
rickets cases. Marked by bone deformities, particularly in the legs, rickets is caused by
vitamin D deficiency (Wagner, Taylor, & Hollis, 2008). As adults and children spent
more time indoors, out of natural sunlight, average vitamin D levels fell, leading to this
epidemic of rickets (Wagner et al., 2008). A national campaign was initiated and foods
such as milk and juice were fortified with vitamin D starting in 1933 (Committee on Use
of Dietary Reference Intakes in Nutrition Labeling, 2004). This vitamin D
supplementation all but rid the country of rickets (Thandrayen & Pettifor, 2012).
However, starting in the 1970s and then more so in the 1980s, there was another spike in
rickets in the U.S. (Cosgrove & Dietrich, 1985; Harrison, 1975). Those hardest hit by the
rickets resurgence were African Americans and immigrants with darkly pigmented skin
(Thandrayen & Pettifor, 2012). It is proposed that the cause of the increased prevalence
of vitamin D deficiency is multifactorial, but two major health campaigns played a large
2

role; first, a successful campaign against skin cancer leading to minimal sun exposure and
consistent sunscreen use, and second, a successful campaign encouraging exclusive
breastfeeding (Bodnar, Simhan et al., 2007; Wagner et al., 2008). Exclusive
breastfeeding led to increased rates of vitamin D deficiency in infants because lactating
mothers were vitamin D deficient and unable to pass significant amounts of vitamin D to
their infants via breast milk (Hollis & Wagner, 2011; Wagner et al., 2008). Although
both of these campaigns were important for human health and their success should be
encouraged, negative implications regarding vitamin D status are now being discovered.
Maternal transfer of both calcium and vitamin D are critical to the health and
development of the fetus and infant (Kaludjerovic & Vieth, 2010; Mulligan et al., 2010).
The fetal immune system and metabolic function begin to develop in utero and then
continue refinement during infancy and childhood (Walker et al., 2011; Weiss &
Litonjua, 2011). It is accepted that maternal nutritional status can influence the most
fundamental early mechanisms of the fetal immune and metabolic functions. This occurs
by means of fetal programming that carries over in to childhood and adult life, negatively
impacting health status (Kaludjerovic & Vieth, 2010; Thandrayen & Pettifor, 2012;
Weiss & Litonjua, 2011). The fetus may be affected and if the infant is then exclusively
breastfed, the lack of maternal vitamin D stores leads to poor vitamin D content in breast
milk, compounding infant vitamin D deficiency (Hollis & Wagner, 2011; Mulligan et al.,
2010).
Vitamin D deficiency in childbearing women leads to deficiency in their infants,
exacerbated among infants who exclusively breastfeed (Hollis, 2007). Breast milk is the
ideal form of infant feeding, containing a full complement of nutrients perfectly suited to
3

meet infants’ needs (Riordan & Countryman, 1980). The exception is vitamin D, which
due to inadequate levels in the mother, is generally not transferred in sufficient amounts
to meet infant needs (Basile, Taylor, Wagner, Horst, & Hollis, 2006; Hollis & Wagner,
2004a; Merewood et al., 2010; Saadi et al., 2009; Wagner, Hulsey, Fanning, Ebeling, &
Hollis, 2006). Prevalence of vitamin D deficiency in childbearing women and newborns
ranges from 5-100% and 9.7-90%. (Bodnar et al., 2007; Collins-Fulea, Klima, &
Wegienka, 2012; Dror, King, Durand, & Allen, 2011a; Holmes, Barnes, Alexander,
McFaul, & Wallace, 2009; Merewood et al., 2010; Thomson, Morley, Grover, &
Zacharin, 2004). Variability exists based on definition of vitamin D deficiency, race and
ethnicity, climate, and level of vitamin D supplementation.
Infantile rickets is the primary outcome of vitamin D deficiency, however there is
a growing body of knowledge that links maternal and early infancy hypovitaminosis D to
many other diseases. Currently, research in regards to the association of vitamin D
deficiency and disease covers a wide array of topics including breast cancer, colon
cancer, atherosclerosis, diabetes I and II, obesity, depression, schizophrenia,
preeclampsia, innate immune response, and multiple autoimmune disorders (Akbar &
Zacharek, 2011; Arnson & Amital, 2011; T. Barker et al., 2013; Di Rosa et al., 2012;
Eliades & Pittas, 2009; Kamen et al., 2006; J. J. McGrath, Burne, Feron, Mackay-Sim, &
Eyles, 2010; Munger, Levin, Hollis, Howard, & Ascherio, 2006). Because of the role
vitamin D may play in the prevention of so many diseases, it is critical that infants
receive adequate amounts. The extent to which vitamin D transfers through breast milk
is still unclear, although emerging research indicates vitamin D sufficient women can
pass adequate doses of vitamin D to their infants without the need for direct infant
4

supplementation (Basile et al., 2006; Hollis & Wagner, 2004b; Saadi et al., 2009; Wagner
et al., 2006). Recommendations designed to improve adequate maternal vitamin D status
will promote vitamin D transfer to the developing fetus in utero and to the infant during
lactation, thus potentially improving the health of women and their infants. Adult onset
vitamin D deficiency related disorders and diseases could be substantially reduced
through optimal infant vitamin D status during the vulnerable periods of fetal and infant
development (Brannon, 2012; Christesen, Elvander, Lamont, & Jorgensen, 2012;
Pludowski et al., 2013).
Problem Statement
There is currently a lack of evidence to identify best practice in maternal dosing
of vitamin D supplementation during pregnancy and lactation. Epidemiologic data
supports the notion that a majority of pregnant women, their fetuses, and newborns are
vitamin D deficient, yet health care practitioners are unable to offer evidence-based
advice regarding supplementation. There is a significant need to address the gap in
knowledge regarding the specific needs for vitamin D supplementation in pregnant and
lactating women that would promote vitamin D transfer to meet the needs of the
exclusively breastfed infant.
Purpose Statement
The objective of this study was to identify the combined effect of maternal
prenatal and postnatal vitamin D supplementation on vitamin D transfer to infants during
exclusive breastfeeding. A randomized controlled trial was designed to generate
evidence that will add to what is known regarding the influence of maternal vitamin D
supplementation in late pregnancy and lactation on vitamin D transfer via breast milk.
5

By identifying the outcome of the optimal dosage and timing of maternal vitamin D
supplementation on infant vitamin D status, we have the potential to greatly improve
maternal health and establish lifelong benefits for babies starting before birth.
Therefore, this study was conducted to test the central hypothesis that maternal
supplementation with vitamin D during pregnancy and lactation will significantly
increase circulating vitamin D levels during lactation in mothers and their exclusively
breastfed infants. As vitamin D is a key regulator of immune response, a secondary
hypothesis that increased vitamin D levels in the mother would result in decreased proinflammatory cytokines and an increase in an anti-inflammatory cytokine was tested.
The rationale for this study is that establishment of conditions that support maternal
delivery of adequate vitamin D to infants, along with other essential nutrients through
breast milk, will reduce the need for infant vitamin D supplementation while optimizing
infant health. A growing body of evidence suggests that sufficient vitamin D may be
transferred to the infant through breast milk if the maternal vitamin D status is adequate
(Basile et al., 2006; Hollis & Wagner, 2004b; Saadi et al., 2009; Wagner et al., 2006),
however, the optimal timing and dosage of vitamin D supplementation during gestation
and lactation to achieve maternal vitamin D adequacy and breast milk transfer is
unknown. There is, therefore, a critical need to determine the dosage and timing of
maternal vitamin D supplementation necessary to achieve maternal vitamin D adequacy
and transfer via breast milk for vitamin D adequacy in infants.
Research Hypotheses
To achieve the objectives of this proposal, the following hypotheses were tested:
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Central Hypothesis: Maternal supplementation with vitamin D during pregnancy and
lactation will significantly increase circulating vitamin D levels during lactation in
mothers and their exclusively breastfed infants;
1. Women who receive supplemental vitamin D starting in the early third trimester
of pregnancy will have significantly higher 25[OH]D serum levels compared to
control participants by delivery;
2. Women who receive supplemental vitamin D starting in the early third trimester
of pregnancy and continue with this dosing during the early postpartum will
maintain significantly higher serum 25[OH]D levels than control participants
during lactation;
3. Infants born to women who receive supplemental vitamin D starting in the early
third trimester of pregnancy will have significantly higher 25[OH]D levels at birth
compared to control infants;
4. Infants who exclusively breastfeed from a mother receiving supplemental vitamin
D will have significantly higher 25[OH]D levels than infants exclusively
breastfeeding in the control group at 4-6 weeks of age.
Due to immune and inflammatory modulating effects of vitamin D, the following
secondary hypotheses were tested:
1. Women with higher vitamin D levels will have decreased levels of proinflammatory cytokines (TNF-α and IL-6);
2. Women with higher vitamin D levels will have increased levels of an antiinflammatory cytokine (IL-10).

7

The findings from this study are expected to add to current evidence regarding the
recommended dosage and duration of vitamin D supplementation during pregnancy and
lactation necessary to achieve adequate infant vitamin D status. This study is innovative
in its approach to initiate maternal vitamin D supplementation during pregnancy and
continue in to early lactation, which has not been previously studied.
Theoretical Framework
This study was conceptualized using the Developmental Origins of Health and
Disease hypothesis (DOHaD), also known as the Barker Hypothesis (Cota & Allen,
2010). Dr. David Barker is currently a professor of clinical epidemiology at the
University of Southampton, UK, and professor in the Department of Cardiovascular
Medicine at Oregon Health and Science University. Dr. Barker was one of the first
epidemiologists to widely disseminate research underscoring the importance of the
maternal nutritional environment on infant health and development of later adult disease
(D. J. Barker, 1994; D. J. Barker, 1997). The focus of his work has been on the
development of disease in the adult whose mother experienced famine or malnutrition
during pregnancy (D. J. Barker, 1995). In his early investigation of maternal undernutrition in pregnancy and long-term health risks in offspring, he explored the connection
between low birth weight and development of heart disease (D. J. Barker & Fall, 1993).
In his 1997 work, Dr. Barker hypothesized that many adult diseases are set in motion or
even programmed during fetal life (D. J. Barker, 1997).
The DOHaD hypothesis is founded on statements of causal relationships, namely
that maternal nutriture has life-long effects on the infant. As a predictive theory, DOHaD
researchers seek to test these causal relationships until agreement is reached that a true
8

relationship exists and predictions of disease risk can be made (McEwen & Wills, 2010).
However, DOHaD researchers including Dr. Barker warn against oversimplification of
findings and acknowledge that environmental influences beyond in utero exposures affect
disease development (D. J. Barker, 1997). Gleaned from reading Dr. Barker’s work
along with other DOHaD researchers, the following theoretical statements influenced this
project:


A woman’s nutritional status prior to and during pregnancy affects the
lifelong health of her offspring;



The intrauterine environment, including such variables as vitamin transfer,
hormonal milieu, and physiologic mechanisms, has health impacts on the
fetus that can last a lifetime;



The fetus responds to under-nutrition, or vitamin deficiency, with
permanent physiologic and metabolic adaptations;



Poverty, poor living conditions, social disparities based on race and
ethnicity, and continued nutritional deficits experienced during childhood
increase the risk of adult onset disease later in life.

The underlying processes of DOHaD are two-fold: developmental plasticity and
fetal programming. Developmental plasticity refers to the ability of the developing
embryo or fetus to change phenotype (appearance) without change in genotype (genetic
sequence) (Cota & Allen, 2010; Kaludjerovic & Vieth, 2010). There may be critical
periods during embryogenesis and fetal development where particular organs, tissues, or
mechanisms are more susceptible to outside influences and demonstrate physiologic
9

change as a means of adaptation (Cota & Allen, 2010). An example of physiologic
adaptation occurring in utero is the increased growth of the placenta seen with undernutrition in the fetus (D. J. Barker, 1997). When exposed to a lack of calories, the fetus
limits cell division in the body and increases cell division in the placenta, theoretically to
increase surface area from which to draw nutrition. This ability to change the course of
development without changing the genome is an example of developmental plasticity.
Fetal programming refers to the sometimes permanent nature of these phenotypic
changes (Cota & Allen, 2010). When exposed to under-nutrition followed by an enlarged
placenta the fetus develops hypertension, which appears to persist through adult life (D. J.
Barker, 1997). The body is programmed based on the available nutrition, hormones, and
physiologic mechanisms found in utero (Kaludjerovic & Vieth, 2010). Barker (1997)
states that permanent changes caused by under-nutrition during fetal development
include, “change in the distribution of cell types, hormonal feedback, metabolic activity,
and organ structure” (p. 807). Several researchers exploring fetal development have
stated that vitamin D deficiency may be the key feature of disease programming
(Kaludjerovic & Vieth, 2010; J. McGrath, 2001; Thandrayen & Pettifor, 2012; Weiss &
Litonjua, 2011).
A plausible explanation for the developmental plasticity and fetal programming
described by the DOHaD hypothesis is the theory of epigenetics. Epigenetics is the study
of inherited changes in phenotype or gene expression caused by mechanisms other than
changes in the underlying DNA sequence (Baccarelli & Bollati, 2009; Gravina & Vijg,
2010). The changes that do occur are in DNA strand structure through processes of
histone modification and DNA methylation (Baccarelli & Bollati, 2009; Gravina & Vijg,
10

2010). Epigenetic expression can be altered by environmental toxins, heavy metals, and
also nutrients and hormones found naturally occurring in the body (Baccarelli & Bollati,
2009). The period of fetal development is considered a critical time for epigenetic
expression because of the rapid cell differentiation and proliferation as well as
development of metabolic pathways. Epigenetic changes in gene expression in the fetus
and infant may be set in motion by low vitamin D levels in utero and in breast milk,
leading to future disease (Kaludjerovic & Vieth, 2010; J. McGrath, 2001; Thandrayen &
Pettifor, 2012; Weiss & Litonjua, 2011). It is clear from current research that the
placenta is altered by maternal vitamin D levels, increasing the risk for preeclampsia in
the mother and therefore hypertension in her offspring (Baker et al., 2010; Haugen et al.,
2009; Robinson et al., 2010). Concurrently, there is increasing evidence that
hypovitaminosis D in utero and in early infancy can increase risk for asthma and
respiratory infections (Camargo et al., 2011), juvenile arthritis (Ellis, Munro, &
Ponsonby, 2010), allergic rhinitis (Erkkola et al., 2009; Erkkola, Nwaru, & Viljakainen,
2011), type 1 diabetes (Cooper et al., 2011; Marjamaki et al., 2010), eczema (Miyake,
Sasaki, Tanaka, & Hirota, 2010), and poor innate immune response (Erkkola et al., 2011;
Walker et al., 2011). Continued research in this field is necessary in order to determine
threshold vitamin D requirements for the pregnant woman, the lactating woman, and her
infant. By exposing the unborn fetus to adequate vitamin D through maternal
supplementation, there is the potential to reduce future adult diseases.
Although the broad concepts of the DOHaD and epigenetics cover large areas of
scientific research, particularly as it relates to maternal nutrition, this study took a
narrower focus of maternal/newborn vitamin D supplementation. Researchers studying
11

the effects of vitamin D deficiency in pregnancy, the fetus, and the infant are finding that
the current recommendation of 600 IU/d vitamin D for women is inadequate to reach or
maintain adequate serum vitamin D levels (Hollis, 2009; Hollis & Wagner, 2011; Hollis,
Johnson, Hulsey, Ebeling, & Wagner, 2011). This knowledge combined with the
emerging data that vitamin D deficiency is linked to multiple disorders and diseases
requires researchers to determine adequate supplementation doses. This study adds to
this knowledge base regarding dosage and timing of vitamin D supplementation for
pregnant and lactating women and the influence on vitamin D status in exclusively
breastfed newborns.
Significance of the Study
There are a growing number of randomized controlled trials investigating
appropriate dosing of vitamin D during pregnancy and lactation to achieve and maintain
maternal and infant 25[OH]D levels in the sufficient range (Basile et al., 2006; Hollis &
Wagner, 2004b; Hollis et al., 2011; Merewood et al., 2010; Saadi et al., 2009; Thiele,
Senti, & Anderson, 2013; Wagner et al., 2006). Evidence is mounting that vitamin D
deficiency plays a significant role in fetal programming of later disease including
cancers, cardiovascular disease, susceptibility to infection, and metabolic disorders such
as diabetes. Providing pregnant and lactating women with appropriate vitamin D will
benefit both mother and infant. This study adds information regarding vitamin D dosing
during pregnancy and lactation that results in adequate maternal 25[OH]D levels and
adequate transfer of vitamin D to exclusively breastfed infants.

12

Assumptions


Women will be willing to join the study as participants.



Acquired sample size will be adequate.



Participants will take their assigned supplements on a daily basis.



Participants will fill out their questionnaires and tools accurately.



Adequate numbers of participants will continue exclusively breastfeeding through
4-6 weeks postpartum.



Supplementation with higher dose vitamin D will significantly increase 25[OH]D
levels in maternal participants.



Supplementation with higher dose vitamin D will significantly increase 25[OH]D
levels in infant participants born to and breastfeeding from maternal participants
receiving the supplementation.
Summary of Key Points



Vitamin D is important in multiple body functions and overall health.



A majority of pregnant women and newborns are vitamin D deficient.



Vitamin D supplementation may be an easy intervention for improved health.



A gap in the literature exists in regards to appropriate dosing of vitamin D
supplementation for pregnant and lactating women.



This study adds new information regarding vitamin D supplementation initiated in
pregnancy and continued through early postpartum and its impact on newborn
25[OH]D levels in the exclusively breastfed infant.
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This study investigated the impact of supplemental vitamin D on in vivo cytokine
production in pregnant women.
Operational Definitions
In order to lend clarity to the results of this study, the following definitions are

used throughout:


IU: International Unit



Supplemental Vitamin D: vitamin D3, cholecalciferol



25-hydroxyvitamin D (25[OH]D, calcidiol): serum value used for
evaluation of vitamin D status



1-25-dihydroxyvitamin D (1,25[OH]2D, calcitriol): serum value of
biologically active vitamin D



Data Collection Time Points
o Enrollment: baseline data collected on the maternal participant
including FFQ data, and blood for analysis of 25[OH]D and
cytokines
o Delivery: blood collected within 24 hours of birth on maternal
participant for evaluation of 25[OH]D and cytokines and on the
infant for evaluation of 25[OH]D
o Lactation: follow-up data collected 4-6 weeks after birth on the
maternal participant including FFQ and blood for 25[OH]D and
cytokines, and blood collected on the infant for evaluation of
25[OH]D
14



A priori vitamin D status definitions
o Sufficiency: 25[OH]D serum level > 32 ng/mL
o Insufficiency: 25[OH]D serum level 20-32 ng/mL
o Deficiency: 25[OH]D serum level < 20 ng/mL
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CHAPTER II
LITERATURE REVIEW
Introduction
Discrepancies regarding the 25[OH]D serum status that provides maximal health
benefits as well as appropriate supplementation doses for all age groups remain and are in
fact currently highlighted due to the recent Institute of Medicine (IOM) vitamin D
supplementation recommendations (Institute of Medicine (US) Committee to Review
Dietary Reference Intakes for Vitamin D and Calcium, 2011). It is the purpose of this
study to add to the body of scientific and nursing knowledge regarding vitamin D transfer
from mother to infant during exclusive breastfeeding when the mother is supplemented
with vitamin D. There is no more critical time than during pregnancy, lactation and
fetal/neonatal development to insure appropriate nutritional status.
A review of the extant literature informs the background and methods for this
study. Topics to be reviewed include: history of vitamin D deficiency, vitamin D status
definitions and supplementation recommendations, current estimates of vitamin D
deficiency prevalence, the functional role of vitamin D in the human body, impact of
vitamin D on health outcomes, maternal health effects of vitamin D deficiency, infant
health effects of maternal vitamin D deficiency during pregnancy and lactation, and
evidence of vitamin D transfer through breast milk.
16

History of Vitamin D Deficiency
With the recent emphasis on vitamin D in the scientific literature, health care
providers are left to wonder how one vitamin has become so important to researchers and
how it could possibly have so many significant effects in the body. In fact, vitamin D is a
steroid hormone precursor formed in the skin when the skin is exposed to ultraviolet B
(UVB) wavelengths (Holick, 2011). The compound now recognized as vitamin D was
historically noted to exist naturally in cod liver oil and to be responsible for preventing
and curing rickets (Wagner et al., 2008). Because the nature of the compound was
unknown, it was thought to be a vitamin and was thusly named. Cod liver oil is one of
the few naturally occurring dietary sources of vitamin D. Other natural sources include
fatty fish, dried mushrooms, and egg (Holick, 2011). These dietary sources contain very
small amounts of vitamin D when compared to the physiologic amounts produced in the
skin when exposed to UVB (Haddad, Matsuoka, Hollis, Hu, & Wortsman, 1993;
Matsuoka, Wortsman, Haddad, & Hollis, 1989). It is believed that early humans evolved
in order to respond to the amount of sunlight present in their environment (Yuen &
Jablonski, 2010). For instance, humans living in much of Africa would be exposed to
tremendous amounts of UVB when their skin was exposed to sunlight, conditions which
increased heavier pigmentation in the skin for protection. As humans moved away from
Africa and into areas further from the equator, it would be beneficial to lose skin pigment
in order to convert adequate vitamin D in the skin in lower light conditions (Yuen &
Jablonski, 2010). Therefore, if exposed to the same sunlight intensity and time, a white
person would create more vitamin D in their skin compared to a darker skinned
individual. This is exemplified in the literature by the consistently higher prevalence of
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vitamin D deficiency amongst African Americans compared to individuals from other
ethnic groups who typically have lighter pigmentation (Ginde, Liu, & Camargo, 2009).
Because humans evolved to spend much of their time outdoors, the transition
from agrarian societies to industrialized societies played a significant role in the
prevalence of vitamin D deficiency. First identified in the 1600s, rickets became a
prominent childhood disease during the industrial revolution of the 18th and 19th centuries
(Holick, 2006; Rajakumar, 2003). Because of the shadowing effect of buildings in the
cities, long days spent working inside factories, and pollution blocking UVB radiation,
children were not able to maintain adequate vitamin D levels to prevent rickets (Holick,
2006). By 1921 it was estimated that approximately 75% of the children in New York
City had rickets, already identified as a nutritional disorder (Centers for Disease Control
and Prevention (CDC), 1999). As a matter of national health, scientists worked to
identify the nutritional deficit causing rickets and found that both sunlight and cod liver
oil could cure rickets (McCollum, Simmonds, Becket, & Shipley, 1922). Once clearly
established as the compound in cod liver oil that was affecting bone health, vitamin D
fortification was enacted and foods including milk and juice were fortified in order to
eradicate rickets on a national level. This campaign was very successful and rickets was
quickly viewed as a disease of the past (Rajakumar, 2003).
Around the time that rickets was being effectively prevented on a national scale,
fears of vitamin D toxicity began to surface (Wagner et al., 2008). These fears were
based on cases in which young children were given hundreds of thousands or millions of
international units (IUs) of vitamin D and in a few cases, these children died (Wagner et
al., 2008). Several decades later, cases of children with hypercalcemia and elfin facies
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were thought to be victims of vitamin D toxicity and this was additionally linked to risk
of developing supravalvular aortic stenosis (SAS) (Wagner et al., 2008). In fact, in the
1960s it was believed that maternal supplementation with vitamin D during pregnancy
was the most likely cause of SAS and the concomitant hypercalcemia and elfin facies
(Wagner et al., 2008). This certainly put physicians and patients on alert to avoid
excessive vitamin D during pregnancy and vitamin D gained a reputation for causing
irreversible harm. It was not until the early 1990s that it was known that an underlying
genetic disorder, Williams’ syndrome, was causing the SAS and faulty vitamin D
metabolism, which led to the hypercalcemia and toxicity (Wagner et al., 2008). In the
1980s and 1990s, there was a concurrent emphasis on sunscreen use, which led to further
vitamin D deficiency as sunscreen blocks UVB rays from the skin, therefore limiting or
completely inhibiting cutaneous vitamin D production (Thandrayen & Pettifor, 2012).
All of these factors combined to move us toward the 21st century with an increasing
prevalence of vitamin D deficiency.
Vitamin D Status Definitions and Supplementation Recommendations
Because vitamin D deficiency has such high prevalence, it was important for
scientists to create efficient means for testing human blood levels of vitamin D. When
testing an individual’s functional vitamin D level the blood analysis used is 25hydroxyvitamin D (25[OH]D). Also known as calcidiol, 25[OH]D is the major
circulatory form of vitamin D found in the blood. There is inconsistency in the units of
measure used to describe 25[OH]D levels and in the units of measure used for vitamin D
dosing (Table 1).
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Table 1. Commonly used units and conversions for 25[OH]D levels and vitamin D
supplementation doses.
Unit of 25[OH]D
Abbreviation
Conversion
Example
Measure
factor
Nanograms per
ng/mL
milliliter
1 ng/mL =
32 ng/mL =
2.496 nmol/L
80 nmol/L
Nanomoles per
nmol/L
liter
Dose measures
International Units
IU
1 IU = 0.025 µg
40 IU = 1 µg
Microgram
µg

Opinions as to what level of serum 25[OH]D is sufficient vary widely as well
(Table 2).
Table 2. 25[OH]D level considered adequate by recommending agency.
American
American College of
Institute of
Endocrine
Academy of
Obstetricians and
Organization
Medicine1
Society2
Pediatrics3
Gynecologists4
20 ng/mL and 32
Sufficient
20 ng/mL
ng/mL noted as
16-20 ng/mL
30 ng/mL
25[OH]D
Infants and
widely accepted in
All ages
All ages
Level
children
non-pregnant
individuals
1 – Institute of Medicine (US) Committee to review dietary reference intakes for
vitamin D and calcium (2011). The National Academies Press.
2 – Holick, et al. (2011). Evaluation, treatment, and prevention of vitamin D
deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical
Endocrinology and Metabolism, 96(7), 1911-1930.
3 – Wagner & Greer (2008). Prevention of rickets and vitamin D deficiency in
infants, children, and adolescents. Pediatrics, 122(5), 1142-1152.
4 - ACOG Committee on Obstetric Practice. (2011). ACOG committee opinion
no. 495: Vitamin D: Screening and supplementation during pregnancy. Obstetrics and
Gynecology, 118(1), 197-198. doi:10.1097/AOG.0b013e318227f06b.

In addition there is inconsistency regarding agency recommendations for daily
vitamin D intake (Table 3). It remains unclear if the same 25[OH]D level should be used
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to define adequacy across the lifespan, in different geographic locations across the globe,
between genders, ages and ethnicities.
Table 3. Recommendations for daily vitamin D intake by recommending agency.
Daily Intake:
Daily Intake:
Daily Intake: Adult
Organization
Infants to one
Pregnancy/
(age 1-70 years)
year
Lactation
Institute of
400 IU
600 IU
600 IU
Medicine1
At least 400 IU,
At least 600 IU,
At least 600 IU, may
2
Endocrine Society
may need 1000
may need 1500need 1500-2000 IU
IU
2000 IU
American Academy
400 IU
N/A
N/A
of Pediatrics3
1000-2000 IU
American College of
when deficiency
Obstetricians and
N/A
N/A
during pregnancy
Gynecologists4
is noted
1 – Institute of Medicine (US) Committee to review dietary reference intakes for
vitamin D and calcium (2011). The National Academies Press.
2 – Holick, et al. (2011). Evaluation, treatment, and prevention of vitamin D
deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical
Endocrinology and Metabolism, 96(7), 1911-1930.
3 – Wagner & Greer (2008). Prevention of rickets and vitamin D deficiency in
infants, children, and adolescents. Pediatrics, 122(5), 1142-1152.
4 - ACOG Committee on Obstetric Practice. (2011). ACOG committee opinion
no. 495: Vitamin D: Screening and supplementation during pregnancy. Obstetrics and
Gynecology, 118(1), 197-198. doi:10.1097/AOG.0b013e318227f06b

Researchers use several physiologic markers to explicate their support of specific
levels set for vitamin D sufficiency. Vitamin D plays an important role in mineral
homeostasis in the body, affecting parathyroid hormone (PTH) production in order to
stimulate release of calcium from the bone when serum calcium levels fall (Holick,
2006). Researchers argue that the serum 25[OH]D level that corresponds to maximal
suppression of PTH is a good benchmark for 25[OH]D sufficiency (Gloth, Tobin,
Sherman, & Hollis, 1991; Gloth, Gundberg, Hollis, Haddad, & Tobin, 1995; Lips et al.,
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1988; Vieth, Ladak, & Walfish, 2003). Several studies have investigated the 25[OH]D
level that corresponds to development of secondary hyperparathyroidism and conclude
that levels dropping below 15 to 20 ng/mL stimulate this response (Gloth et al., 1991;
Gloth et al., 1995; Lips et al., 1988). Vieth, Ladak, and Walfish (2003) demonstrated that
in older adults, PTH is maximally suppressed with 25[OH]D levels above 32 ng/mL and
therefore, this level has become widely used as a cutoff for sufficiency.
Another measure that can be used to determine appropriate levels for vitamin D
sufficiency is intestinal calcium absorption. Heaney, Dowell, Hale, and Bendich (2003)
found that there is a continuum of calcium absorption across the 25[OH]D range and that
individuals with levels ≤ 20 ng/mL absorbed less calcium through the intestine compared
to individuals with levels ≥ 32 ng/mL. A third marker that can be used to determine
25[OH]D levels that correspond to sufficiency is bone mineral density (BMD). In 2004,
Bischoff-Ferrari, Dietrich, Orav, and Dawson-Hughes found that in the adult population
25[OH]D levels have a positive correlation to BMD and that optimal BMD is found with
25[OH]D levels above 32 ng/mL. Vitamin D researcher, Dr. Bruce Hollis, reviewed the
research regarding PTH, calcium absorption, and BMD as biomarkers of 25[OH]D
sufficiency and concluded “nutritional vitamin D deficiency should be defined as <80
nmol (32 µg/L) circulating 25[OH]D…” (Hollis, 2005, p. 320). Another vitamin D
researcher, Dr. Michael Holick (2007) stated that clinicians should strive for 25[OH]D
levels of >30 ng/mL in children and adults in order to optimize physiologic processes.
After reviewing data on BMD, lower-extremity function, dental health, and risk of falls,
fractures, and colorectal cancer, Bischoff-Ferrari, Giovannucci, Willett, Dietrich, and
Dawson-Hughes (2006) found that, “for all endpoints, the most advantageous serum
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concentrations of 25[OH]D begin at 75 nmol/L (30 ng/mL), and the best are between 90
and 100 nmol/L (36-40 ng/mL)” (Bischoff-Ferrari, Giovannucci, Willett, Dietrich, &
Dawson-Hughes, 2006, p. 18). Audran and Briot (2010) noted that serum levels of
vitamin D greater than 75 nmol/L (30 ng/mL) are needed for bone health, but for
protection from other diseases even higher levels might be necessary. Cannell, Hollis,
Zasloff, and Heaney (2008) set their recommended serum level of 25[OH]D at > 40
ng/mL (100 nmol/mL) as this corresponds to levels seen in people exposed to moderate
amounts of UVB year round.
Similarly, recommendations for adequate intake or optimal supplementation of
vitamin D for infants, children and adults also vary (Table 1). The IOM provides
recommendations in terms of Adequate Intake (AI), which is used when a Recommended
Dietary Allowance (RDA) cannot be determined and is an approximation of the amount
assumed to be adequate for the population. The RDA is the dietary intake needed to meet
the needs of 97.5% of a particular group (Institute of Medicine (US) Committee to
Review Dietary Reference Intakes for Vitamin D and Calcium, 2011). The current RDA
from the Food and Nutrition Board (FNB) of the IOM is 600 IU per day for ages 1
through 70 years (Institute of Medicine (US) Committee to Review Dietary Reference
Intakes for Vitamin D and Calcium, 2011). The IOM report suggests a Tolerable Upper
Intake Level (TUIL) of 2,500 IU daily for ages 1-3; 3,000 IU daily for ages 4-9, and
4,000 IU daily for ages 9-70+. The revised recommendations do not include any
difference in RDA or TUIL during pregnancy or lactation separate from all other adult
populations (Institute of Medicine (US) Committee to Review Dietary Reference Intakes
for Vitamin D and Calcium, 2011). Interestingly, the FNB set an AI of 400 IU per day
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for infants up to 12 months, but they do not give an RDA. The TUIL for 0 to 6 months is
1,000 IU daily and for 6 to 12 months it is 1,500 IU daily. The recent report states that
vitamin D supplementation recommendations were set based on the desire to achieve
25[OH]D levels of 16 ng/mL and that this is “consistent with the intended nature of an
average requirement, in that it reflects the desired level for a population median – it meets
the needs of approximately half the population” (Institute of Medicine (US) Committee to
Review Dietary Reference Intakes for Vitamin D and Calcium, 2011, p. 8). The
American College of Obstetricians and Gynecologists (ACOG Committee on Obstetric
Practice, 2011) does not recommend routine screening for vitamin D deficiency during
pregnancy or lactation, but states that if found, it should be treated with 1000-2000 IU
vitamin D per day.
Although the recommendations for both intake and 25[OH]D levels have been set
higher than the previous IOM recommendations from 1997, they have still sparked
controversy. There is evidence that current RDAs, especially those outlined by the IOM,
are inadequate and will not provide optimal protective effects against disease (Grant,
2011b; Heaney & Holick, 2011; Hollis & Wagner, 2011). Weaver and Fleet (2004) cite
multiple reasons for the variation in recommendations including poor control over
fortification of foods, concluding that research regarding calcium absorption indicates a
need for vitamin D intake > 2000 IU/d. Matsuoka, Wortsman, Haddad, and Hollis (1999)
and Haddad, Matsuoka, Hollis, Hu, and Wortsman (1993) found that a white person
exposing their total body to sunlight in summer for 10 to 15 minutes will produce 10,000
to 20,000 IU of vitamin D cutaneously, indicating that these doses are physiologic and
would not cause harm. Cannell et al. (2008) found that obese, elderly, and dark-skinned
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individuals need to ingest 5000 IU per day to maintain an adequate serum level in the
absence of adequate sunlight. In 2005, Hollis stated that further research was needed but
that vitamin D intake exceeding 2000 IU/d was probably necessary to bring blood levels
up to sufficiency for the average adult. Bischoff-Ferrari et al. (2008) conclude that intake
of 1000 IU/d vitamin D is needed to bring at least 50% of the population up to
sufficiency levels.
Safety and Efficacy of Supplementation
Non-Pregnant Adult Populations
Earlier work synthesizing the evidence regarding safe upper limits of vitamin D
intake was completed by Vieth (1999) who concluded that adults receiving 10,000 IU
daily may reach 25[OH]D levels of 140 nmol/L but that there were no corresponding
markers of toxicity or adverse effects. Vieth, Chan, and MacFarlane (2001) conducted a
trial of healthy adult men and women (N=61) randomized to receive either 1000 IU or
4000 IU daily for 2 to 5 months starting in the winter. They concluded that 4000 IU/d for
adults did not cause toxicity even with extended dosing and that this dosing would be
necessary to raise 25[OH]D levels to adequacy. The authors reported a dose-response
increment of 0.56 nmol/L per microgram or 0.014 nmol/L per IU in the group receiving
vitamin D 4000 IU daily (Vieth, Chan, & MacFarlane, 2001). A similar study by
Heaney, Davies, Chen, Holick, and Barger-Lux (2003) randomized healthy men (N=67)
to receive 0, 1000, 5000, or 10,000 IU per day of vitamin D. They found a similar doseresponse relationship to Vieth et al. (2001) of 0.70 nmol/L per microgram, or 0.0175
nmol/L per IU (0.007 ng/mL per IU), across all dosage groups (Heaney, Davies, Chen,
Holick, & Barger-Lux, 2003). In a response paper to the new IOM recommendations,
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Heaney and Holick (2011) point to this evidence to support recommendations for
increases in 25[OH]D resulting from vitamin D supplementation, stating that for every
increase of 100 IU of vitamin D taken per day there will be a subsequent increase of
approximately 1 ng/mL in the 25[OH]D level (Heaney & Holick, 2011).
Pregnant/Lactating Populations
In a recent article reviewing safety considerations for designing randomized
controlled trials of vitamin D supplementation in pregnancy, Roth (2011) encourages
researchers to use vitamin D doses that will be sufficient in raising maternal 25[OH]D
levels to the normal range. Roth (2011) states that doses sufficient to bring the 25[OH]D
level of the intervention group up to >80 nmol/L are necessary to achieve valid results,
and that doses <10,000 IU daily can be considered as these are considered safe in nonpregnant adults (Roth, 2011).
Intervention studies of vitamin D supplementation have been conducted using
almost exclusively adult non-pregnant participants. There is a lack of contemporary
research in regards to efficacy and safety of vitamin D supplementation during
pregnancy. In 2000, Mahomed and Gulmezoglu completed a meta-analysis for the
Cochrane Review regarding vitamin D supplementation in pregnancy and were only able
to include 4 studies (Brooke et al., 1980; Brooke, Butters, & Wood, 1981; Mallet et al.,
1986; Maxwell, Ang, Brooke, & Brown, 1981) and excluded an additional 3 published
studies (Ala-Houhala, Koskinen, Terho, Koivula, & Visakorpi, 1986; Delvin, Salle,
Glorieux, Adeleine, & David, 1986; Marya, Rathee, Lata, & Mudgil, 1981) found from
1980 to 1986 (Mahomed & Gulmezoglu, 2000). After completing this review Mohamed
and Gulmezoglu (2000) concluded that insufficient evidence was available to recommend
26

routine prenatal vitamin D supplementation. This review has since been withdrawn
citing outdated content. In 2012, De-Regil, Palacios, Ansary, Kulier, and Pena-Rosas
completed a new review of vitamin D supplementation for women during pregnancy.
They were able to include 6 trials after excluding those that did not meet the criteria of
being a randomized or quasi-randomized trial. The authors concluded that vitamin D
supplementation during pregnancy raised 25[OH]D levels in the pregnant woman, but
correlations between increased 25[OH]D and improved health outcomes were weak (DeRegil, Palacios, Ansary, Kulier, & Pena-Rosas, 2012). Outcomes of interest included
rates of preeclampsia, gestational diabetes, cesarean section, and neonatal admission to
the intensive care unit, among others. In conclusion they called for high quality,
randomized controlled trials that evaluate the role of vitamin D supplementation in
pregnancy. Unfortunately, after completion of the De-Regil et al. (2012) review, two
high quality randomized controlled trials (reviewed later) evaluating effects of different
doses of maternal vitamin D supplementation were published, and therefore were not
included in the review (Hollis et al., 2011; Wagner, McNeil et al., 2013a).
Literature related to maternal vitamin D status during pregnancy dates back to the
1980s. Ala-houhala et al. (1986) demonstrated in a sample of 49 pregnant women that
those who received 2000 IU daily of vitamin D during pregnancy had significantly higher
vitamin D levels at 8 weeks than women who had taken 1000 IU vitamin D in pregnancy.
Marya et al. (1981) randomized pregnant women to receive no vitamin D (N= 75), 1200
IU daily (N= 25), or 2 doses of 600,000 IU one month apart at the end of the third
trimester (N= 20). Women receiving 1200 IU daily had lower serum alkaline
phosphatase levels as did infant cord blood in this group, but calcium and phosphate were
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similar to the no vitamin D group. The women in the group receiving 600,000 IU twice
at the end of pregnancy had higher calcium and phosphate and lower alkaline
phosphatase levels compared to controls and the 1200 IU daily group with no adverse
outcomes. Delvin et al. (1986) conducted a study with 40 women randomized to receive
either 1000 IU vitamin D daily (N= 20) in the third trimester or no vitamin D
supplementation (N= 20). Both the women and the infants in the 1000 IU group had
significantly higher 25[OH]D compared to the controls. The infants born to women who
had been supplemented showed a decrease in serum calcium at 4 days after birth, but it
was significantly less than infants born to none supplemented mothers. Of the studies
that were included in the earlier meta-analysis (Brooke et al., 1980; Brooke et al., 1981;
Mallet et al., 1986; Maxwell et al., 1981), Brooke, Butters, and Wood (1981) randomized
126 pregnant Asian women to receive either 1000 IU vitamin D daily (N=59) in the third
trimester or no supplementation (N=67). They reported no differences between the two
groups in terms of infant weight or measurements at birth, however the infants from the
treated group were significantly heavier at each data point thereafter (3, 6, 9, and 12
months). Using the same data set, Brooke et al. (1980) reported that women receiving
1000 IU vitamin D daily gained more weight during pregnancy than the nonsupplemented group participants. Five of the infants in the control group developed
symptoms of hypocalcemia whereas none did in the 1000 IU group. Additionally, there
were significantly more infants born small for gestational age and with large fontanelles
in the control group suggesting that bone growth and ossification were impaired. Mallet
et al. (1986) randomly assigned women to receive 1000 IU vitamin D daily in the third
trimester (N=21), a one-time dose of 200,000 IU in the seventh month (N=27), or no
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vitamin D supplement (N=29). There were no significant differences between the two
treatment groups in terms of maternal or infant serum 25[OH]D or calcium, but both
treatment groups had significantly higher serum 25[OH]D and serum calcium levels than
controls. They reported no difference in birth weight between any of the groups.
Maxwell, Ang, Brooke, and Brown (1981) randomized Asian pregnant women to receive
1000 IU vitamin D daily (N= 59) or no supplement (N= 67). Women in the
supplemented group gained weight faster than those in the control group and infants born
to women who were supplemented were significantly heavier at birth than infants in the
control group.
In 2002, Datta et al. completed a prospective study of pregnant women of ethnic
minority origins in South Wales. Women were from African, Afro-Caribbean, Asian,
Far-Eastern, and Middle-Eastern ethnic groups. A total of 160 women had their
25[OH]D levels checked at their first antenatal visit and those with levels < 8 ng/mL
were enrolled in the study (N= 80). All participants were started on 800 IU/d of
calciferol (vitamin D3). There was no control group used. The women were then retested
for 25[OH]D levels at 36 weeks followed by an increase in vitamin D supplementation to
1600 IU/day if levels were still below 8 ng/mL. The vitamin D supplemented women
had a final blood analysis to determine status at delivery. By delivery, the mean had
almost doubled to 11.24 (± 6.34 SD) ng/mL. By current conservative IOM standards, the
women would still be considered deficient. The authors did not find abnormal PTH,
alkaline phosphatase, calcium, or phosphate levels in the intervention group (Datta et al.,
2002). This study was limited by poor methodology including lack of a control group
and extremely low definition of vitamin D deficiency.
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Yu, Sykes, Sethit, Teoh, and Robinson (2009) completed an intervention study in
the United Kingdom using a diverse group of pregnant women (N=180). Women were
enrolled at 27 weeks gestation and randomized to receive 200,000 IU vitamin D as a onetime oral dose (N=60), 800 IU daily (N=60), or no treatment through delivery (N=60).
Yu et al. reported a significant difference between the two intervention groups and the no
treatment group in terms of 25[OH]D levels at delivery, fetal cord-blood 25[OH]D levels,
and maternal secondary hyperparathyroidism. There was not a significant difference
between the two intervention groups. Only 30% of women and 8% of newborns achieved
adequate 25[OH]D (> 50 nmol/L) levels by delivery in the intervention groups (Yu,
Sykes, Sethi, Teoh, & Robinson, 2009).
In 2011, Hollis et al. reported results from a randomized clinical trial of vitamin D
supplementation in pregnancy. Participants were randomized to receive 400 (N= 166),
2000 (N= 167) or 4000 (N=169) IU vitamin D3 daily from 12-16 weeks through delivery.
Vitamin D sufficiency was set at a 25[OH]D level of 80 nmol/L. The authors reported a
significant increase in mean 25[OH]D levels achieved between the group that received
vitamin D 2000 IU/day versus 400 IU/day and in the group given vitamin D 4000 IU/day
versus those who received 400 IU/day, but not between the 2000 IU and 4000 IU groups
although the 4000 IU group did have the highest mean 25[OH]D level. By the end of the
study, 82% of the women in the 4000 IU vitamin D group had reached vitamin D
adequacy, demonstrating the need for long term supplementation before levels rise
sufficiently. This was a large study with over 300 women participating from early
pregnancy through delivery. The authors reported no adverse outcomes or abnormal
biomarkers. Further, 25[OH]D levels of 30 ng/mL were necessary to normalize calcium
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excretion in the urine and reduce PTH levels and levels of 40 ng/mL were necessary to
support maximum 1,25(OH)2D production, which is the hormonally active form of
vitamin D responsible for increasing calcium absorption from the gut. In summary, there
are very few studies examining vitamin D supplementation during pregnancy, but in
those that exist, doses of 4000 IU daily over extended time periods demonstrate efficacy
and safety, whereas doses less than 2000 IU daily are minimally effective.
Using an almost identical protocol to that of Hollis et al. (2011), Wagner et al.
(2013) reported the findings of a randomized trial of 257 pregnant women. Women were
enrolled into the study at 12-16 weeks gestation and all were provided with 2000 IU
vitamin D daily for one month. They were then randomized to receive 2000 IU vitamin
D daily (N=130) or 4000 IU vitamin D daily (N=127). This study design did not include
a control group as it was deemed by the researchers and review board to be unethical to
treat a group with 400 IU only as most of them would remain vitamin D deficient through
the trial. The researchers defined vitamin D deficiency as < 20 ng/mL, insufficiency as ≥
20-32 ng/mL and sufficiency as > 32 ng/mL, but only include women achieving a
25[OH]D of > 40 ng/mL when discussing rates of sufficiency in particular groups. The
overall mean 25[OH]D level at enrollment was 22.7 (± 9.7) ng/mL. Both intervention
groups saw significant increases in mean 25[OH]D level by delivery, but there was no
statistically significant difference between the two intervention groups in terms of mean
25[OH]D. There were no incidences of vitamin D toxicity as evidenced by urine and
serum calcium levels staying in the normal range. The neonatal cord blood mean
25[OH]D level was significantly higher in the infants born to women in the 4000 IU daily
group than the 2000 IU daily group. Additionally, the researchers found a decline in
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pregnancy complications with increasing serum 25[OH]D level, but this was not
statistically significant between groups.
A review of the current literature reveals 4 contemporary articles that explore the
efficacy and safety of vitamin D supplementation during lactation for both mother and
infant (Basile et al., 2006; Hollis & Wagner, 2004b; Saadi et al., 2009; Wagner et al.,
2006). When vitamin D passes through breast milk it is referred to as the antirachitic
effect of the milk because the main clinical outcome of vitamin D is rickets prevention.
In each of the 4 studies, women were recruited and randomized at one month postpartum.
Basile et al. (2006) randomized 64 lactating women to receive either 2000 or 4000 IU
daily. Of this original sample, 25 continued exclusive breastfeeding through the study
period of 3 months. Basile et al. reported that serum calcium remained normal in both
mothers and infants in all groups and mothers did not have increased urine calcium.
Wagner et al. (2006) enrolled 19 women to receive either 400 (N= 10) or 6400 (N= 9) IU
vitamin D daily during lactation. There was no difference in maternal or infant serum
calcium or phosphorus levels and no difference in urinary calcium to creatinine ratios
between the two groups. Hollis and Wagner (2004) randomized 64 lactating women to
receive either 2000 or 4000 IU daily of vitamin D. Of those, 18 women, 9 in each group,
completed the study. Hollis and Wagner reported no adverse outcomes and 4000 IU had
great efficacy in increasing maternal and infant 25[OH]D levels over the study period. In
2009, Saadi et al. assigned 90 women to receive either 2000 IU daily vitamin D or 60,000
IU monthly oral dose for 3 months. Only one participant was lost to follow-up due to
breastfeeding cessation. Saadi et al. reported no adverse events related to vitamin D
exposure and the daily and monthly regimens were equally effective in raising maternal
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and infant 25[OH]D levels. To summarize the safety and efficacy data from these
studies, there were no reports of any adverse outcomes or effects and biomarkers of
toxicity such as serum calcium remained in the normal range for mothers and infants. In
terms of efficacy, doses above 4000 IU daily were most effective at bringing a majority
of women into the sufficient 25[OH]D range along with exclusively breastfed infants
(Thiele et al., 2013).
Current Estimates of Vitamin D Deficiency Prevalence
Adults
The National Health and Nutrition Examination Surveys (NHANES) have
provided good data in regards to vitamin D and health status. In a recent National Center
for Health Statistics (NCHS) Data Brief, researchers Looker et al. (2011) explored
vitamin D status in populations living in the United States. Using the designations of
sufficiency (>50 nmol/L), inadequacy (30-49 nmol/L), and deficiency (< 30 nmol/L) set
by the IOM, they reported overall population rates of 67%, 24%, and 8%, respectively.
Females, across the lifespan, are at greater risk of vitamin D deficiency with 12% being
deficient versus 8% of males. However, women who were pregnant or lactating were at
lower risk of deficiency compared to other adult women, which differs from findings of
most studies. Those categorized as non-Hispanic black and Mexican American persons
were more likely than whites to be in the deficient category, with 73% of black
Americans in the combined inadequate and deficient group. Certainly the rates of
insufficiency and deficiency would be higher if the 25[OH]D levels used for these status
definitions were reflective of those used by most researchers, namely >80 nmol/L for
sufficiency.
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Pregnant and lactating women and their infants
The World Health Organization (FAO/WHO, 2004) described risks for vitamin D
deficiency in their report, “Vitamin and Mineral Requirements in Human Nutrition”.
Infants are described as an at-risk group due to their rapid growth and reliance on
maternal stores of vitamin D during fetal and newborn development. In a French study,
Zeghoud et al. (1997) found that 64% of infants had 25[OH]D levels below 30 nmol/L at
birth. Studies based in several different states in the U.S. document the extent of vitamin
D deficiency among newborns. Dror, King, Durand, and Allen (2011) from Oakland,
California found 90% of infants and 54% of mothers had 25[OH]D levels <75 nmol/L.
Basile et al. (2007) in South Carolina report 65.5% of African American infants and 24%
of white infants had cord blood 25[OH]D levels <11 ng/mL. In Massachusetts in 2010,
Merewood et al. found that 58% of infants and 35.8% of mothers had 25[OH]D levels <
20 ng/mL and 38% of infants and 23.1 % of mothers had 25[OH]D levels < 15 ng/mL.
In the relatively sun rich area of Sacramento, California, Liang, Chantry, Styne, and
Stephensen (2010) found that 28.3% of infants had 25[OH]D levels < 75 nmol/L with
exclusive breastfeeding being a significant risk factor for vitamin D deficiency. CollinsFulea, Klima, and Wegienka (2012) found that amongst 2839 pregnant women in Detroit,
92.5% had 25[OH]D levels <30 ng/mL and 71.7% had levels <20 ng/mL. This was one
of few studies that included a relatively large percentage of non-white participants. The
authors found that significant risk factors for vitamin D deficiency included being Middle
Eastern, African American, or Asian and wearing the hijab as part of their cultural dress.
In British Columbia, Li et al. (2011) found that 65% of pregnant women between 20 and
35 weeks gestation had 25[OH]D levels < 30 ng/mL and 24% had 25[OH]D levels < 20
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ng/mL. Participants in the study regularly took supplements containing ≥ 400 IU daily
(80%), however, deficiency was still prevalent. In contrast, Bendall, de Costa, Woods,
and Howat (2012) from Australia found that out of 116 women, only 6.9% had 25[OH]D
levels <30 ng/mL, thus they questioned the need for routine screening or supplementation
in Australia. In New Orleans, Gangat, Ponnapakkam, Bradford, Katikaneni, and Gensure
(2012) found that African American infants (N=26) had significantly lower mean cord
blood 25[OH]D levels than Caucasian infants (43 ± 2.8 nmol/L vs 69.2 ± 4.2 nmol/L, P <
.001). Infants across the globe are at risk for deficiency as Agarwal, Faridi, Aggarwal,
and Singh (2010) reported. 70% of mothers and 55.67% of infants at 10 weeks
postpartum had 25[OH]D levels < 11ng/mL and that at 6 months 16.49% of infants
developed rickets as defined by the authors as serum alkaline phosphatase > 420 IU/L.
Infants with darker skin pigmentation, who were kept out of sunlight, born in the winter
and exclusively breastfed by a vitamin D deficient mother were at greatest risk for
vitamin D deficiency (Greer, 2008; Thandrayen & Pettifor, 2012).
Researchers in New England recently found that of infants at 4 months of age (N=
177), 11.9% had 25[OH]D levels < 20 ng/mL (Merewood et al., 2012). They did not
report findings using any biologically based definition of vitamin D sufficiency, namely
> 32 ng/mL. The strongest predictor of vitamin D deficiency in the infants was lack of
appropriate supplementation. This underscores the necessity of all infants to receive
appropriate external vitamin D, whether from infant formulas, sufficient breast milk
vitamin D content, or a vitamin D supplement. Of infants who were exclusively
breastfed without vitamin D supplementation, 40% had 25[OH]D levels < 20 ng/mL,
compared to 6% of formula fed infants. Researchers in Turkey also examined a group of
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4-month-old exclusively breastfed infants (Halicioglu et al., 2012). Mothers had been
instructed to give 400 IU of oral vitamin D to their infants and were supplied with the
supplement. Despite “regular use” of the supplement (> 6 times per week), 28% of
infants had 25[OH]D levels < 20 ng/mL and in infants with “irregular use” of the
supplement (<6 but >3 times per week) 38.5% had vitamin D deficiency.
Ethnicity certainly plays a significant role in vitamin D deficiency as well. In a
recent study, cord blood was collected at birth from black (N=75) and white (N= 38)
male infants (Eichholzer et al., 2013). The mean 25[OH]D level in black infants was
significantly lower than the mean 25[OH]D level in white infants (11.44 vs. 18.24
ng/mL). Of the black infants 84% had 25[OH]D levels < 20 ng/mL compared to 63% of
white infants, which demonstrates the high rate of vitamin D deficiency in both groups.
Children
In 2009, Mansbach, Ginde, and Camargo reviewed the 25[OH]D levels obtained
on children aged 1 to 11 years through the National Health and Nutrition Examination
Survey (NHANES). A total of 4558 children had a 25[OH]D level checked between
2001 and 2006. Of those children, 69% had serum 25[OH]D levels less than 75 nmol/L
(30 ng/mL). Analysis by ethnicity demonstrated that 92% of non-Hispanic black and
80% of Hispanic children fell into this category. Because this is a nationally
representative sample, the authors conclude that millions of children may have
insufficient vitamin D levels. They reiterate that further research is necessary for
improved understanding of how this affects health outcomes and what supplementation
doses might be used to correct this widespread problem.
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Madden et al. (2012) collected blood samples on 511 critically ill children
admitted to the Pediatric Intensive Care Unit. Of these participants, 40.1% had 25[OH]D
levels < 20 ng/mL and the mean 25[OH]D level was only 22.5 ng/mL. Due to the role
vitamin D seems to play in the immune response, the authors recommended screening
critically ill children for vitamin D deficiency.
The Functional Role of Vitamin D in the Human Body
Although the compound known as vitamin D has been studied for almost a
century, the mechanisms by which it has an impact on human health have only recently
become clearer. Because of the observations that serum 25[OH]D seems to impact many
disease processes, biological researchers have set out to determine specific actions that
vitamin D has on human genes, cells, tissues, and systems. It is now understood that, like
all endocrine functions, there is an exquisite balancing of vitamin D production and
feedback regulation in the body. When our skin is exposed to UVB radiation from the
sun in the 290-315 nm wavelength range, the provitamin D3, a cholesterol precursor 7dehydrocholesterol, is converted to previtamin D3, which is then further transformed
into cholecalciferol or vitamin D3, see Figure 1 (Lappe, 2011). The cholecalciferol
compound is able to bind to vitamin D binding protein (DBP) and is then carried into the
blood stream (Holick, 2006; Mulligan et al., 2010). Once present in the blood stream,
cholecalciferol is either stored in fat or converted in the liver by a 25-hydroxylation
process completed by a cytochrome P-450 enzyme (25-hydroxylase) forming 25[OH]D.
Whether from a dietary source such as fatty fish, from a supplement, or from the skin as
vitamin D3 (cholecalciferol), the precursor compounds will be metabolized in to the
circulating 25[OH]D form. The conversion of previtamin D to 25[OH]D is directly
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proportional to vitamin D synthesis or intake, therefore 25[OH]D is used as the blood
marker of overall vitamin D status.
When acting as an endocrine prohormone, circulating 25[OH]D is further
metabolized by 1-α-hydroxylase, typically present in the kidney. The vitamin D is then
in its active hormonal form 1,25– dihydroxyvitamin D (1,25[OH]2D, calcitriol), which
has high affinity with vitamin D receptors (VDR) throughout the body (Lappe, 2011).
One of its primary functions is to affect calcium absorption in the intestine relative to

Figure 1. Metabolism of vitamin D in the human body.
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calcium intake. The unbound, free 1,25[OH]2D is able to cross the cell membrane in the
intestine, bind to the VDR and increase expression of the epithelial calcium channel,
which leads to increased calcium absorption (Holick, 2011).
It is now understood that cells outside the kidney are able to convert 25[OH]D to
1,25[OH]2D, which then has an autocrine or paracrine effect (Lappe, 2011). The 1-αhydroxylase needed for this conversion has been found in cells of the skin, placenta,
colon, prostate, brain, lungs, monocytes and macrophages (Holick, 2011). In these cells
1,25[OH]2D induces transcription of proteins or other molecules the cell has been
signaled to produce. This allows for cell and tissue specific conversion of 25[OH]D to its
biologically active form (Lappe, 2011). The action of the 1,25[OH]2D can also be
slowed or stopped inside the cell by the action of vitamin D 24-hydroxylase, providing a
homeostatic balance inside the cell itself (Lappe, 2011).
The historically understood role of vitamin D in the body is calcium and
phosphorus homeostasis (Holick, 2006). The biologically active 1,25[OH]2D encourages
calcium and phosphorus absorption in the intestine as well as inducing osteoclasts to
promote bone resorption when dietary calcium is lacking (Holick, 2006). Calcium
homeostasis is imperative to the functioning of muscle, including the heart, bone
formation, growth and strength, and many metabolic functions (Lappe, 2011). Because
vitamin D is primarily formed in the skin and only minimally acquired through diet,
anything that affects skin exposure to UVB wavelengths will affect 25[OH]D production.
These factors can include skin pigmentation, geographic latitude, use of sunscreen, aging,
cloud cover or pollution, winter season, skin covering (clothing), and time spent indoors.
If someone has minimal UVB exposure for any of these reasons and their 25[OH]D level
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falls, calcium absorption is then diminished and the subsequent calcium deficiency leads
to increased production of parathyroid hormone (PTH) (Figure 2). PTH causes increased
reabsorption of calcium in kidney tubules in an effort to maintain tight control of serum
calcium levels. The PTH also signals the kidney to increase production of 1,25[OH]2D,
which results in increased calcium and phosphorus absorption in the gut as well as

Figure 2. Vitamin D deficiency and the compensatory parathyroid hormone mechanism.

increased bone turnover and loss in order to maintain serum calcium. Although this is a
functional homeostatic reaction of the endocrine system, it is meant to be short term,
perhaps needed only briefly in the winter, and not a long term consequence of vitamin D
deficiency. This process can lead to rickets, osteomalacia, and osteoporosis as the body
needs to use more and more bone to maintain serum calcium levels.
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Impact of Vitamin D on Health Outcomes
There has been rapid dissemination of vitamin D research as it relates to disease
prevention and treatment (Grant, 2011a). Although not all studies find a correlation
between 25[OH]D levels or vitamin D intake and disease, there is growing evidence that
vitamin D deficiency may be an important modifiable risk in global health. The areas of
inquiry reviewed here are bone health, cardiovascular disease, diabetes, cancer, and
immune function.
Bone
The most widely accepted consequence of vitamin D deficiency is rachitic
deformities in children (Thandrayen & Pettifor, 2012), and osteoporosis in adults
(Epstein, 2006). Rickets is the consequence of extremely low vitamin D levels
experienced in infancy (Thandrayen & Pettifor, 2012), whereas osteoporosis is a longlatency disease found most often in the elderly and signals both vitamin D and calcium
deficiencies (Epstein, 2006). Biochemical markers of rickets disease can be noted before
the visible physical changes occur. These markers include high alkaline phosphatase,
low 25[OH]D levels with paradoxically normal 1,25-OHD levels, secondary
hyperparathyroidism, low serum phosphorus, and hypocalcemia (Ponnapakkam,
Bradford, & Gensure, 2010). Other physical symptoms that may be noted are splaying of
the growth plates in the wrists and knees noted on X-ray (Ponnapakkam et al., 2010). On
the other end of the age spectrum, vitamin D deficiency results in osteoporosis with 50%
of those > 50 years having either diagnosed osteoporosis or low bone mineral density
(BMD) (Epstein, 2006). Osteoporosis can result in bone fractures and significant
morbidity and mortality (Epstein, 2006). When vitamin D levels are insufficient to signal
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for increased calcium absorption from the intestine over long periods of time there is a
compensatory mechanism that pulls calcium from the bone to maintain serum calcium
homeostasis (Figure 2). This leads to decreased BMD and osteoporosis, a significant cost
to health and well-being (Epstein, 2006). In summary, there is significant evidence that
vitamin D deficiency can have subtle effects on bone development and maintenance and
if severe enough can lead to rickets.
Cardiovascular Disease
Cardiovascular disease can have many components, but one common underlying
dysfunction is hypertension. Vaidya and Forman (2010) completed an analysis of the
existing data regarding vitamin D effects on blood pressure. Most studies are
observational and have varying results regarding the magnitude of vitamin D’s effect
(Vaidya & Forman, 2010). There is some convincing evidence that vitamin D has an
effect on the renin-angiotensin system leading to decreased hypertension rates, with some
studies completed with mice (Y. C. Li, 2003) and others with humans (Vaidya &
Williams, 2012; Vaidya, Sun, Larson, Forman, & Williams, 2012). In a meta-analysis,
Feneis and Arora (2010) found that 8 of the 10 reviewed observational studies describe
an inverse relationship between vitamin D and blood pressure. Grant (2011a) compiled
existing literature regarding vitamin D levels and multiple disease outcomes. Part of this
analysis included describing a hazard ratio for serum 25[OH]D and mortality from
cardiovascular disease and concludes that the hazard ratio drops by 18% with an increase
in serum 25[OH]D from 54 to 110 nmol/L. Certainly there is sufficient evidence of a
relationship to warrant support for RCTs of vitamin D and cardiovascular risks.
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Diabetes
The mechanisms by which vitamin D may have an effect on type 2 diabetes
include impact on beta cell function, insulin action, and general inflammation (Eliades &
Pittas, 2009). Much like studies regarding vitamin D and cardiovascular outcomes,
studies examining vitamin D and diabetes are mostly observational. Although they offer
evidence of the effect and the mechanism of action, conclusions regarding widespread
supplementation cannot be made from these studies (Eliades & Pittas, 2009).
Intervention studies on humans are limited as they have been part of larger studies not
investigating the relationship between vitamin D and diabetes (Orwoll, Riddle, & Prince,
1994). Alemzadeh, Kichler, Babar, and Calhoun (2007) found a positive correlation
between 25[OH]D and insulin sensitivity and a negative correlation between 25[OH]D
and hemoglobin A1C in obese children, indicating that earlier intervention of vitamin D
supplementation may help prevent development of impaired glucose metabolism.
Cancer
Early prospective studies noted that people with higher circulating serum vitamin
D had a significantly decreased risk of several cancers (C. F. Garland et al., 1989; F. C.
Garland, Garland, Gorham, & Young, 1990). This was more recently explicated in a
larger review (C. F. Garland et al., 2009). Newhouser et al. (2008) examined the
relationship between vitamin D insufficiency and breast cancer survivors. When
controlling for mediating variables, the stage of disease independently predicted serum
vitamin D levels with more advanced disease being associated with lower levels of
vitamin D. Overall, 75.6% of participants (N= 790) had low serum vitamin D levels. A
meta-analysis of the relationship among vitamin D, calcium, and breast cancer prevention
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identified a significant relationship between serum vitamin D and breast cancer (Chen et
al., 2010). Women in the highest quartile of circulating 25[OH]D had a 45% decreased
risk of breast cancer and those in the highest quartile of circulating calcium had a 19%
decreased risk of breast cancer. Studies investigating colorectal cancer found that higher
circulating vitamin D status was associated with decreased risk of colon cancer (Touvier
et al., 2011) and resulted in decreased mortality rates from colorectal cancer after that
diagnosis had been made (Ng et al., 2009).
Immune Function
Vitamin D plays a role in both the innate immune response (Lagishetty et al.,
2011) and in modulation of autoimmune diseases (Waterhouse, Perez, & Albert, 2009).
Waterhouse et al. (2009) report that some of the diseases showing a favorable response to
vitamin D supplementation are systemic lupus erythematosis, rheumatoid arthritis,
scleroderma, sarcoidosis, psoriasis, and autoimmune thyroid disease. Kamen et al.
(2006) reported significantly lower mean 25[OH]D levels in Caucasian patients with
lupus versus healthy controls. In an in-depth description of the mechanism by which
vitamin D affects the innate immune response, Lagishetty et al. (2011) state that T-cells,
B-cells and macrophages express the vitamin D receptor (VDR) and are able to
synthesize the biologically active 1,25[OH]2D form. Lagishetty et al. also report that
antibacterial action of monocytes is linked with their ability to metabolize vitamin D,
which then induces the innate immune response. Because of the correlation between
vitamin D deficiency and poor immune response, immunologists have been researching
the direct impact that vitamin D has on inflammation and cytokine production. Vitamin
D’s impact seems to be directly aimed at monocytes and macrophages and their
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production of cytokines (Di Rosa et al., 2012; Tiosano et al., 2013). Several studies have
found that vitamin D will inhibit production of tumor necrosis factor alpha (TNF-α) and
interleukin 6 (IL-6), which are both pro-inflammatory (Di Rosa et al., 2012; Thota et al.,
2013). It has also been found that vitamin D can increase production of the antiinflammatory cytokine interleukin 10 (IL-10) (Thota et al., 2013; Tiosano et al., 2013).
Looking specifically at vitamin D deficient adults, researchers have observed increased
TNF-α, IL-6 and decreased levels of IL-10 (T. Barker et al., 2013). A recent randomized
controlled trial investigated the impact of 4000 IU vitamin D daily for 5 days on the
production of inflammatory markers following myocardial infarction (Arnson et al.,
2013). The researchers found that vascular cell adhesion molecules, C-reactive protein,
and IL-6 were produced at a significantly lower rate amongst the participants receiving
the vitamin D compared to those who did not. They conclude that even modest doses of
vitamin D can have immediate benefit on the inflammatory response (Arnson et al.,
2013).
Maternal Health Effects of Vitamin D Deficiency
Preeclampsia
Contemporary research demonstrates widespread vitamin D deficiency amongst
pregnant women (Basile, Taylor, Wagner, Quinones, & Hollis, 2007; Collins-Fulea et al.,
2012; Hollis & Wagner, 2006; Hollis, 2009; Lee et al., 2007; Merewood et al., 2010;
Mulligan et al., 2010; Robinson et al., 2010). Merewood et al. (2010) explored the
physiologic underpinnings of vitamin D in the human body and how it affects many body
tissues and functions. They describe preeclampsia and hypertensive disorders as the most
well documented effects of vitamin D deficiency in pregnancy. Robinson et al. (2010)
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completed a case-control investigation of women diagnosed with early-onset severe
preeclampsia (EOSPE) (N= 50). They found a significant relationship between vitamin
D serum levels and EOSPE and concluded that a 10 ng/mL increase in serum 25[OH]D
yielded a 63% decrease in the odds of developing EOSPE.
Haugen et al. (2008) correlated data regarding vitamin D intake from the
Norwegian Mother and Child Cohort Study with subsequent risk of preeclampsia
development (N= 23,423). Participants reported general health and diet factors at 15, 22
and 30 weeks gestation. Haugen et al. report an odds ratio of 0.76 for preeclampsia for
women ingesting 600-800 IU daily compared with those ingesting less than 200 IU daily.
When vitamin D supplement intake was separated from dietary intake the researchers
found a 27% reduction in risk for preeclampsia in women taking 400-600 IU daily
compared to no supplementation.
In 2010 Baker et al. reported the association of midgestation 25[OH]D level and
later development of severe preeclampsia. Participants who developed severe
preeclampsia (N= 51) had lower 25[OH]D levels at midgestation than those who
remained healthy (N= 204). Further, a midgestation 25[OH]D level of < 50 nmol/L was
associated with an almost 4 fold increase in development of severe preeclampsia.
Similarly, Wei, et al. (2012) found that midgestation (24-26 week) 25[OH]D levels < 50
nmol/L was accompanied by a 3.24 fold risk of preeclampsia development.
Gestational Diabetes
There is a growing body of evidence that vitamin D affects glucose homeostasis
and that deficiency in vitamin D may increase risk for gestational diabetes (Senti et al.,
2012). In another case-controlled investigation of 204 women, Soheilykhah et al. (2010)
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found that women diagnosed with gestational diabetes mellitus (GDM) were 2.66 times
more likely to have a deficient vitamin D level compared to pregnant women without
GDM. Additionally, women with one abnormal glucose test were significantly more
likely to have vitamin D deficiency than women with no abnormal glucose tolerance.
Maghbooli et al. (2008) investigated the correlation between gestational diabetes
and vitamin D in 741 pregnant women in Tehran, Iran. They found an overall 25[OH]D
deficiency rate of 70.6% with a cut-off of < 25 nmol/L. A positive correlation between
25[OH]D levels and insulin sensitivity was found as well as a negative correlation
between 25[OH]D and GDM. In a nested case-control study of 57 women diagnosed
with GDM and 114 healthy controls, Zhang et al. (2008) found a 2.66 fold increased risk
of developing GDM when vitamin D deficient, defined as < 20 ng/mL. Clifton-Bligh et
al. (2008) used midgestation blood samples from women (N= 264) at high risk of GDM
and report an inverse relationship between 25[OH]D level and PTH, fasting glucose,
fasting insulin, and insulin resistance. However, not all studies find significant
relationships. Farrant et al. (2009) found that 66% of participants (N= 559) had 25[OH]D
levels less than 50 nmol/L and 31% less than 28 nmol/L, but there was no association
between 25[OH]D levels and GDM. Women with higher 25[OH]D levels did have
significantly lower (p = 0.03) 30 minute glucose concentrations during their glucose
tolerance test.
Parlea (2012) compared women with GDM (N= 116) to those without (N= 219)
and found that women with GDM had significantly lower 25[OH]D levels. Women who
had 25[OH]D levels that fell below the top quartile (< 73.5 nmol/L) had a 2.21 fold
increased risk for developing GDM. Similarly, Burris et al. (2012) found a linear
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relationship between 25[OH]D level and glucose tolerance at 26-28 weeks gestation.
Overall, women with 25[OH]D level < 25 nmol/L had a 2.2 fold increased risk of
developing GDM. However, not all studies support a relationship between 25[OH]D
level and GDM. Baker, Haeri, Camargo, Stuebe, and Boggess (2012) compared a
population of 60 women with GDM with 120 controls. There was not a significant
relationship between 25[OH]D level and GDM. Their population had relatively high
25[OH]D levels with 73% of them having levels > 75 nmol/L.
Immune Modulation
During normal pregnancy, there seems to be only moderate changes to the
expression of immune response as evidenced by changes in cytokine production. There
are differing results in the literature examining normal cytokine production in pregnancy.
Palm, Axelsson, Wernroth, Larsson, and Basu (2013) found that, among 37 women
experiencing normal pregnancy and delivery, IL-6 does steadily increase over the course
of a pregnancy, whereas there seems to be no significant change in TNF-α (Palm,
Axelsson, Wernroth, Larsson, & Basu, 2013). This is different than the findings of
Denney et al. (2011) who found that amongst 45 pregnancies, TNF-α, IL-6, and IL-10
response steadily declined throughout pregnancy, with the change in IL-6 and IL-10
being significant (Denney et al., 2011). It seems that IL-10 plays a critical role in
allowing pregnancy to continue without the maternal inflammatory response causing a
rejection, or miscarriage, to occur (Denney et al., 2011; Palm et al., 2013).
Simultaneously, increased levels of TNF-α and IL-6 are associated with early
miscarriage, especially in the presence of infections (Denney et al., 2011). There seems
to be a significant role for these cytokines in process of preeclampsia as well (Sharma,
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Satyam, & Sharma, 2007). It has been demonstrated that there is a significant increase in
the pro-inflammatory cytokines TNF-α and IL-6 accompanied by a decrease in the antiinflammatory cytokine IL-10 when a woman is experiencing preeclampsia (Sharma et al.,
2007). Few studies exist investigating the impact of vitamin D supplementation on
human cytokine production during pregnancy (Barrera et al., 2012; Thota et al., 2013).
Barrera et al. (2012) noted that both IL-10 and calcitriol (1,25[OH]2D) independently
inhibit production of pro-inflammatory cytokines in the placenta (Barrera et al., 2012).
They exposed human trophoblast cells, obtained from normal and preeclamptic
pregnancies, to calcitriol and TNF-α, expecting to see increased IL-10 production in both
instances. However, they found that calcitriol actually suppressed IL-10 production and
TNF-α stimulated increased IL-10 production, in the normal and preeclamptic cells.
They hypothesize that calcitriol suppresses all cytokine production and the antiinflammatory impacts of calcitriol negate the need for increased IL-10 production.
Thota, Farmer, Garfield, Menon, and Al-Hendy (2013) used a similar method with
human myometrial cells stimulated with bacterial endotoxin to simulate infection (Thota
et al., 2013). They found that then exposing the cells to vitamin D resulted in decreased
TNF-α production and increased IL-10 production, supporting their hypothesis that
vitamin D would have anti-inflammatory impacts in a uterine infection model (Thota et
al., 2013).
Infant Health Effects of Maternal Vitamin D Deficiency During Pregnancy and Lactation
Health consequences for the fetus and infant from exposure to maternal vitamin D
deficiency can be found in the immediate neonatal period or later in childhood. Problems
from the neonatal period reviewed here include hypocalcemic seizure and rickets, and
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later onset diseases include asthma, upper respiratory infection (URI), atopic dermatitis,
and type 1 diabetes.
Rickets
Although easily prevented with low doses of vitamin D and thought to be
vanished from the United States, rickets reemerged as a public health concern in the
1980s (Thandrayen & Pettifor, 2012). Most cases of rickets seen in the 1980s involved
dark-skinned infants who were exclusively breastfed and from families who had
immigrated to the U.S. (Thandrayen & Pettifor, 2012; Wagner et al., 2008). Rickets has
now been identified as a significant problem globally because of the rapid
industrialization of developing countries leading to indoor work environments and
increased pollution (Thandrayen & Pettifor, 2012). The calcium-vitamin D relationship
between mother and fetus or newborn plays a role in the development of rickets. If a
pregnant woman is calcium or vitamin D deficient this process will be altered and the
fetus may have disordered bone development. Likewise, 25[OH]D crosses the placenta
readily but 1,25[OH]2D does not cross the placenta easily, leading to 25[OH]D deficiency
in the fetus or infant born to a 25[OH]D deficient mother (Thandrayen & Pettifor, 2012).
This generational vitamin D deficiency can continue if the vitamin D deficient mother
exclusively breastfeeds her infant who is undergoing rapid bone growth. The end result
can be nutritional rickets, seen rarely as a congenital disorder and more often during the
early lactation stage of infancy (Thandrayen & Pettifor, 2012).
Hypocalcemic Seizures
Another consequence of severe vitamin D deficiency in infants is hypocalcemic
seizures (Balasubramanian, Shivbalan, & Kumar, 2006; Balasubramanian & Ganesh,
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2008; Balasubramanian, 2011; Camadoo, Tibbott, & Isaza, 2007; Teaema & Al Ansari,
2010). Again, this is most often seen in infants with dark skin who are exclusively
breastfed (Salama & El-Sakka, 2010). In 2010, Salama and El-Sakka reported maternal
25[OH]D status in lactating women whose infants developed rickets with hypocalcemic
seizures. Of the 32 infants who were diagnosed with rickets, 9 developed hypocalcemic
seizures. Salama and El-Sakka found that 69% of the mothers and 72% of the infants had
25[OH]D levels < 20 ng/mL. They conclude that maternal supplementation with vitamin
D might prevent some of the hypocalcemic seizures in these infants (Salama & El-Sakka,
2010).
Wheeze, Asthma, and Respiratory Infection
Interesting research is emerging in regards to long latency disease and vitamin D
deficiency during fetal and neonatal development. Camargo et al. (2011) correlated cord
blood 25[OH]D levels obtained at birth (N= 823) with later development of wheeze or
asthma up to age 5 and with respiratory infection before the age of 3 months. Results
included an inverse relationship between fetal 25[OH]D levels and risk of respiratory
infection by age 3 months, risk of wheezing by 15 months, 3, and 5 years of age. There
was not a correlation between fetal 25[OH]D status at birth and development of asthma
(Camargo et al., 2011). In a study that compared 25[OH]D levels in newborns admitted
to the neonatal intensive care unit with acute lower respiratory infection with a group of
healthy newborns, Karatekin, Kaya, Salihoglu, Balci, and Nuhoglu (2009) found that the
ill newborns (N= 25) had significantly lower 25[OH]D levels compared to healthy
controls (N= 15). This study also reports that 87.5% of all the newborns had serum
25[OH]D levels less than 20 ng/mL.
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Atopic Dermatitis
In 2011, Peroni, Piacentini, Cametti, Chinellato, and Boner reported their findings
regarding atopic dermatitis severity in children (N= 37) aged 8 months to 12 years and its
correlation to 25[OH]D status. In this study, children with mild disease had significantly
higher 25[OH]D levels compared to children with moderate or severe atopic dermatitis.
Additionally, the children were tested for specific IgE to Staphylococcus aureus and
Malassezia furfur revealing an inverse correlation between vitamin D deficiency and
prevalence of the IgE.
Type 1 Diabetes
In a study that spanned 30 years and included 10,821 infants in Finland,
researchers found that infants who regularly received 2000 IU daily of vitamin D had an
80% decreased risk of developing type 1 diabetes over the course of their first year
compared to infants who did not receive regular supplementation (Hypponen, Laara,
Reunanen, Jarvelin, & Virtanen, 2001). Additionally, children who had been suspected
of having rickets during their first year of life had a relative risk of 3.0 of developing type
1 diabetes compared to those who never had a suspicion of rickets (Hypponen et al.,
2001). In 2011, Bin-Abbas, Jabari, Issa, Al-Fares, and Am-Muhsen completed a study in
Saudi Arabia designed to examine the prevalence of vitamin D deficiency amongst
children with type 1 diabetes. Among the 100 children diagnosed with type 1 diabetes
compared with 100 healthy controls, those children with type 1 diabetes had significantly
lower 25[OH]D levels, with 84% being defined as vitamin D deficient versus 59%
vitamin D deficiency among the healthy controls. In summary, there is evidence that
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deficient 25[OH]D levels are associated with increased risk of developing type 1
diabetes.
Evidence of Vitamin D Transfer Through Breast Milk
Seminal research from the 1980’s began exploring maternal supplementation of
vitamin D and its effect on infant (birth through age 10 months) vitamin D levels (AlaHouhala, 1985; Ala-Houhala et al., 1986; Greer, Hollis, Cripps, & Tsang, 1984; Greer,
Hollis, & Napoli, 1984; Hollis, 1983; Kunz, Niesen, von Lilienfeld-Toal, & Burmeister,
1984). It was noted in these studies that vitamin D did pass through breast milk and was
the main antirachitic factor in breast milk, with average amounts of 20-70 IU per liter of
breast milk passing from mother to infant (Hollis, Roos, Draper, & Lambert, 1981;
Hollis, Roos, & Lambert, 1982; Hollis, Pittard, & Reinhardt, 1986). Additionally,
researchers revealed that the vitamin D content of breast milk increased when lactating
mothers were either supplemented with vitamin D or exposed to ultraviolet light (Greer et
al., 1984; Greer et al., 1984). It was acknowledged that skin color played a role in breast
milk vitamin D content with African American women having lower vitamin D levels in
their milk than white women (Specker, Tsang, & Hollis, 1985). Kunz, Niesen, von
Lilienfeld-Toal, and Burmeister (1984) reviewed the vitamin D content of breast milk,
cow’s milk, and infant formulas. Participants took a prenatal vitamin containing 400 IU
D2, but it is unclear if similar supplementation was continued postpartum. Interestingly,
the authors found over the course of lactation the level of vitamin D in breast milk
steadily dropped, demonstrating that this low dose was not adequate to maintain breast
milk vitamin D content.
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As there have been advances in our understanding of vitamin D physiology in
general, there have been specific advances in our understanding of vitamin D physiology
during pregnancy and lactation. The physiologic adaptations that occur during pregnancy
and lactation coincide with the increased calcium demands of the growing fetus and
infant. Fetal serum calcium levels are maintained at slightly higher than maternal levels
by active transport of calcium by the placenta (Thandrayen & Pettifor, 2012). Maternal
calcium absorption increases during pregnancy, especially in the third trimester as the
fetal skeleton is being developed (Thandrayen & Pettifor, 2012). There is an increase in
maternal 1,25[OH]2D that promotes increased intestinal absorption of calcium, along
with other factors (Wagner et al., 2008). If a pregnant woman is calcium or vitamin D
deficient, this process will be altered and the fetus may have disordered bone
development. Likewise, 25[OH]D crosses the placenta readily but 1,25[OH]2D does not
cross the placenta easily, leading to 25[OH]D deficiency in the fetus or infant born to a
25[OH]D deficient mother (Thandrayen & Pettifor, 2012). The calcium needs of the
infant far exceed those of the fetus with approximately 300 mg of maternal calcium being
transferred to the infant daily via breast milk (Thandrayen & Pettifor, 2012). During
pregnancy, the increased calcium need is achieved from increased maternal intestinal
calcium absorption whereas during lactation, the increased calcium need comes from
maternal bone turnover (Thandrayen & Pettifor, 2012). The transfer of vitamin D from
mother to infant is much different in lactation than during pregnancy. The infant receives
vitamin D from breast milk in its parent form before it is converted by the liver to
25[OH]D, the form received via placental transfer by the fetus (Thandrayen & Pettifor,
2012; Wagner et al., 2008). Therefore, it is critical that maternal serum vitamin D levels
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remain adequate despite the fact that vitamin D has a short half-life and is quickly
converted to 25[OH]D (Wagner et al., 2008).
An exhaustive review of the literature revealed 3 contemporary randomized
controlled trials in which lactating mothers were supplemented with vitamin D and then
followed for measurement of their 25[OH]D levels along with those of their infants
(Thiele et al., 2013). There were no studies found in which participants started vitamin D
supplementation during pregnancy and continued through lactation (Hollis & Wagner,
2004b; Saadi et al., 2009; Wagner et al., 2006). Researchers begin their intervention
during the lactation period in order to minimize the high attrition from breastfeeding in
the first month postpartum and because of the relative difficulty in doing intervention
studies with pregnant participants. However, this method allows for a majority of
pregnant women and infants to be vitamin D deficient through the critical time in
pregnancy in which the mother transfers a large amount of calcium to her fetus and then
again through the first month of lactation when significant maternal bone turnover occurs
in order to support the rapidly growing infant skeleton (Thandrayen & Pettifor, 2012).
Because of the significant role that vitamin D sufficiency plays in bone stability and
mineral homeostasis in the body, it is critical that this time frame of the life cycle be
examined in terms of vitamin D needs.
In 2004, Hollis and Wagner enrolled lactating women (N= 18) at one month
postpartum into a study giving them 2000 IU (1600 IU as D2 and 400 IU as D3) or 4000
IU (3600 IU as D2 and 400 IU as D3) daily for a 3 month period. Enrollment mean
25[OH]D level was 27.6 ± 3.3 ng/mL in the 2000 IU group and 32.9 ± 2.4 ng/mL in the
4000 IU group. Both the 2000 IU group and the 4000 IU group had significant increase
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in mean 25[OH]D levels to 36.1 ± 2.3 ng/mL and 44.5 ± 3.9 ng/mL, respectively.
Infants of mothers in both groups had significant increases in circulating 25[OH]D.
Infants of mothers in the 2000 IU group went from a mean 25[OH]D level of 7.9 ± 1.1
ng/mL to 27.8 ± 3.9 ng/mL after 3 months of maternal supplementation. Infants of
mothers in the 4000 IU group also had significant change from a mean 25[OH]D of 13.4
± 3.3 ng/mL to 30.8 ± 5.0 ng/mL. The group taking 4000 IU daily made much more
progress toward adequate vitamin D amounts in breast milk to result in adequate serum
levels for their infants. This study was limited in scope due to a small sample size,
however, despite the small number of participants the study still had adequate power to
demonstrate statistical significance. This underscores the large effect size of maternal
vitamin D supplementation on transfer to the exclusively breastfed infant.
In 2006, Wagner et al. enrolled exclusively breastfeeding women at 1 month
postpartum for a 6 month trial in which they either received 400 IU vitamin D3 or 6400
IU vitamin D3 daily (N= 10 after loss to follow-up and breastfeeding attrition). Women
in group 1 receiving 400 IU vitamin D3 daily were assigned to give their infant 300 IU
vitamin D3 by liquid drop each day, and women in group 2 gave one drop of liquid
placebo to their infant each day. This regimen was continued for 6 months after
enrollment. The two groups did not differ in demographics or adherence to protocol,
with about 80% compliance with maternal vitamin supplementation and 61% compliance
with infant vitamin supplementation. Results showed that women taking vitamin D3 400
IU per day had 25[OH]D levels slowly decrease over the first 5 months of the study and
then increase slightly as increased sun exposure was experienced for the last 2 months.
Women in group 2 had dramatic increases in 25[OH]D levels (mean of 34.0 ng/mL at
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enrollment to mean of 58.8 ng/mL 6 months later) that stabilized around month 3 and
were maintained over the course of the study. Women receiving only the vitamin D 400
IU daily had the vitamin D content of their milk slowly decrease over the study period
but with little variation. The women receiving vitamin D3 6400 IU daily had a 10 fold
increase in the amount of vitamin D in their breast milk (82 to 873 IU per liter). This
resulted in their infants having a steady rise in circulating 25[OH]D levels nearly
equivalent to the infants receiving vitamin D 300 IU directly via supplementation. This
study demonstrates that infants can receive doses of vitamin D through breast milk that
are equivalent to oral dosing of 300 IU per day. This study was limited by very small
sample size, but regardless was able to demonstrate a tremendous improvement in breast
milk antirachitic activity with high dose maternal supplementation. This improvement
would only be enhanced by earlier maternal supplementation in order to reach
appropriate serum 25[OH]D levels in the mother earlier in the breastfeeding relationship.
In 2006, Basile, Taylor, Wagner, Horst, and Hollis randomized lactating mothers
at 1 month postpartum to receive vitamin D3 2000 IU (N= 12) or 4000 IU (N= 14) daily
for 3 months. Because one of the early signs of hypervitaminosis D can be
hypercalcemia, the authors sought to determine if high dose vitamin D could possibly
cause excessive calcium to be transferred to breast milk. Outcome measures included
serum 25[OH]D in mother and baby as well as serum calcium and breast milk calcium
levels. There were no incidences of hypercalcemia in mothers or infants and no episodes
of hypercalciuria in mothers. The authors found that both groups had increase in serum
25 [OH] D levels in both mother and baby, and there was no significant difference in
milk calcium levels or serum calcium levels. Enrollment maternal mean 25[OH]D level
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was 22.4 ± 8.8 ng/mL in the 2000 IU group and 28.5 ± 8.6 ng/mL in the 4000 IU group.
Both the 2000 IU group and the 4000 IU group had significant increase in mean
25[OH]D levels to 33.9 ± 6.5 ng/mL and 43.0 ± 11.6 ng/mL, respectively. Infants of
mothers in both groups had significant increases in circulating 25[OH]D. Infants of
mothers in the 2000 IU group went from a mean 25[OH]D level of 7.8 ± 1.1 ng/mL to
27.8 ± 3.9 ng/mL after 3 months of maternal supplementation. Infants of mothers in the
4000 IU group also had significant change from a mean 25[OH]D of 13.4 ± 3.3 ng/mL to
30.8 ± 5.0 ng/mL. The findings from this study demonstrate that over a 3 month period
of time, doses of 2000 IU and 4000 IU daily do not raise 25[OH]D serum levels high
enough to produce any markers of toxicity. The mothers in the vitamin D 4000 IU per
day group increased their serum and milk 25[OH]D levels significantly more than the
women in the vitamin D 2000 IU per day group and the infants of mothers receiving
vitamin D 4000 IU per day displayed significantly higher 25[OH]D serum levels by the
end of the study.
In 2009, Saadi et al. undertook a larger study involving 90 breastfeeding women
in the United Arab Emirates (UAE). Women were randomly assigned to receive vitamin
D2 2000 IU daily (N= 45) or 60,000 IU monthly (N= 45). All infants were supplemented
with vitamin D2 400 IU daily for three months. Because of the difference in group
supplementation schedule, this study was not blinded to researchers or participants. The
mothers and their babies had enrollment 25[OH]D levels measured at entry to the study
and monthly before administration of their next monthly dose, with a final 25[OH]D level
measured after the 3 month period. Infants had a second 25[OH]D measurement at the
end of the 3 month study. The authors set the vitamin D deficiency level at ≤ 15 ng/mL
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(≤ 37.5 nmol/L) based on two older reports regarding physiologic measures. Enrollment
25[OH]D levels were available on 92 infants (two sets of twins) and revealed 95%
deficiency. Mothers had an 88% deficiency, even with the extremely low cut off value
mentioned above. After 3 months of their assigned regimens, the infants had drastically
increased their mean serum 25[OH]D levels, however 23% in the daily regimen group
and 38% in the monthly regimen group still met the definition of deficiency. Circulating
vitamin D levels in the mothers had shown improvement as well, but 36% of the daily
regimen group and 50% of the monthly regimen group continued to meet the definition of
deficiency. The researchers were also able to analyze vitamin D levels in the breast milk
of 8 women. Levels were undetectable at the beginning of the study and increased to a
median of 50.9 IU/L. Although this study concluded that significant increases were seen
in both maternal and infant serum vitamin D levels, the increases were not sufficient over
the 3 month study period to correct a majority of the deficiency seen, especially if more
contemporary deficiency cutoffs were used. This study was limited by the use of vitamin
D2 for supplementation, which is less effective at raising serum 25[OH]D levels
(Heaney, Recker, Grote, Horst, & Armas, 2011).
It is clear from these randomized trials that lactating women receiving what are
considered high doses of vitamin D have an increase in their serum 25[OH]D levels,
increases in the vitamin D content of their breast milk, and their infants have subsequent
increases in serum 25[OH]D levels. In a recent letter to the editor of Public Health
Nutrition, Hollis and Wagner (2011) speak to the issue of vitamin D supplementation
efficacy during lactation (Hollis & Wagner, 2011). They extrapolate from the existing
data that for every 25 µg (1000 IU) of vitamin D ingested by the mother she will pass 2.5
59

µg (100 IU) of vitamin D to her breastfeeding infant. The linear relationship between
maternal vitamin D intake and vitamin D transferred through breast milk in a 10 to 1 IU
ratio was also shared by Dr. B.W. Hollis during a study design consultation (personal
communication, September 21, 2010). Therefore, they argued if a woman receives 150
µg (6000 IU) daily of vitamin D, she will be able to replete herself and provide about
12.5 µg/L (500 IU per liter) of vitamin D to her infant. One liter would be a typical
amount of breast milk for an infant to ingest in 24 hours. Hollis and Wagner (2011)
reiterate that these doses have been used in several studies and there have been no
adverse events. This speaks to the efficacy and safety of high dose vitamin D in lactating
women and their exclusively breastfed infants. The reviewed studies are somewhat
limited by sample size or lack of diversity amongst participants, however no adverse
events or markers of toxicity were seen, which does bolster confidence in the safety of
these doses. Studies with more participants and over longer periods of time are necessary
to make further conclusions about efficacy and safety. It will also be critical to
investigate the outcomes seen with vitamin D supplementation started during pregnancy
and continued through lactation.
Gap in Knowledge Regarding Vitamin D Transfer Through Breast Milk
This study was designed to generate novel evidence regarding the effect of
maternal supplementation during pregnancy and lactation on the resultant maternal and
infant serum vitamin D levels. As described above, prior research has focused either on
supplementation with vitamin D during pregnancy or during lactation, but studies
spanning these two stages could not be found. This research study is innovative in its
approach to start supplementation during pregnancy with the hypothesis that both
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pregnant women and newborns will benefit from this longer term supplementation.
Additionally, due to the extent of vitamin D deficiency, more time is needed for serum
levels to reach adequacy before participants will be able to transfer adequate vitamin D
through breast milk. Many of the studies presented above enrolled fewer than 20
participants and were able to document statistically significant relationships.
Additionally, no studies investigating the impact of vitamin D supplementation on
inflammatory cytokine production in vivo were identified. This study provides novel
evidence of the effect of maternal vitamin D status on maternal inflammatory response.
This study helps develop the growing body of knowledge regarding treatment of vitamin
D deficiency and has the potential to generate evidence to support changes to the current
recommendations for maternal and infant supplementation with vitamin D.
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CHAPTER III
METHOD
Introduction
A gap in knowledge exists regarding adequate doses of maternal vitamin D
supplementation during pregnancy and lactation that yield adequate infant serum
25[OH]D levels. The objective of this study is to identify the effect of continuous
maternal prenatal and postnatal vitamin D supplementation on maternal 25[OH]D status
and vitamin D transfer to exclusively breastfed infants through breast milk as evidenced
by infant 25[OH]D status. The methodology used for this study including research
design, study intervention, population and sampling, protection of human subjects, data
collection, laboratory methods, statistical methods and analytic plan are described in this
chapter.
Objectives and Hypotheses
The primary objectives of this study were to evaluate the effect of maternal
vitamin D supplementation initiated during the third trimester and continued through
early lactation on: 1. maternal 25[OH]D levels at delivery, 2. infant 25[OH]D levels at
birth, and 3. both maternal and infant 25[OH]D levels at 4-6 weeks of lactation in
exclusively breastfeeding dyads. To meet this objective, the following hypotheses were
tested:
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Central Hypothesis: Maternal supplementation with vitamin D during pregnancy and
lactation will significantly increase circulating vitamin D levels during lactation in
mothers and their exclusively breastfed infants;
1. Women who receive supplemental vitamin D starting in the early third trimester
of pregnancy will have significantly higher 25[OH]D serum levels compared to
control participants by delivery;
2. Women who receive supplemental vitamin D starting in the early third trimester
of pregnancy and continue with this dosing during the early postpartum will
maintain significantly higher serum 25[OH]D levels than control participants
during lactation;
3. Infants born to women who receive supplemental vitamin D starting in the early
third trimester of pregnancy will have significantly higher 25[OH]D levels at birth
compared to control infants;
4. Infants who exclusively breastfeed from a mother receiving supplemental vitamin
D will have significantly higher 25[OH]D levels than infants exclusively
breastfeeding in the control group at 4-6 weeks of age.
Due to immune and inflammatory modulating effects of vitamin D, the following
secondary hypotheses were tested:
1. Women with higher vitamin D levels will have decreased levels of proinflammatory cytokines (TNF-α and IL-6);
2. Women with higher vitamin D levels will have increased levels of an antiinflammatory cytokine (IL-10).
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Research Design
This study used a double blinded randomized controlled trial design. This design
was chosen in order to test the effect of vitamin D supplementation on maternal and
neonatal vitamin D status during pregnancy and lactation. A randomization scheme was
used in order to generate two comparison groups (control and experimental) of
approximately the same size in a 1:1 ratio (Moher et al., 2010). Randomization was
achieved with the use of computer software provided by statistical consultant Dr. David
Roth and monitored by Dr. Jody Ralph, a member of the dissertation committee and data
safety monitoring board. Allocation concealment was used during the recruitment
process. Prior to initiation of participant enrollment, Dr. Jody Ralph created enrollment
packets that contained the necessary paperwork, blood tubes, and study pills
corresponding to the random assignment, all labeled with participant numbers. After
agreeing to participate and providing informed consent, participants were linked to the
group assignment based on order of recruitment. The list of corresponding participant
codes associated with predetermined group allocations was kept in a locked cabinet with
Dr. Jody Ralph at the University of North Dakota in Grand Forks, North Dakota. All
members of the research team, as well as the participants, were blinded to participant
group assignment.
Protection of Human Subjects
This study received Institutional Review Board (IRB) approval through the
University of North Dakota (UND) and Altru Health System (Appendix A). Several
changes to the study protocol were made and implemented after approval by both IRB
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entities. An IRB Authorization Agreement was provided between UND and Oregon
Health and Science University, the PI’s employer (Appendix A).
Participants received both verbal and written study information. This included
reassurance that they were under no obligation to participate and lack of participation
would not change the course of their medical care. Support for the study was provided
by the clinic where recruitment took place (Appendix B).
A Data Safety Monitoring Board (DSMB) was created and included Dr. Elizabeth
Tyree, Dr. Jody Ralph, Dr. Leah Whigham, and Dr. Edward Sauter. Dr. Jody Ralph
reviewed 25[OH]D results as a member of the DSMB in order to implement steps to
assure participant safety. The DSMB received a quarterly report from the PI, which
included an update on participant recruitment and study procedures. The DSMB was
notified immediately upon knowledge of any adverse event. In the case of potential
adverse events, both IRB entities were also officially notified and provided with the
DSMB’s report. Enrollment maternal 25[OH]D serum levels were reviewed by the PI
and data from subsequent collection periods were reviewed by Dr. Jody Ralph thereafter
to preserve PI blinding. Any 25[OH]D serum level equal to or exceeding 90 ng/mL was
reported to the DSMB. At that time, the participant would be asked to exit the study with
follow-up evaluation of serum 25[OH]D level in one month.
Population and Sampling Procedures
Subjects for this study were recruited from an obstetrical practice serving local
and surrounding communities of Grand Forks, North Dakota. All patients receiving care
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from this practice planned to deliver at Altru Health System in Grand Forks, North
Dakota, which has about 1500 deliveries per year, with a majority coming from this
obstetrical practice. Prior studies completed with participants engaged in care through
this practice demonstrated the sample population would be comprised of 81% Caucasian,
7% Native American, 4% African American, 2% Asian, 3% Latina, and 3% multi-racial
women (C.M. Anderson, personal communication, June 1, 2012). All participants
continued to receive routine care with their physicians or nurse practitioners during their
pregnancy, intrapartum and postpartum periods.
Advertisements for the study were placed in several locations in the obstetrical
clinic (Appendix C). Women who wished to participate were able to contact the PI
directly to be evaluated for meeting inclusion and exclusion criteria. Additionally, key
clinic staff were contacted every weekday morning to determine if there were potentially
eligible patients who were scheduled for prenatal visits that day. The clinic personnel
were able to determine if clients met the basic requirements of gestational timing in
pregnancy and parity status of 1 or greater. When a potential participant was identified,
she was met at her prenatal visit and introduced to the study to determine interest. If the
participant was interested, a full discussion was initiated regarding requirements of the
study, rights of the participant, and evaluation for meeting inclusion and exclusion
criteria. The advertisement notified women that they were eligible to receive up to 40
dollars in incentive gift cards (10 dollars at delivery and 30 dollars at the final lactation
visit) upon completion of the study. Incentive payment information was reiterated in
verbal communications prior to informed consent.
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Inclusion criteria were: pregnancy between 24 and 28 weeks, history of
breastfeeding for at least 4 weeks with a prior infant, intent to breastfeed for at least 4-6
weeks, and maternal age greater than 18. Starting the intervention in the early third
trimester allowed for enough time to elicit a full effect in the mean 25[OH]D levels of
the intervention group by the time participants delivered and simultaneously kept the
length of the study feasible (Heaney & Holick, 2011; Hollis & Wagner, 2011). The study
was limited to participants who have previously breastfed to diminish the high rate of
attrition due to failure to breastfeed, which can exceed 50% in women who have never
breastfed before. Additionally, women who were recruited planned to breastfeed
exclusively for 4-6 weeks as this was essential to determining the transfer of vitamin D
through breast milk only without outside sources of vitamin D in the newborn’s diet.
Participants were at least18 years old in order to negate any differences in calcium and
vitamin D physiology inherent in adolescent woman (Jamali et al., 2013). Exclusion
criteria include: preexisting type 1 or type 2 diabetes, preexisting hypertension,
parathyroid disease, uncontrolled thyroid disease, and use of vitamin D supplements
beyond a prenatal vitamin in the last 6 months (Hollis & Wagner, 2004b; Wagner et al.,
2006). Women with underlying metabolic disorders as listed above were excluded due to
confounding effects of medications they may be taking along with possible underlying
disruptions in their ability to metabolize vitamin D. Women who might be medically
fragile, such as those with hypertension, were excluded to limit the possibility that
vitamin D supplementation would interfere with medical care. In order to properly
monitor and protect participants from vitamin D toxicity and to compile a typical
population sample, women who were already taking vitamin D supplementation beyond
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that found in a typical prenatal vitamin were excluded. Exclusion criteria for the infants,
which would have excluded an infant from continuing in the study, included birth prior to
37 weeks gestation, admission to the neonatal intensive care unit for any reason, or
congenital anomaly that prevented exclusive breastfeeding.
Based on data from previously published studies for the primary outcome of
infant 25[OH]D at 4-6 weeks lactation, a sample size of 14 participants, equally divided
between the intervention and control groups, was needed to detect a mean difference of 8
ng/mL with a standard deviation of 5, using alpha = 0.05 and assuming 80% power
(Basile et al., 2006; Hollis & Wagner, 2004b; Hollis et al., 2011; Saadi et al., 2009;
Wagner et al., 2006). A total of 8 women were recruited in each arm of the study in order
to achieve a total sample size of 16, adequate to offset loss to follow-up.
Study Intervention
The study intervention included two groups, the control and experimental groups,
as illustrated in Figure 3. Participants in both groups received a prenatal vitamin (Target
brand, Minneapolis, MN) containing a complement of vitamin and mineral supplements
including 400 IU of vitamin D3 (cholecalciferol). In addition to the prenatal vitamin,
control group participants received a compounded microcrystalline vegetable cellulose
filled placebo capsule. Experimental group participants received the same prenatal
vitamin with an additional compounded capsule containing microcrystalline vegetable
cellulose plus 3400 IU vitamin D3. The experimental group therefore received a total of
3800 IU vitamin D/day. Both the prenatal vitamin and the study capsule were taken daily
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from initiation at 24-28 weeks gestation through 4-6 weeks postpartum. All
compounding was provided by InHealth Specialty Pharmacy, Fargo, ND. InHealth is
licensed and accredited by the North Dakota Board of Pharmacy.

Figure 3. Study intervention time line and data points.
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Although an intake of 600 IU daily is recommended by the Office of Dietary
Supplements of the National Institutes of Health for all pregnant women, the study team
could not locate a prenatal vitamin that contained this dose, therefore a supplement
containing 400 IU was used (Table 4).
Table 4. Nutrient content of the prenatal vitamin received by all participants.
Nutrient
Amount
Percent of Daily Allowance
Vitamin A (100% as Beta

4000 IU

50

Vitamin C

120 mg

200

Vitamin D

400 IU

100

Vitamin E

30 IU

100

Thiamin

1.8 mg

106

Riboflavin

1.7 mg

85

Niacin

20 mg

100

Vitamin B6

2.6 mg

104

Folic Acid

800 mcg

100

Vitamin B12

8 mcg

100

Calcium

200 mg

15

Iron

28 mg

156

Zinc

25 mg

167

Carotene)
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The placebo pill used in the control group was indistinguishable in appearance
from the additional vitamin D capsule used in the experimental group (Figure 4). This
allowed for continuous blinding of study team members and participants.

Placebo Capsule

Experimental Capsule

Figure 4. Photo demonstrating similarity of capsules used for the control and
experimental groups.

Study Procedures
After being identified as a potential participant by the clinic personnel, women
were approached by a study team member and the study explained. The study team
consisted of Doria K. Thiele, MN, CNM, IBCLC and PI on the study, Dr. Cindy M.
Anderson, PhD, WHNP-BC, FAAN and chair to the PI’s dissertation committee, and
Michelle Wright, RN, PhD Candidate. All study team members completed human
subjects training through University of North Dakota. When a woman indicated interest
in participation, full informed consent was provided verbally and the participant was
given time to read the Consent to Participate and Authorization for Access to Personal
Health Information documents (Appendix D). Participants had the opportunity to ask
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questions and discuss the study procedures and timing. Both the Consent to Participate
and Authorization for Access to Personal Health Information documents were then
signed in duplicate to provide one set for the participant to keep and one to be retained
for study records. Participants were encouraged to call the PI at any time with concerns
or questions and contact information was provided on the Consent to Participate.
All participants were recruited during the same season, summer 2012, thus
removing season as a confounding factor in the study. Season can have a significant
effect on maternal and newborn vitamin D status due to variation in sun exposure and
angle of UVB light (Eichholzer et al., 2013; Halicioglu et al., 2012; Seckmeyer et al.,
2013; Utrillas et al., 2013). The timing of participant recruitment was coordinated with
routine blood sample collection for screening of gestational diabetes. Women who
consented to participate were accompanied to the laboratory where further discussion
took place. The gestational diabetes screening test includes an hour of waiting time and
allowed for the time needed to complete a Food Frequency Questionnaire (FFQ,
Appendix E) to assess for dietary vitamin D intake, as well as answer questions and
establish rapport. Random assignments were predetermined so that the correct study pills
and blood collection tubes were used at the recruitment visit with the participant.
Participants were shown their study pills and prenatal vitamins and their proper use was
explained. When maternal venipuncture for the routine screening tests was underway,
additional blood was collected in study-provided blood tubes. Please see section Blood
Collection for details on these methods and procedures.
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The PI contacted participants 2 weeks after recruitment to assess for compliance
with the study intervention including daily ingestion of a prenatal vitamin and assigned
study capsule and to be available for questions to be answered. Prenatal vitamins were
provided in 90 day supply and study pills were provided in a 30 day supply. Participants
were met at their prenatal visits at approximately 32 weeks, 36 weeks, and at delivery in
order to exchange their previous study pill bottle for a new study pill supply. Participants
were told to bring their study pill bottle with any remaining pills at each meeting so that
compliance could be monitored. After each in-person meeting, the participant was
contacted by the PI about 2 weeks later for another assessment of intervention
compliance and to answer questions. This scheme allowed for every 2 week contact with
participants, which supported participant compliance and intervention fidelity.
Participants were provided with a small slip of paper to take to the hospital when
they were in labor that allowed hospital staff to identify them as a participant in the study.
This slip of paper had a sunshine printed on it, as well as study team contact information,
but no other identifying information to maintain privacy and confidentiality. The hospital
staff notified the researcher that the participant was in labor. It was then arranged for the
participant and her infant to have their blood draws completed approximately 24 hours
after delivery. The participant was visited by a study team member while still in the
hospital and provided another 30-45 day supply of study pills and prenatal vitamins. The
number of pills provided was determined by when the final visit was scheduled. If the
participant was finishing her study pills prior to the 4-6 week postpartum visit extra pills
were mailed to her with her permission. Participants were instructed to continue to take
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their assigned supplements daily through 4-6 weeks postpartum. The participant was also
provided with the Infant Intake Tool (IIT, Appendix F) along with instructions as to how
to record any formula or vitamin D supplement given directly to the infant for the next 46 weeks.
Participants were contacted by the PI two weeks after delivery to assess for both
compliance with the study intervention and exclusivity of breastfeeding. During this
conversation, the PI and participant discussed scheduling for final data collection visit at
4-6 weeks after delivery. At the time of the meeting for final data collection at the Grand
Forks Human Nutrition Research Center (GFHNRC), maternal and infant blood samples
were collected and the participant completed a second FFQ.
Data collected included maternal dietary intake via a FFQ at enrollment and
lactation, maternal prenatal health parameters via the Record Retrieval Form (RRF,
Appendix G), intrapartum and postpartum health parameters for mother and infant via the
Postpartum Record Retrieval Form (PRRF, Appendix H), and infant supplementation
with formula and vitamin D via the IIT. In addition, blood was collected to assess for
maternal 25[OH]D, and cytokine (TNF-α, IL6, and IL10) levels at enrollment, delivery,
and lactation, while infant blood was collected to assess 25[OH]D levels at delivery and
lactation (Figure 3). Specific approaches to data collection including tools used are
outlined in proceeding sections.
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Instrumentation
Maternal Prenatal and Postnatal Dietary Intake
A FFQ was completed by each participant at entry to the study and at 4-6 weeks
postpartum in order to assess maternal intake of foods containing vitamin D. The FFQ
was developed by GFHNRC staff and patterned after the Harvard Service FFQ format
(Suitor, Gardner, & Willett, 1989). Reliability and validity testing have not been
completed on the FFQ, however other published studies have used the same form for
quantification of maternal dietary intake (Swensen, Harnack, & Ross, 2001; Tande et al.,
2012). The FFQ includes individually described food items. The participant indicated
how often she ate that food in the previous 3 months. Serving sizes were indicated such
as “milk, 8 fluid ounces” or “whole wheat bread or rolls, 1 slice”. All food items on the
FFQ are matched to food codes from Release 24 of the USDA Nutrient Database for
Standard Reference (U.S. department of agriculture, agricultural research service. 2011.
USDA national nutrient database for standard reference, release 24.2011) or the USDA
Food and Nutrient Database for Dietary Studies 5.0, which are linked with the GFHNRC
GRAND nutrient database (Ahuja et al., 2012). The GRAND nutrient database allowed
for conversion of foods consumed on a monthly or weekly basis to an average daily
consumption and then analyzed for nutrient content.
Maternal and Newborn Health Parameters
An RRF was used to collect data on maternal health status from the medical
record began at enrollment to the study. The PI arranged access to participant health
records with the administration of the Altru Health System Medical Records Department.
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A designated computer was used to access health records, which had the necessary
software and safety features required by Altru. Access to participant health records was
limited to only information that pertained to this study and was limited in time to extend
from time of enrollment to just after delivery. Data collected with the RRF included
obstetric history, history of medical conditions, current medications and supplements,
typical parameters from prenatal visits such as blood pressure and weight, and results
from screening tests such as initial urine and blood screens. The RRF also included
sections for recording additional laboratory tests that would be completed by the
participant’s obstetric provider if the participant was diagnosed with complications of
pregnancy, as well as areas to record fetal surveillance if that were necessary.
After delivery, a PRRF was used to gather pertinent data about maternal and
infant health. PRRF data were collected by the PI using the electronic access described
above. The PRRF included data regarding labor and delivery outcomes for participant
and infant, maternal diagnoses since delivery, infant diagnoses since delivery, infant
anthropomorphic measures, and breastfeeding status while in the hospital.
The IIT was designed to record newborn dietary intake other than breast milk to
include formula and supplements. Participants were asked to document a daily recording
of their infant’s formula or vitamin D intake from birth through 4-6 weeks of age.
Because formulas contain vitamin D and participants were encouraged to follow the AAP
guideline regarding infant supplementation with daily vitamin D, this instrument
provided data to quantify infant vitamin D intake from non-breast milk sources.
Blood Collection and Processing
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Blood samples were collected from the mother via venipuncture at enrollment,
delivery, and lactation. Whenever possible, venipuncture samples were collected in
conjunction with other routine laboratory analyses that were a typical part of prenatal and
postpartum care. The enrollment blood samples were collected by staff at the clinic
laboratory utilized by the obstetric practice in conjunction with laboratory tests routinely
ordered at 24-28 weeks of gestation. After signing the Consent to Participate
documentation and discussing the study, participants were accompanied to the laboratory
for their blood draw. The laboratory technician was provided with four additional 6mL
blood tubes (Fisher Scientific, New Hampshire). These additional tubes included two
ethylenediaminetetraacetic acid (EDTA) coated purple top vacutainer tubes and two
serum separator red top vacutainer tubes. The EDTA coating on the purple top tubes
stops the coagulation process. Samples collected in EDTA coated vacutainer tubes were
put on ice until sample preparation. The serum separator red top tubes are used to form a
clotted sample and these samples are stable at room temperature. Samples were allowed
to separate prior to sample preparation. Appropriate universal precautions were used for
blood handling and transport. The blood collection tubes were taken to the GFHNRC for
processing. Blood samples were centrifuged at 3000rpm for 10 minutes at 4°C.
Centrifugation allowed for separation of the serum and plasma from the whole blood. A
range of 0.5-1.0mL of serum was removed from the red top tubes and placed into 8
individual 2mL Eppendorf cryotubes. Plasma was removed in 1mL volumes from the
EDTA purple top tubes and aliquoted into 2mL labeled Eppendorf cryotubes. The
Eppendorf cryotubes were labeled with the participant number and sample source and
stored at -80°C.
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At delivery, blood collection was completed by Altru Hospital staff. The
maternal samples were collected via venipuncture using study supplied blood tubes and
processed as described previously. Infant blood samples were collected via heel stick.
The heel was warmed using study supplied infant heel warmers (VWR Scientific,
Bridgeport, NJ). Once the heel was warmed, a newborn lancet (BD, Franklin Lakes, NJ)
was used to puncture the skin at no more than 1.0mm depth. Hospital staff was supplied
with pediatric EDTA purple top and serum separator red top tubes, each holding a
maximum of 500µL (Fisher Scientific, New Hampshire). Each infant had blood samples
collected in 1 EDTA purple top pediatric tube and 1 to 2 serum separator red top pediatric
tubes at the time of routine metabolic screen, when possible. The purple top pediatric
tubes were put on ice and all samples were immediately transported to the GFHNRC for
processing and storage. All pediatric tubes were spun at 3000rpm for 10 minutes at 4°C.
Volumes of 0.5mL serum were aliquoted into 2mL Eppendorf cryotubes. All samples
were appropriately labeled with participant code and stored at -80°C. The final blood
collection at lactation for both maternal participants and infants took place at the
GFHNRC. Maternal participants completed the second FFQ and returned the IIT.
Maternal and infant participants had blood collected for serum and plasma collection as
previously described. Blood samples were collected, processed and stored as outlined
previously.
Laboratory Analyses
Maternal and Infant 25[OH]D Laboratory Methods
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Maternal and infant blood samples were processed and stored at the GFHNRC as
described previously. Maternal samples were batch analyzed at regular intervals using
the Immunodiagnostic Systems Ltd (IDS) 25-Hydroxyvitamin D enzymeimmunoassay
(EIA) kit. Frequent analysis allowed for data safety monitoring regarding serum
25[OH]D status.
The IDS-EIA kit system was analyzed on the NexGen platform by Dr. Holly
Brown-Borg’s lab in the department of Pharmacology, Physiology & Therapeutics,
School of Medicine and Health Sciences at the University of North Dakota (Dr. Holly
Brown-Borg, Dr. Lalida Rojanathammanee, and Ms. Sharlene Rakoczy). For each
sample, 25 µl of serum was added to 1 mL of a biotin solution, which acts to dissociate
the vitamin D from its binding proteins. Samples were then placed in an antibody coated
plate and incubated for 2 hours. The NexGen automated platform washed the samples
with a peroxidase solution for binding with the biotin complex. Color was developed
using a chromogenic substrate and the absorbance of each well measured at 450 nm. IDS
reports a correlation coefficient (r) of 0.9 when compared to a recognized
radioimmunoassay. This method is considered comparable in sensitivity and accuracy to
radioimmunoassay, but without the technical expertise and use of radioactive solutions
needed to run the radioimmunoassay (Kimball & Vieth, 2007; Wallace, Gibson, de la
Hunty, Lamberg-Allardt, & Ashwell, 2010). This method is also approved and
monitored by the Federal Drug Administration (FDA).
Maternal Inflammatory Markers
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Maternal samples were also analyzed for inflammatory markers including TNF-α,
IL6, and IL10. All inflammatory markers were analyzed using the enzyme-linked
immunosorbent assay (ELISA) method. Analysis included use of the Quantikine High
Sensitivity ELISA for IL-10, IL-6 and Quantikine ELISA for TNF-α (R & D Systems,
Minnesota). All sample values are reported in picograms/mL (pg/mL). Plasma was
batch analyzed for cytokines at the end of the study to minimize variability. The specific
assay procedures for the three analyses were identical except for variation in amounts of
solution added and the wavelength used for determination of optical density as the last
step in the process; therefore, the procedures will be described here as representative of
all three assays. The assay procedures include first creating a normal curve using the
standards provided by the manufacturer. This allows for laboratory standardization and
calibration for result analysis. For all three assays a normal curve was created to compare
samples against. Plates were prepared and included a diagram for recording placement of
specific participant samples. Each well in the plate is prepared with the appropriate assay
diluents to which either standard, control, or sample is added. The plates are then
incubated at room temperature for 2 hours. After the incubation period, the wells are
aspirated of fluid and precisely washed with the wash buffer. Each well is then applied
with the corresponding conjugate (TNF-α, IL-10, or IL-6) and again incubated for 2
hours. At the end of the incubation period, substrate solution was added followed by a 1
hour incubation, and addition of amplifier solution (IL-10 and IL-6 only). Each well is
then exposed to a stop solution that stops the reaction and causes a visible color change
indicating appropriate chemical processing. The plates are then read on the NextGen
Bioplex using 490 nm wavelength for IL-10 and IL-6 and 450 nm wavelength for TNF-α.
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Most samples were run in triplicate, although for IL-10 some samples were run in
duplicate and in single due to lack of well space in the plate.
Data Analysis
The data gathered on the FFQ, RRF, PRRF, IIT, and blood analysis data were
entered into IBM SPSS Statistics version 21 by the PI. Data collected from instruments
including, but not limited to, baseline maternal characteristics, characteristics of labor and
delivery, dietary intake, and newborn characteristics were tested for normality. The
intention-to-treat model was used throughout. Mean values for maternal characteristics at
enrollment, including 25[OH]D level, were compared between the control and
intervention groups to analyze for selection bias. Descriptive statistics including mean
and variance measures (standard error of the mean/standard deviation), were computed
for maternal and infant 25[OH]D level at enrollment, delivery, and lactation, and for
maternal inflammatory markers at enrollment, delivery, and lactation. Interaction and
treatment effects between group allocation and 25[OH]D level were determined by
independent samples t-tests and Analysis of Covariance (ANCOVA) while adjusting for
maternal enrollment 25[OH]D level. ANCOVA included estimated marginal means and
standard error of the mean. The estimated marginal means describe what the means
would have been if a covariate had not had an influence on the outcome. In this case, the
enrollment values were controlled for as the covariate. Repeated measures ANCOVA
was used to determine the impact of the intervention across the entire study period while
controlling for maternal enrollment 25[OH]D level. Cytokine data were analyzed by
ANCOVA, controlling for the influence of enrollment cytokine value by removing it as a
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covariate. Additionally, likelihood of participants and infants to achieve a significant
25[OH]D level at delivery and lactation was calculated as a relative benefit increase.
Significance was established at p ≤ 0.05.
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CHAPTER IV
RESULTS
Introduction
This study aimed to quantify the transfer of vitamin D from mother to exclusively
breastfed infant by evaluating the relationship between maternal and infant 25[OH]D
serum levels, using a randomized controlled trial design. Participants were assigned to
either the experimental or control group, receiving a total of 3800 IU of vitamin D or 400
IU of vitamin D, respectively. This chapter includes the findings of statistical analyses
completed on the study data and is organized in terms of the four research hypotheses and
two secondary hypotheses. The results of enrollment demographic data are presented,
followed by results related to individual hypotheses.
Trial Profile and Participant Progression
The study protocol dictated the course of the study and participants were tracked
to determine adherence to the study protocol and desire to continue the study. As
described by Moher et al. (2010), consistency in reporting findings from randomized
controlled trials will improve understanding of such studies and improve future use of
this study design (Moher et al., 2010). In order to provide consistent reporting of
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findings, the recommendations from the Consolidated Standards of Reporting Trials
(CONSORT) have been followed (Figure 5). Of the 20 women identified by clinic staff
as eligible, 2 declined to participate and 2 did not meet inclusion criteria. The remaining
16 eligible participants who elected to participate were randomly assigned to either the
experimental or control group (N=8/group). After enrollment, one participant in the
control group was taking daily cod liver oil. Cod liver oil can contain over 1000 IU of
vitamin D per teaspoon, which is in excess of that found in a prenatal vitamin thus
disqualifying this individual from participating in the study. The reason for exclusion
was discussed with the participant and she exited the study. Additionally, one participant
from each group exited the study prior to initiating the intervention; one was moving out
of state and the other did not give a reason. Therefore, 6 participants in the control group
were followed through delivery and 7 participants in the experimental group were
followed through delivery. Three participants in the control group failed to appear for
their final visit. Follow up visits were scheduled at the convenience of participants. The
participants that failed to keep appointments for final visits did not respond to attempts to
reschedule. All 7 participants in the experimental group attended the final visit.
Therefore, a total of 3 women in the control group and 7 women in the experimental
group completed the intervention by remaining in the study through lactation.
For all participants completing data collection at delivery and lactation, blood was
collected on maternal and infant participants. Using the intention to treat method, final
analysis was completed on 6 maternal and infant participants in the control group, and 7
maternal and infant participants in the experimental group.
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Figure 5. CONSORT statement for trial profile and participant retention. The diagram
demonstrates flow of participants and participant contact through the study as
recommended by Moher et al. (2010).
Safety Considerations
During the course of the study, one participant experienced development of
kidney stones at 33 weeks gestation that required a 24 hour hospitalization, which was
investigated as an adverse event. Dr. Jody Ralph, unblinded member of the DSMB, was
notified and was able to determine the participant’s enrollment 25[OH]D level, which
was low-normal. During the participant’s hospital stay, her urine and blood were not
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analyzed for calcium levels. The participant notified the primary care physician of her
participation in the study. Upon discussion between a research team member and the
participant’s primary practitioner, it was determined that the incident was not related to
her study participation. Adverse event forms were sent to Altru Health System and UND
IRB entities and the DSMB was notified and provided with as much information as was
available (Appendix I). It was determined that this event was unrelated to study
participation. No participants experienced a 25[OH]D level in excess of 90 ng/mL at any
of the three data points and there were no other adverse event reports to the DSMB.
Description of Sample
Random sampling and random assignment were implemented to control for
confounders, which are assumed to occur equally in the two groups. All participants
were recruited during the same season, summer 2012, thus removing season as a
confounding factor in the study. Analysis of normality was completed on all 25[OH]D
data including evaluation of skewness and kurtosis. Data fell on a normal curve and were
evenly distributed. Because values fell on a normal curve, the data were able to be
analyzed using standard statistical methods.
Demographic data are shown in Table 5. Enrollment characteristics are reported
as mean (±SD) for the 13 participants. Enrollment variables include ethnicity, serum
25[OH]D, daily dietary vitamin D intake, season of enrollment, age, gestation at
enrollment, parity, and body mass index (BMI) at enrollment. Enrollment characteristics
were compared between the groups using independent samples t-tests. There were no
statistically significant differences in enrollment characteristics between the experimental
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and control groups at enrollment. The absence of group differences demonstrates
successful randomization in that the two groups are homogeneous allowing for
comparison and evaluation of the impact of the intervention.
All participants self-identified as white ethnicity and all were recruited in the
summer season; therefore these two characteristics were not analyzed. At enrollment,
participants were an average age of 29 (± 5.6) years and 28 (±0.9) weeks gestation. The
Table 5. Enrollment maternal characteristics.
Experimental
Variable

Total Sample

Control Group

P value
Group

25[OH]D Serum
31.87 ± 3.82

32.39 ± 3.48

31.43 ± 4.31

0.664

529 ± 186

587 ± 234

479 ± 131

0.348

Age (years)

29 ± 5.6

27 ± 5.5

30 ± 6

0.231

Parity

1.7 ± 1.4

1 ± .4

2 ± 1.8

0.202

28 ± 0.9

29 ± 1.22

28 ± 0.70

0.292

30.5 ± 7.3

28.65 ± 7.6

32.1 ± 7.2

0.426

Level (ng/mL)
Dietary Vitamin D
(IU/day)

Gestation at
Enrollment (weeks)
Body Mass Index* at
Enrollment
Descriptive statistics include mean ± standard deviation.
*Body mass index is defined as body mass in kilograms divided by height in meters
squared.
Significant differences between experimental and control groups were determined at p ≤
0.05.
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mean BMI of all participants was 30.5 (± 7.3). Overall, participants had a mean
25[OH]D level of 31.87 (± 3.82) ng/mL and average daily dietary intake of vitamin D of
529 (± 186) IU. At enrollment, 2 of the 6 control group participants had 25[OH]D levels
≥ 32 ng/mL, defined as sufficient. Three of the 7 participants in the experimental group
at enrollment had 25[OH]D levels ≥ 32 ng/mL.
Maternal and infant characteristics at delivery were analyzed (Table 6) to

Table 6. Maternal and infant characteristics at delivery.
Experimental
Variable

Total

Control Group

P Value
Group

Gestation at Delivery
39.2 ± 0.76

39.5 ± 0.66

39 ± 0.8

0.221

32.37 ± 7.3

30.68 ± 7.12

33.81 ± 7.7

0.465

3588 ± 471

3643 ± 507

3541 ± 473

0.716

20.8 ± 0.89

20.8 ± 1.2

20.75 ± 0.7

0.875

34.75 ± 1.6

34.7 ± 1.6

34.8 ± 1.7

0.875

(weeks)
Maternal Body Mass
Index* at Delivery
Infant Birth Weight
(grams)
Infant Birth Length
(inches)
Infant Head
Circumference
(centimeters)
Descriptive statistics include mean ± standard deviation.*Body mass index is defined as
body mass in kilograms divided by height in meters squared. Significant differences
between experimental and control groups were determined at p ≤0.05.
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determine differences between groups. Mean maternal delivery BMI was 32.37 (± 7.3)
and mean gestation at delivery was 39.2 (0.76) weeks. Infant characteristics showed a
mean birth weight of 3588 (± 471) grams, birth length of 20.8 (± 0.89) inches, and head
circumference of 34.75 (± 1.6) centimeters. There were no statistical differences between
the experimental and control groups on any of these outcomes.
Impact of Vitamin D Supplementation on Maternal 25[OH]D at Delivery
Hypothesis 1: Women who receive supplemental vitamin D starting in the early third
trimester of pregnancy will have significantly higher 25[OH]D serum levels compared to
control participants by delivery.
In order to test this hypothesis, a t-test of independent variables was used

Mean maternal serum 25[OH]D
(ng/ml)

comparing experimental and control group means for 25[OH]D levels (Figure 6).
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Figure 6. Influence of maternal supplementation on maternal 25[OH]D levels at delivery.
Descriptive statistics include mean ± standard deviation.
Significant differences between experimental and control groups were determined at
p≤0.05.
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Results indicate differences between groups based on group means (±SD). T-test
analysis demonstrates no statistically significant difference in maternal serum 25[OH]D
levels between the experimental and control groups (32.48 ± 10.75 vs. 24.44 ± 4.57
ng/mL, p=0.108). The difference in group means was 8.04 ng/mL, which may have
clinical implications, but was not a statistically significant finding.
However, further analysis was necessary because maternal mean 25[OH]D for a
given group is dependent on the enrollment 25[OH]D values for the participants in that
group (Table 7). In order to separate out the influence of the intervention from the
influence of enrollment 25[OH]D level, a univariate Analysis of Covariance (ANCOVA)
test was used. The ANCOVA allowed for comparison of means while controlling for the
influence of a covariate, in this case enrollment 25[OH]D level. This analysis also
produced estimates of effect size (partial eta squared) and power (observed power).
Table 7. Observed and estimated means for maternal 25[OH]D at delivery.
Estimate
Control
Experimental
P
Variable
of Effect
Group
Group
Value
Size

Observed
Power

Observed Mean
24.44 ± 4.57

32.48 ± 10.75

0.108

N/A

N/A

23.78 ± 2.94

33.05 ± 2.72

0.044

0.346

0.548

(ng/mL)
Estimated Mean
(ng/mL)
Observed mean (± SD) and estimated mean (± SEM) for maternal 25[OH]D at delivery.
Significant differences between experimental and control groups were determined at p
≤0.05.
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Additionally, ANCOVA analysis produced estimated marginal means, also called
corrected means, which are the means that would have been achieved in the two groups
had the covariate (enrollment 25[OH]D level) not had an influence. Using this technique
with the maternal data at delivery estimated means of 33.05 ± 2.72 and 23.78 ± 2.94
ng/mL were generated in the experimental and control groups, respectively, which were
statistically significant (p= 0.044).
The 2 participants who had had sufficient 25[OH]D levels at enrollment in the
control group dropped below 32 ng/mL at delivery. One of the 6 maternal participants in
the control group increased from 31 ng/mL to 32 ng/mL, thus putting her in the sufficient
category. Three of the 7 participants in the experimental group had sufficient 25[OH]D
status at delivery; two were previously sufficient and increased their 25[OH]D levels, and
one was newly sufficient at delivery. This demonstrates a 157% benefit increase of the
intervention on achieving sufficiency in maternal participants by delivery.
Impact of Vitamin D Supplementation on Maternal 25[OH]D at Lactation
Hypothesis 2: Women who receive supplemental vitamin D starting in the early third
trimester of pregnancy and continue with this dosing during the early postpartum will
maintain significantly higher serum 25[OH]D levels than control participants during
lactation.
Three of the 6 participants in the control group failed to attend the final visit for
data collection. In order to manage missing data, the last observation carried forward
method was used. Data collected on the maternal and infant participants at delivery were
91

carried forward to the lactation data point for the 3 maternal and infant participants with
missing data. In order to test the hypothesis, an independent samples t-test was used
comparing the experimental and control group means for maternal lactation 25[OH]D.
There was a significant difference in means between the experimental group and the

Mean maternal serum 25[OH]D (ng/ml)

control group at lactation (35.57 ± 8.87 vs. 22.38 ± 2.82 ng/mL, p=0.007) (Figure 7).
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Figure 7. Influence of maternal supplementation on maternal 25[OH]D level at
enrollment, delivery, and lactation.
Descriptive statistics include mean ± standard deviation. Significant differences between
experimental and control groups were determined at p ≤0.05. Mean maternal 25[OH]D
levels increased in the experimental group and declined in the control group at lactation
(p=0.007).

Using the univariate ANCOVA method outlined previously, the data for mean
maternal 25[OH]D at lactation was analyzed. This analysis produced estimated marginal
means, which describe what the means for the two groups would have been at lactation
had enrollment 25[OH]D level not had an influence. This produced a statistically
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significant result (p= 0.002). Additionally, estimated marginal means, estimates of effect
size, and observed power demonstrated a large effect size and strong power (Table 8).
There was a difference in maternal observed means of 13.19 ng/mL 25[OH]D at
lactation, which may also have clinical implications.
Table 8. Observed and estimated means for maternal 25[OH]D at lactation.
Estimate
Control
Experimental
Observed
Variable
P Value of Effect
Group
Group
Power
Size
Observed Mean
22.38 ± 2.82

35.57 ± 8.87

0.007

N/A

N/A

21.9 ± 2.48

35.98 ± 2.3

0.002

0.632

0.961

(ng/mL)
Estimated Mean
(ng/mL)
Observed mean (± SD) and estimated mean (± SEM) for maternal 25[OH]D at lactation.
Significant differences between experimental and control groups were determined at p
≤0.05.
None of the 6 control group maternal participants had sufficient 25[OH]D status
at lactation, whereas 4 of the 7 experimental group participants achieved sufficiency,
demonstrating a 688% benefit increase of the intervention on achieving sufficiency.
Additionally, mean maternal 25[OH]D level at lactation was highly correlated with mean
maternal 25[OH]D level at delivery (p< .0001), but not at enrollment (p= 0.370)
demonstrating the impact of maternal vitamin D supplementation during pregnancy.
Considering that maternal 25[OH]D serum level at both delivery and lactation is a
function of the participant’s enrollment 25[OH]D serum level, further analysis was
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undertaken to separate the impact of the intervention from the impact of maternal
enrollment 25[OH]D over the course of the entire intervention (Figure 8). In order to
achieve this, a repeated measures ANCOVA was used to determine the combined impact
of vitamin D supplementation on delivery and lactation 25[OH]D levels, while adjusting
for enrollment maternal 25[OH]D level. By using this method, it is possible to assess the
impact of the intervention over time and to estimate the means of the groups without the
impact of enrollment input. The results showed that there were no within subjects effects
(F= 1.032; P = 0.334), indicating no difference in the outcome over time. The between
groups analysis produced estimated marginal means, which indicate what the means of
the groups would have been had the covariate of enrollment not had an impact. The

Estimated marginal mean maternal 25[OH]D
(ng/ml)

estimated marginal mean (± SEM) for the experimental group was 34.52 (± 2.35 ng/mL)
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Figure 8. Estimated marginal means for maternal 25[OH]D levels. Estimated marginal
means for maternal 25[OH]D serum levels at delivery and lactation for the control and
experimental groups were significantly different (p=0.007). Significant differences
between experimental and control groups were determined at p ≤0.05.
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and for the control group was 22.84 (± 2.54 ng/mL). This was statistically significant (p
= 0.007), with estimated power of 0.857 and estimated effect size of 0.531. The
difference between estimated means was 11.68 ng/mL, which is a greater than 50%
increase between control and experimental means.
Impact of Maternal Vitamin D Supplementation on Infant 25[OH]D at Delivery
Hypothesis 3: Infants born to women who receive supplemental vitamin D starting in the
early third trimester of pregnancy will have significantly higher 25[OH]D levels at birth
compared to control infants.
A t-test of independent variables was used comparing the experimental and
control group means for infant serum 25[OH]D at delivery. There was a significant
difference in mean (± SD) serum 25[OH]D levels between infants in the experimental
group and the control group at delivery (32.33 ± 6.15 vs. 23.67 ± 5.50 ng/mL, p=0.021).
The difference in means was 8.66 ng/mL, which may have clinical implications beyond
its statistical significance. Additionally, infant mean serum 25[OH]D level was highly
correlated with maternal serum 25[OH]D levels at delivery (p = .001). In order to
separate the impact of maternal enrollment 25[OH]D levels from the impact of the
intervention, a univariate ANCOVA was used as described above. Estimated marginal
means for infant 25[OH]D at delivery were significantly different (32.57 ± 2.17 vs. 23.38
± 2.35 in the experimental and control groups respectively, p= 0.017) with a mediumlarge effect size (0.450) and fairly strong power (0.732) (Table 9).
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One of the 6 control group infants reached defined level of sufficiency and 5 of
the 7 infants in the experimental group achieved sufficient levels at delivery. This
equates to a 328% benefit increase to the infants in the experimental group.
Table 9. Observed and estimated means for infant 25[OH]D at delivery.
Estimate
Experimental
Observed
Variable
Control Group
P Value of Effect
Group
Power
Size
Observed Mean
23.67 ± 5.50

32.33 ± 6.15

0.021

N/A

N/A

23.38 ± 2.35

32.57 ± 2.17

0.017

0.450

0.732

(ng/mL)
Estimated Mean
(ng/mL)
Observed mean (± SD) and estimated mean (± SEM) for infant 25[OH]D at delivery.
Significant differences between experimental and control groups were determined at p
≤0.05.
Impact of Maternal Vitamin D Supplementation on Infant 25[OH]D at Lactation
Hypothesis 4: Infants who exclusively breastfeed from a mother receiving supplemental
vitamin D will have significantly higher 25[OH]D levels than infants exclusively
breastfeeding in the control group at 4-6 weeks postpartum.
In order to test this hypothesis, a t-test of independent variables was used
comparing experimental and control group infant data. The experimental group infants
had a mean (± SD) 25[OH]D level of 24.9 (±12.81) ng/mL and the control group infants
16.98 (±8.71) ng/mL (p = 0.216). There was a difference in means of 7.92 ng/mL, which
may have clinical implications despite the lack of statistical significance (Figure 9).
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Mean infant serum 25[OH]D (ng/ml)
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Figure 9. Influence of maternal supplementation on infant 25[OH]D levels at delivery
and lactation. Mean infant 25[OH]D levels in the experimental and control groups
demonstrating a decrease in both groups with the experimental group maintaining a mean
25[OH]D level approximately 8 ng/mL greater than the control group infants.
Significant differences between experimental and control groups were determined at p
≤0.05.
Considering that infant 25[OH]D serum level at lactation is a function of the
maternal enrollment 25[OH]D serum level, further analysis was undertaken to separate
the impact of the intervention from the impact of maternal enrollment. A univariate
ANCOVA revealed no significant difference in means (p= 0.256) with a small effect size
(0.127) and very low power (0.193). Table 10 displays these findings along with the
estimated marginal means for infant 25[OH]D at lactation.
In order to evaluate the impact of the intervention on infant 25[OH]D over the
course of the entire intervention, a repeated measures ANCOVA was used to analyze
differences in mean 25[OH]D levels between the control and experimental group infants
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Table 10. Observed and estimated means for infant 25[OH]D at lactation.
Estimate
Control
Experimental
Observed
Variable
P Value of Effect
Group
Group
Power
Size
Observed Mean
16.98 ±8.71

24.9 ± 12.81

0.216

N/A

N/A

16.99 ± 4.79

24.89 ± 4.43

0.256

0.127

0.193

(ng/mL)
Estimated Mean
(ng/mL)
Observed mean (± SD) and estimated mean (± SEM) for infant 25[OH]D at lactation.
Significant differences between experimental and control groups were determined at p
≤0.05.
at delivery and lactation, while adjusting for enrollment maternal serum 25[OH]D level.
By using this method, it is possible to assess the impact of the intervention over time
while controlling for the impact of maternal enrollment input. The results showed that
there were no within subjects effects (F= 0.166; P = 0.693), indicating no difference in
the outcome over time. The between subjects effect indicated that infants in the
experimental group achieved an estimated marginal mean of 28.73 ± 2.78 ng/mL and the
control infants 20.19 ± 3.01 ng/mL (p= 0.065). The estimated power was 0.466 with an
estimated effect size of 0.301. The overall impact of the intervention for infants at
delivery and lactation approached significance. It is of greater clinical significance that
there was a difference between estimated means of 8.54 ng/mL, with a medium effect
size of 0.3 although adequacy of power was lost.
There was no statistically significant correlation between maternal and infant
25[OH]D level at lactation (p=0.163). None of the 6 control group infants were sufficient
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and 2 of the 7 experimental group infants were sufficient at lactation, consistent with a
337% benefit increase to those infants breastfeeding from a mother receiving the
intervention.
Impact of Vitamin D Supplementation on Maternal Cytokine Production
Secondary Hypothesis 1: Women with higher 25[OH]D levels will have decreased levels
of pro-inflammatory cytokines.
Maternal means for pro-inflammatory cytokines TNF-α and IL-6 were compared
in maternal plasma between the experimental and control groups using t-tests of
independent variables. There were no significant differences between the experimental
and control groups for these pro-inflammatory markers at enrollment, delivery, or
lactation (Table 11). The mean minimum detectable dose for the IL-6 assay used was
0.039 pg/mL. All participants had values well above this mean minimum detectable
dose. The mean minimum detectable dose for the TNF-α assay used was 1.6 pg/mL. Ten
samples fell below this minimum detectable dose amount. All TNF-α and IL-6 samples
were analyzed in triplicate.
In order to evaluate the impact of maternal vitamin D supplementation
independently from the impact of maternal pro-inflammatory cytokine levels at
enrollment, TNF-α and IL-6 were analyzed using the ANCOVA method adjusting for
enrollment. When maternal pro-inflammatory cytokine TNF-α was analyzed using
ANCOVA, adjusting for enrollment TNF-α level, there was no significant difference
between the experimental and control groups in TNF-α at delivery or lactation.
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Table 11. Maternal pro-inflammatory plasma cytokine levels.
Variable

Enrollment

Delivery

Lactation

TNF-α

Control

4.45 ± 6.88

12.63 ± 12.11

6.35 ± 8.28

(pg/mL)

Experimental

3.01 ± 3.10

12.36 ± 13.58

8.69 ± 8.78

IL-6

Control

6.99 ± 3.94

5.27 ± 1.81

11.10 ± 6.45

(pg/mL)

Experimental

5.47 ± 1.85

4.08 ± 3.39

14.57 ± 6.60

Mean (± SD) maternal plasma TNF-α and IL-6 at enrollment, delivery, and lactation for
the control and experimental groups were not significantly different.
Significant differences between experimental and control groups were determined at p
≤0.05.
When maternal pro-inflammatory cytokine IL-6 was analyzed using ANCOVA,
adjusting for enrollment IL-6 level, there was no significant difference between the
experimental and control of IL-6 at delivery or lactation. This demonstrates that maternal
vitamin D supplementation did not impact the production of these circulating proinflammatory cytokines.

Secondary Hypothesis 2: Women with higher 25[OH]D levels will have increased levels
of an anti-inflammatory cytokine.
In order to test this hypothesis, t-tests of independent samples were used to
compare the group means of the anti-inflammatory cytokine IL-10 in the experimental
and control groups at enrollment, delivery, and lactation (Table 12). There were no
statistical differences in IL-10 between groups, suggesting that maternal vitamin D
supplementation did not influence circulating maternal plasma IL-10 levels. The mean
detectable dose for the assay used was 0.09 pg/mL. Ten of the samples fell below this
minimum detectable amount and an additional 4 samples had undetectable IL-10 levels.
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Additionally, 24 samples were run in duplicate and 13 in single due to lack of funding to
purchase enough assay trays for analysis in triplicate.
Table 12. Maternal anti-inflammatory plasma cytokine levels.
Variable

Enrollment

Delivery

Lactation

IL-10

Control

0.12 ± 0.12

0.33 ± 0.34

0.10 ± 0.15

(pg/mL)

Experimental

0.13 ± 0.07

0.12 ± 0.08

0.11 ± 0.06

Mean (± SD) maternal plasma IL-10 levels in the experimental and control groups at
enrollment, delivery, and lactation were not significantly different between groups.
Significant differences between experimental and control groups were determined at p
≤0.05
Because IL-10 levels at delivery and lactation are impacted by maternal
enrollment circulating IL-10, the impact of maternal vitamin D supplementation on
differences in IL-10 were analyzed using the univariate ANCOVA method adjusting for
enrollment IL-10 plasma level. The impact of vitamin D supplementation on plasma IL10 demonstrated a fairly robust effect size of 0.290 with a power of 0.446 and p = 0.071
(Table 13).
Table 13. Maternal vitamin D supplementation influence on maternal IL-10 plasma
levels.
Estimated
Group

Marginal Mean

Effect Size

Power

P Value

0.290

0.446

0.071

(pg/mL)
Control Group

0.28 ± 0.06

Experimental
0.11 ± 0.06
Group

Estimated marginal means (± SEM) for maternal plasma IL-10 in the experimental and
control groups adjusted for enrollment IL-10 plasma level. Significant differences
between experimental and control groups were determined at p ≤0.05.
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The difference between group means demonstrates an effect that opposes the hypothesis,
with the control group having a higher mean IL-10 value than the experimental group,
therefore this hypothesis was rejected.
Summary of Key Findings
In summary, study results demonstrate that random sampling was achieved and
the participants in the experimental and control groups did not differ in any enrollment
measures. Analysis reveals a statistically significant impact of prenatal and postnatal
vitamin D supplementation on mean maternal 25[OH]D level by delivery and continued
through lactation when the impact of enrollment 25[OH]D is excluded. The intervention
showed strong effect size and power. Analysis of infant data reveals statistically
significant impact of the intervention on mean 25[OH]D at delivery, but by lactation this
impact is lost and there is only a minimal correlation between maternal and infant
25[OH]D levels by 4-6 weeks postpartum. Adjusting for maternal enrollment 25[OH]D
level brought the difference in mean infant 25[OH]D levels at delivery and lactation
toward significance with a moderate effect size and low power. Minimal correlations
were found between maternal 25[OH]D levels and inflammatory markers. There was no
impact of vitamin D supplementation on pro-inflammatory (TNF-α and IL-6) or antiinflammatory (IL-10) cytokine production. An in-depth discussion of the meaning and
impact of these results can be found in Chapter 5.
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CHAPTER V
DISCUSSION
The purpose of this study was to add novel information to improve understanding
of the transfer of vitamin D from mother to infant during breastfeeding. Specifically, it
was novel to start vitamin D supplementation in participants during pregnancy and
continue that supplementation through 4-6 weeks of lactation, which had not been
previously done. This study also added new information regarding the impact of vitamin
D supplementation on maternal cytokine production during pregnancy, birth and
lactation. This chapter presents an overview of the study, an overview of the
methodology utilized, and an evaluation of the findings presented in Chapter 4 with
respect to the current literature. This discussion is framed by the DOHaD hypothesis,
which underpins the significance of the findings. This chapter also provides a discussion
of the limitations of the study, recommendations for future research, and implications for
nursing research, practice, education, and policy.
Background of the Study
Vitamin D deficiency among pregnant and lactating women is common and
increasing in both prevalence and incidence (Bendall, de Costa, Woods, & Howat, 2012;
Brannon, 2012; Collins-Fulea et al., 2012; Dror, King, Durand, & Allen, 2011b; Hollis et
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al., 2011; Merewood et al., 2010; Wagner, Taylor, Johnson, & Hollis, 2012; Wagner,
McNeil et al., 2013b). There is a growing body of evidence that suggests that vitamin D
deficiency during pregnancy is associated with increased risk of pregnancy complications
including gestational diabetes (Baker et al., 2012; Clifton-Bligh et al., 2008; Maghbooli
et al., 2008; Senti et al., 2012; Soheilykhah et al., 2010) and preeclampsia (Baker et al.,
2010; Haugen et al., 2009; Robinson et al., 2010). In utero exposure to deficient
maternal nutriture is hypothesized to program the fetus for later development of
childhood and adult disease (D. J. Barker, 1997; D. J. Barker, 2000; D. J. Barker,
Eriksson, Forsen, & Osmond, 2002; Young, 2001). Several researchers postulate that in
utero vitamin D deficiency may be a key aspect to programming of later disease
(Kaludjerovic & Vieth, 2010; J. McGrath, 2001; Thandrayen & Pettifor, 2012; Weiss &
Litonjua, 2011). Specifically, exposure to vitamin D deficiency during fetal development
seems to increase risk for asthma, wheeze, respiratory infections, eczema, type 1
diabetes, and general poor innate immune response (Camargo et al., 2011; Cooper et al.,
2011; Erkkola et al., 2011; Karatekin, Kaya, Salihoglu, Balci, & Nuhoglu, 2009; Madden
et al., 2012; Marjamaki et al., 2010; Miyake et al., 2010; Walker et al., 2011).
Following birth, the vitamin D deficient infant is at risk for continued vitamin D
deficiency when exclusively breastfed by a vitamin D deficient mother (Hollis &
Wagner, 2004a; Saadi et al., 2009; Taylor, Wagner, & Hollis, 2006; Thiele et al., 2013;
Wagner et al., 2008). Breast milk is perfectly suited to meet the nutritional needs of the
growing infant, however, when the mother is vitamin D deficient her milk will also be
vitamin D deficient (Basile et al., 2006; Hollis & Wagner, 2004b; Saadi et al., 2009;
Thiele et al., 2013; Wagner et al., 2006). Programming of later disease does not end at
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birth as the infant continues to demonstrate plasticity in developing mechanisms to adjust
to its environment. As the first and only food the exclusively breastfed infant receives,
breast milk serves to impact programming, potentially through epigenetic changes. Due
to these multiple health impacts, maternal health and nutrition should be maximized to
benefit both mother and infant. In two recent studies, researchers looked at the epigenetic
impact of vitamin D (Pereira et al., 2012; Zhu et al., 2013). The authors reported that
vitamin D has effects across the genome by regulating demethylation (Pereira et al.,
2012). Additionally, severely vitamin D deficient African American adolescents
experience differences in methylation in their leukocyte DNA, providing a potential
explanation for the impact of vitamin D on the immune system (Zhu et al., 2013). As
further epigenetic research is completed, it seems likely that more evidence will emerge
about the impact of vitamin D on the epigenome and the resulting changes in gene
expression.
Breast milk vitamin D deficiency is associated with hypocalcemic seizures,
particularly amongst dark skinned infants living at higher latitudes, as well as rickets
(Balasubramanian et al., 2006; Bodnar et al., 2007; Camadoo et al., 2007; Dawodu &
Wagner, 2007; Greer, 2008; Salama & El-Sakka, 2010; Specker et al., 1985; Teaema &
Al Ansari, 2010). Except for exploring the impact of early vitamin D exposure on
multiple sclerosis and schizophrenia (Fernandes de Abreu, Landel, & Feron, 2011;
Hanwell & Banwell, 2011; J. J. McGrath et al., 2010), the relationship between vitamin D
deficiency during infancy and adult onset diseases such as cardiovascular, autoimmune,
and endocrine diseases is wholly unevaluated at this point (Lucas, Ponsonby, Pasco, &
Morley, 2008). In light of the impact on pregnancy related disease and early childhood
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disease, it is critical that researchers determine the most efficient way to bring a majority
of women and their breastfed infants up to a sufficient vitamin D serum level and then
evaluate the impact on disease outcomes.
Purpose Statement and Research Hypotheses
Current research has focused on determining appropriate timing and dosage of
maternal and infant vitamin D supplementation to maximize the potential for achieving
sufficient serum vitamin D levels (Hollis & Wagner, 2004a; Hollis, 2008; Hollis &
Wagner, 2011; Hollis et al., 2011; Wagner et al., 2010; Wagner & Hollis, 2011; Wagner
et al., 2012; Wagner et al., 2013b). However, despite this focus, there are currently no
published studies that evaluate the impact of maternal vitamin D supplementation
initiated during pregnancy and continued through lactation on the vitamin D status of the
breastfed infant. There is a lack of consensus and understanding of the maternal
25[OH]D level that corresponds to maternal vitamin D sufficiency or fetal vitamin D
sufficiency. This lack of consensus and understanding continues in to lactation with
divergent recommendations for maternal 25[OH]D level that will correspond with
sufficiency in the mother and the exclusively breastfed infant. Both the pregnancy and
lactation determinations are further compounded by the lack of understanding of what
amount of vitamin D supplementation will elicit a given serum 25[OH]D level. It is
widely recognized that there is a high prevalence of maternal vitamin D deficiency
(defined either as a 25[OH]D level < 32ng/mL or < 20 ng/mL) due to factors of skin
color, norms of dress, and lifestyles that include little time in the sun. Yet, researchers
and clinicians are not yet able to recommend a specific vitamin D supplementation
regimen or a specific 25[OH]D serum level to maximize health. It will take further
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research, looking at disease outcomes and biomarkers of sufficiency in pregnant women,
their infants, and their infants in to adulthood, to fully elucidate the impact of vitamin D
supplementation and doses necessary to prevent disease.
The objective of this study was to identify the combined effect of maternal
prenatal and postnatal vitamin D supplementation on vitamin D transfer to infants
through breast milk, leading to adequate vitamin D status in infants. In order to meet this
objective the following hypotheses were tested:
Central hypothesis: Maternal supplementation with vitamin D during pregnancy and
lactation will significantly increase circulating vitamin D levels during lactation in
mothers and their exclusively breastfed infants:
1. Women who receive supplemental vitamin D starting in the early third trimester
of pregnancy will have significantly higher 25[OH]D serum levels compared to
control participants by delivery;
2. Women who receive supplemental vitamin D starting in the early third trimester
of pregnancy and continue with this dosing during the early postpartum will
maintain significantly higher serum 25[OH]D levels than control participants
during lactation;
3. Infants born to women who receive supplemental vitamin D starting in the early
third trimester of pregnancy will have significantly higher 25[OH]D levels at birth
compared to control infants;
4. Infants who exclusively breastfeed from a mother receiving supplemental vitamin
D will have significantly higher 25[OH]D levels than infants exclusively
breastfeeding in the control group at 4-6 weeks of age.
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Due to immune and inflammatory modulating effects of vitamin D, the following
secondary hypotheses were tested:
1. Women with higher vitamin D levels will have decreased levels of proinflammatory cytokines (TNF-α and IL-6);
2. Women with higher vitamin D levels will have increased levels of an antiinflammatory cytokine (IL-10).
Review of the Methodology
To generate novel information about the impact of continuous prenatal to
postpartum maternal vitamin D supplementation on the vitamin D status of breastfeeding
infants, a randomized controlled trial design was used. This design allows for creation of
two otherwise equal groups to receive two different interventions. The control group
received a prenatal vitamin containing the typical 400 IU of vitamin D plus a placebo
capsule, while the experimental group received the same prenatal vitamin plus a capsule
containing 3400 IU of additional vitamin D, for a total of 3800 IU daily. Participants
were recruited between 24-28 weeks gestation and provided with written and verbal
informed consent if they desired to participate. They were provided with study pills in 30
day increments, to be taken daily through lactation. Each participant was contacted by
the PI every 2 weeks for evaluation of compliance with study protocol and to arrange for
the next meeting, which occurred approximately every 30 days. Data were gathered at
enrollment, at delivery, and again at lactation, including maternal health characteristics,
dietary intake, and infant supplementation with formula or vitamin D. Blood samples
were collected from the maternal participants at enrollment, delivery, and lactation to
assess 25[OH]D status and cytokine levels, as well as from the infant participants at
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delivery and lactation to assess 25[OH]D status. Data were entered into SPSS Version 21
and analyzed for normality. Analysis included descriptive statistics including mean and
variance measures (standard error of the mean/standard deviation), t-tests for differences
between groups, and ANCOVA to determine impact of the intervention on continuous
data while adjusting for enrollment values. Data were analyzed to determine relative
benefit increase of achieving sufficient 25[OH]D levels for maternal and infant
participants. A p value of ≤ 0.05 was set for determination of significance.
Evaluation of Study Findings
Overview of Current Research
This study is the first to use a randomized controlled trial method to investigate
the impact of maternal vitamin D supplementation on the vitamin D status of maternal
participants and their breastfed infants. There are several studies that used a longitudinal
observation method to determine the typical course of vitamin D status for pregnant and
lactating women and their infants (Bendall et al., 2012; Collins-Fulea et al., 2012; Dror et
al., 2011b; Merewood et al., 2010; Merewood et al., 2012). There are a few additional
studies that used a randomized controlled trial method to observe the impact of vitamin D
supplementation on pregnant women (Hollis et al., 2011; Wagner et al., 2013b). There
are 3 randomized controlled trials of lactating women using higher dose vitamin D
supplementation to impact the 25[OH]D status of participants and their infants (Hollis &
Wagner, 2004b; Saadi et al., 2009; Wagner et al., 2006). However, this is the first study
that spans pregnancy and lactation with an intervention aimed at impacting maternal and
infant 25[OH]D status. The findings from this approach contribute new knowledge
regarding the timing and dosage of maternal vitamin D supplementation needed during
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pregnancy to result in maternal and infant vitamin D sufficiency. Additionally, this study
is the first to investigate the impact of vitamin D supplementation on maternal production
of pro- and anti-inflammatory cytokines in vivo. There is a growing body of evidence
that 25[OH]D level impacts immune response (Akbar & Zacharek, 2011; Di Rosa et al.,
2012; Thota et al., 2013; Tiosano et al., 2013). There has been investigation in to the
normal patterns of cytokine production during pregnancy, labor, and the postpartum
(Denney et al., 2011; Palm et al., 2013). Other studies have used in vitro methods to
elicit cell responses to bacterial endotoxin, using this as a model of chorioamnionitis or
uterine infection during pregnancy (Thota et al., 2013). This is the first study to
investigate differences in cytokine production in vivo between control and vitamin D
supplemented groups of pregnant women. The findings offer additional information
regarding the ability of vitamin D to mediate the inflammatory response in the pregnant
woman.
Influence of Maternal Vitamin D Supplementation During Pregnancy
Of the 20 women screened for participation, 2 did not meet inclusion criteria, and
2 chose not to participate. The resulting 16 participants were enrolled into the study
during the summer months of 2012. Random assignment was predetermined and after
receiving written and verbal informed consent, the participants were randomized to either
the control or experimental group. After randomization, one participant from each group
chose to leave the study, and an additional participant in the control group was found to
not meet exclusion criteria and was exited from the study (control N= 6, experimental N=
7). All participants self-identified as white ethnicity. The two groups were compared to
assess for homogeneity and appropriate random sampling. There was no difference
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between groups in terms of age, body mass index, gestation, or parity at enrollment.
Blood samples from participants at enrollment were batch analyzed for 25[OH]D level.
There was no difference in baseline values between the two groups. Of the 13
participants 5 (38%) had sufficient 25[OH]D values (> 32 ng/mL) at enrollment. This
finding of low prevalence of sufficient vitamin D status is of particular interest for two
reasons: all participants were of white ethnicity and all participants were recruited toward
the end of the summer season. Although this study took place at a northern latitude,
having light skin pigmentation allows for the greater production of vitamin D in a given
amount of time exposed to the sun compared to having darker pigmentation.
Additionally, the summer months are accompanied by access to sunshine and typical
outdoor activities. Therefore, these 25[OH]D levels should reflect the participants’ peak
25[OH]D level for the year. The low prevalence of vitamin D sufficiency in the sample
indicates that a majority of white women in this region remain vitamin D deficient even
when endogenous vitamin D production is possible. It can be inferred that women with
darker skin pigmentation would have even lower rates of sufficiency, even during the
summer months. The finding of 38% vitamin D sufficiency in the early third trimester
correlates well with other studies. Bodnar et al. (2007) found 53% sufficiency amongst
pregnant white women in the northeast, Collins-Fulea, Kilma, and Wegienka (2012)
found 21% of white pregnant women to be sufficient, Dror et al. (2011) found a
sufficiency rate of 46% in women at delivery, Merewood et al. (2010) found a sufficiency
rate of 62%, and Li et al. (2011) found a rate of sufficiency of 35% amongst pregnant
women in Canada (Bodnar et al., 2007; Collins-Fulea et al., 2012; Dror et al., 2011b; W.
Li et al., 2011; Merewood et al., 2010). Rates of maternal 25[OH]D sufficiency in
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pregnancy are much lower for African American, Arab American, and women who cover
with a hijab or other cultural norms of dress that cover most of the skin (Bodnar et al.,
2007; Collins-Fulea et al., 2012; Dawodu et al., 2013; Dror et al., 2011b).
Food frequency questionnaires were analyzed revealing a mean vitamin D dietary
intake of 529 IU/day with no difference between groups. All participants self-reported
100% daily prenatal vitamin ingestion (usually containing 400 IU vitamin D), suggesting
a total average dietary plus supplement intake of about 1000 IU. Interestingly, maternal
dietary vitamin D intake did not correspond to maternal 25[OH]D level. The mean
dietary intake in this study is higher than, but consistent with, findings of other studies
(Dror et al., 2011b; Merewood et al., 2010), except for the recent large randomized
controlled trial by Hollis et al. (2011). Hollis et al. (2011) found mean maternal dietary
vitamin D intakes across pregnancy of less than 200 IU daily. Dror et al. (2011) and
Merewood et al. (2010) found a strong correlation between maternal dietary vitamin D
intake and maternal and neonatal 25[OH]D level at birth. It may be that the findings of
this study are different because this study included an intervention whereas Dror et al.
(2011) and Merewood et al. (2010) are solely observational. Of additional interest, if the
participants in this study were ingesting an average of 1000 IU daily this was still
inadequate to produce a sufficient 25[OH]D level in a majority of the participants. This
signals that perhaps the foods fortified with vitamin D actually contain less vitamin D
than stated or that participants overestimated the amount of certain foods they were
ingesting. In fact, the participant with the highest reported dietary vitamin D intake (> 2
standard deviations above the mean) had the lowest 25[OH]D level by lactation as did her
infant.
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Analysis of the impact of the intervention on maternal 25[OH]D level at delivery
reveals a significant difference between groups when controlling for enrollment 25[OH]D
level. At delivery, the mean maternal 25[OH]D level in the experimental group was
32.48 ng/mL compared to the control group mean of 24.44 ng/mL. One of the 6
participants in the control group had sufficient 25[OH]D status and 3 of the 7 participants
in the experimental group had sufficient 25[OH]D status, demonstrating a 157% benefit
increase of the intervention on achieving sufficiency. In regards to the impact of the
intervention by delivery, findings correspond well with the two other contemporary
intervention studies completed during pregnancy (Hollis et al., 2011; Wagner et al.,
2013a). Hollis et al. (2011) had a similar intervention group (initiating the intervention at
12-16 weeks gestation) receiving 4000 IU of supplemental vitamin D daily and found at
delivery a mean 25[OH]D level of 44.4 ng/mL, which was significantly different than the
control group mean of 31.56 ng/mL (p < 0.0001). These means are higher than those in
this study, which is most likely due to the longer study period and the impact of lower
latitude for location of the Hollis et al. (2011) study. Wagner et al. (2013) randomized
pregnant women between 12-16 weeks gestation to receive either 2000 IU or 6000 IU of
vitamin D daily, without a control group. Maternal 25[OH]D level increased from a
baseline mean of 22.7 ng/mL to 37.9 ng/mL in the 6000 IU daily group. This was
amongst a majority African American or Hispanic population. The findings from this
study are similar to those of these other two randomized trials, thus confirming the
findings of a significant difference in mean maternal 25[OH]D level by delivery. Both
the Hollis et al. (2011) and Wagner et al. (2013) studies began at 12-16 weeks gestation,
therefore offering a much longer duration of the intervention to have an effect, compared
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to this study, which initiated the intervention at approximately 28 weeks gestation.
Hollis et al. (2011) and Wagner et al. (2013) both demonstrated highly statistically
significant results at delivery, which was confirmed by this study when controlling for
maternal enrollment 25[OH]D levels.
Influence of Maternal Vitamin D Supplementation During Lactation on Maternal
25[OH]D
By lactation, the experimental group participants achieved a mean 25[OH]D level
of 35.57 ng/mL and the control group mean of 22.38 ng/mL. None of the 6 control group
participants had sufficient 25[OH]D status, whereas 4 of the 7 experimental group
participants achieved sufficiency, demonstrating a 688% benefit increase of the
intervention on achieving sufficiency. Over the course of the intervention, mean
maternal 25[OH]D level in the control group steadily declined while the mean maternal
25[OH]D level in the experimental group steadily increased. Comparing findings to
those of other researchers demonstrates some consistency. This study differs in that it
spanned pregnancy and lactation, whereas the interventions reported by Hollis and
Wagner (2004) and Wagner et al. (2006) were both initiated at one month postpartum.
Hollis and Wagner (2004) spanned from 1 month postpartum to 4 months postpartum
using supplementation of 4000 IU of vitamin D daily. In the intervention group, the
mean maternal 25[OH]D level increased from 32.9 ng/mL to 44.5 ng/mL demonstrating a
greater increase than was found in the study being described here. Wagner et al. (2006)
completed a 6 months study (1 to 7 months postpartum) using 6400 IU of vitamin D
supplementation daily. Participants had a mean 25[OH]D at baseline of 34 ng/mL, which
increased to 58.8 ng/mL at the end of the study. Wagner et al. (2006) conducted a much
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longer study with a higher dose of vitamin D supplementation and achieved higher mean
25[OH]D levels compared to the Hollis and Wagner (2004) or this study. However, all
three studies demonstrate that long term use of vitamin D supplementation in lactation
does not provoke adverse outcomes and will increase maternal 25[OH]D levels.
Influence of Maternal Vitamin D Supplementation on Infant 25[OH]D at Delivery
Analyzing the impact of the intervention on infant 25[OH]D level at delivery, the
experimental group infants achieved a mean 25[OH]D level of 32.33 ng/mL compared to
the control group infants mean 25[OH]D level of 23.67 ng/mL. In terms of ability to
reach sufficient 25[OH]D levels at delivery, 1 of the 6 control group infants was
sufficient (corresponded to the one mother sufficient at delivery), and 5 of the 7 infants in
the experimental group were sufficient. Comparing the two groups for relative benefit
increase demonstrates a 328% benefit increase to the infants in the experimental group.
The mean infant 25[OH]D level at delivery in the experimental group infants in this study
is very similar to the findings of Wagner et al. (2013) who demonstrated a infant mean
25[OH]D level of 27.0 ng/mL in the 4000 IU daily group at delivery. The mean infant
25[OH]D level at delivery in the experimental group infants in this study differs however,
from the Hollis et al. (2011) findings of mean 25[OH]D amongst the experimental group
infants of 10.6 ng/mL. Although studies by Hollis et al. (2011) and Wagner et al. (2013)
were initiated in early pregnancy, the infants in the 4000 IU daily groups achieved a
lower mean 25[OH]D level by delivery than in the study being described here. The lower
mean 25[OH]D level of the infants at delivery in the experimental group may be due to
methodologic differences in that Hollis et al. (2011) and Wagner et al. (2013) both used
cord blood for neonatal assessment of 25[OH]D level and if cord blood was not available
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they used blood samples taken from the infant up to 2 weeks after delivery. As
evidenced by the results presented in Chapter 4, infant 25[OH]D level seems to drop
rapidly after delivery, therefore a method that includes collecting infant blood up to 2
weeks after birth may be skewing the results in Wagner et al. (2013) and Hollis et al.
(2011) reports. In almost all studies investigating neonatal vitamin D status at birth, the
researchers used cord blood for assessment of neonatal 25[OH]D level (Bodnar et al.,
2007; Bowyer et al., 2009; Dror et al., 2011b; Hollis et al., 2011; Novakovic et al., 2012;
Viljakainen et al., 2010; Wagner et al., 2013a; Wang et al., 2010). It is commonly
assumed that neonatal 25[OH]D level will be 60-80% of maternal as described in several
review articles (Barrett & McElduff, 2010; Brannon, 2012; Kovacs, 2008). This
assumption is upheld by Hollis et al. (2011) with neonatal mean 25[OH]D level only
reaching 40% of maternal at delivery, and by Wagner et al. (2013) with neonatal mean
25[OH]D level reaching 71% of maternal, both in the 4000 IU daily group. However,
several other studies would refute this assumed difference between neonatal and maternal
25[OH]D levels at delivery because they in fact found mean neonatal levels to be higher
than mean maternal (Bowyer et al., 2009; Novakovic et al., 2012; Viljakainen et al.,
2010; Wang et al., 2010). For the results of the study being discussed here, for
participants receiving 3800 IU vitamin D daily the mean 25[OH]D level at delivery was
32.48 ng/mL and 32.33 ng/mL for their infants, demonstrating a nominal difference.
This study used infant heel stick blood collection methods, not cord blood, for analysis.
This technique was described in only one other study, Merewood et al. (2010).
Merewood et al. (2010) describe that some vitamin D deficient participants had infants
who were not vitamin D deficient and some vitamin D replete participants had vitamin D
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deficient infants. Overall, they found that neonatal 25[OH]D levels were about 70% of
maternal at delivery. The difference between the findings of the study being described
here and those of Merewood et al. (2010) may be due to this being an intervention study,
which may change the dynamic of maternal-fetal vitamin D transfer.
Influence of Maternal Vitamin D Supplementation on Infant 25[OH]D at Lactation
Looking at infant mean 25[OH]D levels by lactation, the experimental group
infants had a mean of 24.9 ng/mL and the control group 16.98 ng/mL. The combined
impact of maternal vitamin D supplementation on infant 25[OH]D at delivery and
lactation approached statistical significance when controlling for maternal enrollment
25[OH]D level. There was a reasonably strong effect size at lactation, but power was lost
due to small sample size. Nonetheless, there was about a 8 ng/mL observed difference
between groups in mean 25[OH]D level in the infants at lactation. The difference of 8
ng/mL is an almost 50% increase in mean 25[OH]D value for the experimental group
infants compared to control group infants. At lactation, none of the 6 control group
infants were sufficient and 2 of the 7 experimental group infants were sufficient,
consistent with a 337% benefit increase to those infants breastfeeding from a mother
receiving the intervention. Both the control and experimental group infants demonstrated
a drop in mean 25[OH]D level from delivery to lactation of about 8ng/mL with the
experimental group infants starting and ending about 8 ng/mL above their control group
counterparts. Looking again at studies of similar design and method, Hollis and Wagner
(2004) demonstrate a rise in infant 25[OH]D during lactation among infants
breastfeeding from a mother being supplemented with 4000 IU daily from 13.4 ng/mL to
30.8 ng/mL. Wagner et al. (2006), after 6 months of maternal supplementation with 6400
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IU vitamin D daily, demonstrated a rise in infant 25[OH]D from 14 ng/mL to 46 ng/mL.
Both of these studies demonstrate a greater increase in mean infant 25[OH]D than was
seen in the results of the study being described here because of longer study period,
higher dose of vitamin D supplementation, and perhaps greater maternal compliance with
study protocol. In addition, Hollis and Wagner (2004) and Wagner et al. (2006) both had
larger sample sizes by their final data point.
Influence of Maternal Vitamin D Supplementation on Maternal Cytokines
Both pro-inflammatory (TNF-α and IL-6) and an anti-inflammatory cytokine (IL10) levels were analyzed at enrollment, delivery, and lactation for maternal participants.
There were no observable differences in mean cytokine levels between the experimental
and control groups at enrollment. A lack of difference between group mean cytokine
levels would be expected at enrollment, but after initiation of the intervention it was
expected that TNF-α and IL-6 would be lower in the experimental group and IL-10
would be lower in the control group. The hypothesized differences in group means were
not observed and there were no statistically significant differences in group means for
any of the cytokine results. There are limited other studies to compare these findings
with, but Denney et al. (2011) looked at TNF-α, IL-6 and IL-10 across the course of
uncomplicated pregnancies. Denney et al. (2011) report that TNF-α and IL-6
significantly decreased over the course of pregnancy, which is in opposition to the
findings of this study. Denney et al. (2011) report no change in IL-10 over the course of
pregnancy, which is consistent with the findings of this study. Palm et al. (2013) found a
significant increase in IL-6 over the course of pregnancy, which remained higher during
the postpartum period. Although the study being discussed here did not find an increase
118

in IL-6 from enrollment to delivery, there was an increase in IL-6 at lactation. Palm et al.
(2013) report no change in TNF-α over pregnancy and postpartum, which is consistent
with this study. Barrera et al. (2011) investigated the effects of calcitriol (1-25-dihydroxy
vitamin D) on IL-10 in cultured human trophoblast cells. Barrera et al. (2011) report that
calcitriol inhibited IL-10 production. The findings of the study being discussed here do
not support this in vitro finding as IL-10 was not reduced in pregnant or lactating women
receiving vitamin D supplementation. The findings for IL-10 are somewhat limited in
this study as most of the plasma samples were analyzed in duplicate and some in single,
as opposed to the recommended triplicate, because of lack of available space on the tray
used for analysis.
Maternal and Infant Health Outcomes
In regards to health outcomes at delivery, there were no significant differences
between groups in terms of gestation at delivery, maternal body mass index at delivery,
mode of delivery, infant birth weight, infant birth length, or infant head circumference.
The lack of differences between groups regarding health outcomes is consistent with both
Hollis et al. (2011) and Wagner et al. (2013) who found no statistically significant
difference in health outcomes between the experimental and control groups in the
intervention studies in pregnant women. Wagner et al. (2013) note that there was a
decline in rates of infection, preterm labor, and preterm birth with increases in maternal
25[OH]D, but this was not statistically significant. Merewood et al. (2009) have
previously demonstrated an increased risk of cesarean section with declining 25[OH]D
levels, but the study being discussed here was not powered for this finding and did not
appreciate any difference in mode of delivery (Merewood, Mehta, Chen, Bauchner, &
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Holick, 2009). There may be risks to health with vitamin D deficiency that are not able
to be evaluated within the confines of the study being discussed here.
Limitations
All research studies are limited in one way or another by factors out of the control
of the researcher. The first limitation of this study is in regards to participant loss to
follow-up. There are difficulties inherent in using pregnant and lactating women as
participants in that they have many demands on their time and attention, namely their
older children and family obligations. Participants may have been hesitant to return for
their final study visit knowing that their infant was going to experience a heel stick or that
they were going to experience a blood draw, even though this was fully explained at
enrollment. They may have had additional hesitations due to the harsh winter weather
being experienced around the time that many of the participants were expected for their
final visit. Although enrollment numbers were powered appropriately, more women
were lost to follow-up than estimated and this has the potential to have affected the
findings.
This study was also limited by lack of racial diversity. All participants self
identified as white and because of the large impact that skin color plays in endogenous
vitamin D production, it would be beneficial to evaluate a population with diversity of
skin color. Additionally, there is a fairly robust population of non-white women living in
the northern plains who probably have higher prevalence of vitamin D deficiency and
therefore need particular attention from the medical and research communities.
Conduct of the study was interrupted by the PI moving after establishment of a
study site with IRB approvals in place. This necessitated relationship building with a
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new site and new research partners in order to complete the study. This took several
months and interrupted the study process. However, despite the disruption at the time,
this also allowed for further exploration of methodology and creation of new partnerships
for future research.
Implications for Nursing
This study offers an exploration of the impact of continuous prenatal to lactation
maternal vitamin D supplementation on the vitamin D status of pregnant and lactating
women and their infants. Conducting a randomized controlled trial comes with multiple
layers of complexity that are extremely beneficial to learn how to manage while in a
research-focused doctoral degree program. As a relatively small pilot project, this study
adds novel, significant findings to the science of perinatal health while simultaneously
offering the PI invaluable training for future projects. This study has implications for
nursing research, practice, education, and policy with potential to advance the science.
Implications for Nursing Research
Nurses should seek out opportunities for participating in clinical research that use
the DOHaD hypothesis as its foundation. Nurses can contribute to this field using the
lens of holism that is a hallmark of nursing. By taking a holistic view, nurses are able to
consider all aspects of the human experience when designing and implementing clinical
research trials. The nursing perspective would benefit the science as well as participants
and patients. This study demonstrates the importance of the researcher being directly
interactive with participants in order to improve retention and intervention fidelity.
Nurses are well suited to creating a trusting relationship with participants that would
benefit clinical research.
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This study has helped to further understanding, but there are several strategies for
future investigation that could be made to add further knowledge to the field. It would be
recommended to do a larger study with a more diverse population. This study has
demonstrated a very robust effect size of maternal supplementation on breastfed infant
25[OH]D level. Using these findings to power a future study of similar method
demonstrates the need to enroll approximately 30 women total to result in statistically
significant impact in the infants, including consideration for withdrawal from the study
and loss to follow-up. In order to study our most vulnerable populations, it would be
recommended that at least 15 of the recommended total 30 participants be women of
color. This would allow for loss to follow-up as well as investigation of the protocol’s
impact on non-white women and their infants.
In addition to repeating this study in a larger, more diverse population, it would be
recommended to implement the protocol prior to pregnancy. As was learned in the
discovery of the impact of folic acid supplementation on the decrease in neural tube
defects leading to recommendation of universal folic acid supplementation in all women
of childbearing age, implementing vitamin D supplementation prior to pregnancy may
impact the early stages of placental and embryonic development. This could in turn
result in decreased pregnancy and infant morbidity or improved long-term health
outcomes. Completing a study that would begin in adolescence and span through
pregnancy and lactation would be supported by DOHaD hypotheses and potentially
impact the health of multiple generations. As part of the study being discussed here,
participants consented to be contacted in the future, allowing for evaluation of impact of
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the intervention on infant outcomes including atopic disease and asthma and wheeze, or
any childhood diseases evidenced by current literature.
Implications for Nursing Practice
Based on the findings of this study in conjunction with those of other researchers
(Hollis & Wagner, 2004b; Hollis et al., 2011; Saadi et al., 2009; Wagner et al., 2006;
Wagner et al., 2013a), it is time for clinical practice to be altered to reflect current
understanding. It is clear that a majority of pregnant women and breastfed infants are not
vitamin D sufficient. Vitamin D deficient pregnant women go on to be vitamin D
deficient lactating women, which results in vitamin D deficient breastfed infants. When
we advise lactating women that their exclusively breastfed infant needs supplementation
with any outside substance, we run the risk of undermining her belief in breastfeeding as
the ideal nutrition for her infant. By supplementing pregnant and lactating women with
vitamin D, we are able to impact the vitamin D status of the women as well as their
infants and in turn improve health across at least two generations. It should now be
recommended that all women take enough supplemental vitamin D to raise their serum
25[OH]D levels above 32 ng/mL in order to provide for vitamin D adequacy prior to
pregnancy starting, and throughout the woman’s life. Further investigation is needed to
determine if there is a dose of vitamin D that can be broadly recommended that would
replete a majority of women with vitamin D. While this investigation continues, it would
be recommended that women of all ages have their serum 25[OH]D level analyzed and
take supplementation necessary to titrate this value above 32 ng/mL. This
recommendation is inconsistent with the current IOM recommendation, which is based
on bone health only. Further evidence is needed to bolster the recommendation of serum
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25[OH]D to exceed 32 ng/mL, which is based on multiple other health outcomes beyond
bone health.
Implications for Nursing Education
Vitamin D deficiency amongst pregnant and lactating mothers and their infants is
highly prevalent throughout the United States (Collins-Fulea et al., 2012; Dror et al.,
2011b; Hollis & Wagner, 2004b; Merewood et al., 2010; Wagner et al., 2006). Lifestyle
factors such as avoiding sun exposure and using sunscreen have increased the prevalence
of vitamin D deficiency, but other patient specific factors such as skin color or latitude at,
which the person lives greatly impact endogenous vitamin D production.
Nurses should be educated about the modifiable and non-modifiable risk factors
for vitamin D deficiency among pregnant and lactating women. In addition, nurses
should understand the health implications of vitamin D deficiency for women and their
infants, both short and long term. When educating nurses about fundamental theories of
nursing practice, the DOHaD hypothesis should be included in that conversation in order
to bring awareness of this most important theory to nursing practice. Nurses are educated
to take a broad and holistic view of the patient and educating them about the possible
multi-generational impacts of fetal exposures will bring depth of understanding to
nursing education.
Implications for Nursing Policy
Although the IOM defines 25[OH]D sufficiency as > 20 ng/mL, there is evidence
that bone health is affected, along with rates of cancer and psychological illness, at levels
< 32 ng/mL. Additionally, the IOM recommendation of 600 IU daily of vitamin D would
not be adequate to produce vitamin D sufficiency in a majority of women, even defined
124

as > 20 ng/mL. The Endocrine Society has taken a broader view, as their mandate
allows, and recommends up to 2000 IU vitamin D daily for 25[OH]D deficient adults
including pregnant women. Understanding of vitamin D sufficiency in pregnancy is
rapidly changing. Researchers are finding that production of the biologically active
1,25[OH]2D during pregnancy is maximized when 25[OH]D levels reach 40 ng/mL
(Hollis et al., 2011; Wagner et al., 2013a). This knew understanding led Wagner et al.
(2013a) to define vitamin D sufficiency in pregnancy as a 25[OH]D level > 40 ng/mL
rather than the ≥ 32ng/mL that is typically cited as sufficient. As further research is
completed in participants across the lifespan, including pregnant and lactating women
and their infants, researchers will gain a better understanding of the biological markers
associated with sufficiency. As a consequence of better understanding of a biologically
based definition of sufficiency for different stages of life, policy should reflect the new
understanding and recommendations from all agencies should provide recommendations
that are congruent with improved health outcomes. If recommendations had improved
consistency, policy could reflect this consistency and health would be improved amongst
the population.
Concluding Remarks
This study demonstrated that adequate maternal vitamin D supplementation that
spans pregnancy and lactation results in increased 25[OH]D levels in the mother and her
breastfed infant. Although not always statistically significant, the observed differences
between the experimental and control groups demonstrate clinically significant
differences. Researchers need to continue this line of inquiry so that evidence based
recommendations can be given to pregnant and lactating women about appropriate dosing
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of vitamin D supplementation in order to negate giving infants anything other than breast
milk. Current recommendations of 600 IU daily fail to bring a majority of women to
sufficiency, which has the potential to impact their health and the health of future
generations. Vitamin D has the potential to impact fetal and infant programming of
health outcomes, including mechanisms as fundamental as the action of the innate
immune system. Supported by understanding of the DOHaD hypothesis, clinicians have
the potential to impact the health of multiple generations with interventions initiated
before or during pregnancy, and future research is needed to support the interventions
enacted in the clinical setting.
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Revised Consent Form, version 2 dated_9/12/12.

Other

.

/

Signature of Chairperson or Designated IRB Memba
Altru Health System instiP tional Review Beard
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___

Versin Date

Institutional Review Board (IRB)Jladependen t Ethics Corn mittee (IEC) Authorization
Agreement
Name of Institution or Organization Providing ERR Review (Iitstitution/Organization A):
Umveryf4orth Dakota IiB 1
IRB Registration #

fljQQQO4Q Federaiwide Assurance (FWA) # if any

I WAOOQQO37tL

Name of Institution Relying on the Designated 1kB (Institution B)
OHSU
FWA:

FWA0000016I

The Officials signing below agree that the OHSU
may rely on the designated IRB for review and
continuing oversight of its human subjects research described below: (check one)

(J This agreement applies to all human subjects research covered by Institution B’s FWA.
(X ) Ehis agreement is limited to the following specific protocol(s)
Name of Research Project: Mgcnal
Mothers and Breastfed Infants
Name of Principal Investigator: Doria KJiieIç
Sponsor or Funding Agency: WjQfi
Award Number, if any: JDOOl76

(_j Other (describe):
ihe review performed by the designated IRB will meet the human subject protection requirements of
Institution B’s OHRPapproved FWA. The IRB at institution/Organization A will follow written
procedures for reporting its findings and actions to appropriate officials at Institution B Relevant minutes
of [RB meetings will be made available to Institution B upon request. Institution B remains responsible for
ensuring compliance with the IRB’s determinations and with the lerms of its OHRP approved FWA, flus
document must be kept on file by both parties and provided to OI{RP upon request
Signature of Signatory Official (Inatitutiori/Organization A):
I)ate: June 4 2012

Signature of Signatory Offic

titu tot’ B
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To:

Doria K. Thick, C4, IBCLC, PM) Candidate
Principal inS estigator

From: Michael R Brown, MD
Chief, Obstetrics and Gynecology
Re:

Support for Research Study

Date: January 22, 2012
I his letter eonfinns support for y our proposed study, Maternal Vitamin D
Supplementation to Correct Deficiency in Mothers and Breasifed Infants I
have reviewed your proposal and have determined that this stuth is feasible
and important.
There are minimal risks for the pregnant women enrolled in your stud’
Specimen and data collection will occur at ow office at Altru Oh tetrics and
Gynecology Clinic. There ‘will be no use of Altru Health System resources
during this study.
Your protocol demonstrates minimal staff burden. Your involvement with
our clinic will be limited to support from the nursing staff related to
identifying participants in the late second trimester and alerting our resea ct
staff of participant admission for labor and delivery, Further, medical
records support will be needed in data retrieval from the prenatal and
postnatal record though this will he limited. Qualified members of your
research team with experience as maternal/child professional nurses will
r ricvc data fror medical records
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Looking for Pregnant Women for Vitamin D Study

Participants must be 18 & older, have a
history of breastfeeding a previous baby for 4
or more weeks, and be able to start the study
between 24 and 28 weeks of pregnancy.
Participants should be plannh g to breast feed
for at least one month.

This study looks at how vitamin D passes
from mother to baby during pregnancy and
then through breast milk,

Free high quality prenatal vitamin
Earn up to $40 at completion of the study

Doria Thiele, CNM, IBCLC, PhD Candidate
406-210-4890
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Appendix D
Consent to Participate and Authorization for Access to Personal Health
Information
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UNIVERSITY
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rN

NORTH

DAKOTA

COLLEGE O NURSING
NURSING BUILDING

430 OXFORD STREET STOP 9025
GRAND FORKS ND 58202 9025
(701) 777 4174
FAX (701) 7774096

Research Study: Maternal vitamin D supplementation to correct deficiency
breastfed infants
Version 2: 912.2012

in

mothers and

SEP 2
LTRu

‘

2O2

L7H

7YSTEM
Principal Investigator: Doria Thiele. CNM. APRN. IBCLC
PEIEv -CyP
406-210-4890
400 Oxford Street Stop 9025 Northern Plains Center for Behavioral Research Room 340D Grand Forks,
ND 58202-9025

Co-Investigator: Cindy Anderson, PhD, WHNP-BC. FAAN
701-777-4354
400 Oxford Street Stop 9025 Northern Plains Center for Behavioral Research Room 340D Grand Forks,
ND 58202-9025

Consent to Participate
You are invited by Doria Thiele, CNM, APRN, IBCLC at the University of North Dakota
to participate in a study to identify the ability of mothers to transfer vitamin D to their babies
through breast milk. Vitamin D is something that we make in our skin when we get enough sun
light or if we take it in supplements or certain foods. Adequate vitamin D has been linked with
preventing diabetes, high blood pressure, breast and colon cancer, and several other diseases.
Researchers are still not sure if women can pass enough vitamin D to their babies through breast
milk, hut recent studies show that this is possible if women themselves get enough vitamin D.

STUDY OVERVIEW
You will either be in a group that receives a prenatal vitamin plus a placebo pill without vitamin
D, or the group that receives a prenatal vitamin plus another pill with vitamin D. You would
take your supplements daily during pregnancy and through 4-6 weeks postpartum. Neither you
nor the principal investigator, Doria Thiele, will be aware of which group you are in. Your
participation in this study would require approximately 40 minutes of your time. This would
include Nimg out a questiomtaire about hcw frequently von eat certain fbod and keeping track
vo ne or ba1r’ thr thor cac nhit co ‘ii meet w’tL Dcba ihue n,
o er
ftl e resca
at i duriog y ut regnanc t eno I in toe study aud obtain ai rh
ne e
y wperwork
would hay
b’ood orawi a t hi beginnm
third
trimester, within 72 1ours of delivery, ard lastly at your 4-6 week postpartum visit to test your
vieamir D level and possible other related factors We would also do a heel stick blood test on
your babs within 72 hours of birth and at 4 6 weeks postpartum to test the tamin D level Er
o
stliig
I) lee
d ou
II als
ihle
‘
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identif’ risks for diseases that are associated with vitamin D deficiency. When we see you
during your pregnancy visit, we will collect information related to the study from your medical
records. This will be repeated at the 4-6 week visit. All information is kept confidential and
our name will he removed from any data we collect. It is our aim to minimize any
inconvenience or discomfort to you or your baby.
Your participation in this study is completely voluntary. You may refuse to participate or
withdraw your participation at any time without penalty or loss of benefits. If you decide not to
participate, you will continue to receive the standard of care throughout your pregnancy
postnatal visits.

SEP 2 132012

STUDY SCHEDULE, PROCEDURES, RISKS, AND DISCOMFORT
You will be invited to participate by Dona Thiele, CNM APR14 JBCLC If you agre4fIEM
participate the following will occur:
REVIEW BOARD
Sign this consent form and have your questions answered
Sign a form allowing access to your medical information related to your pregnancy,
delivery, and postpartum course, You will receive a copy of both forms for your records
• At our first visit, a blood sample will be collected to establish your vitamin D levels and
analyze the chemicals “above” your DNA as well as possible other related factors which
may include but not limited to calcium and parathyroid hormone. You will also be asked
to complete a Food Frequency Questionnaire that takes about 20 minutes.
o You will be provided with prenatal vitamins that contain 400 International Units (IU) of
vitamin D. You will also receive a pill without vitamin D (placebo) or a pill containing a
dose of vitamin D in the amount of 3400 113. You will take your prenatal vitamin and
extra capsule every day through your 4-6 week postpartum visit. Neither you nor the
investigator will know which extra capsule you are getting.
• You will receive your vitamins in 30 day supply packs. A member of the research team
will meet with you monthly at your prenatal visits to provide you with further vitamins
and answer any questions. You will be asked to bring all used vitamin packs/bottles to
your prenatal visits. Doria Thiele, Principal Investigator, will also call you each month to
check that you do not have any unanswered concerns or questions.
• Once you deliver your baby, you will have a second blood test. A blood test will also be
done on your baby by pricking his/her heel. These blood samples will be used to test
vitamin D levels and the chemicals “above” the genes as well as possible other related
factors which may include but not limited to calcium and parathvroid hormone. Both of
these blood tests will be completed by hospital or research staff and every attempt will be
made to complete them during other regularly scheduled blood draws, however, it may be
necessary for either you or your baby to have an extra blood draw.
During the early weeks postpartum. you will till in a form each day recording if your
baby received any infant formula, vitamin supplements, or foods other than breast milk.
• A member of the research team will meet with you again duting your 46 week
postpartum visit and request that you complete the Food Frequency Questionnaire again.
A flnal. blood draw for you and your baby will be completed at this time as well.

143

•
•

The visits for the study will be coordinated with the hospital or
provider so any
extra visits will be tuinimized.
Doria Thiele, Principal Investigator,
contact you in the future (up to 15 years from
the end of the study) in order to evaluate health outcomes for you and your infant.
your care

may

pccaliicJiIcs, and Discc mfort
I.
ht
If a recent height measurement is not lncluded in your chart an instrument will measure your
height.
Risks and Discomfort: There are no known risks for this procedure.
II.
Freuenuesaire
You will be given a questionnaire that lists food items that are a usual part of the diet. You will
be asked to mark the number of times you have eaten a particular food item each month, week
and day. Foods are listed in categories that include dairy products, fruit and fmit
vegetables, snacks, sweets and beverages, eggs, meats fish, main dishes and breads and cereals.
The purpose of marking these foods is to estimate usual nutritional intake.
Risks and Discomfort: There are no risks associated with this activity.
juices,

III.
Blood Sampjpg
Blood totaling about 3 tablespoons will be taken from you for testing needed in this study. This
will be accomplished
standard venipuncture at three visits. Blood totaling about 2 to 4
drops will be taken from your infant for analysis in this study. This will be accomplished using
standard heel poke at two visits.
Risks and Discomfort: There may be discomfort for you when the needle enters the skin,
lasting a few seconds. The discomfort due to the needle in the
should be minimal, lasting
less than one minute during collection of the blood. Your infant may experience discomfort with
the heel poke, lasting a few seconds. The discomfort should be minimal and you may hold and
comfort your infant however
wish during this procedure. Genetic information will not be
used in establishing medical diagnoses.
using

vein

you

IV.
Infant Intake Tool
You will be asked to complete an infant intake tool for every day after your baby is born. This
tool asks about formula intake for the day, brand of formula, and if the
given any
other vitamin or supplement. This should take less than one minute per day and will be collected
at your 46 week
Risks and DIscomforts: There are no risks assocIated with thIs activity.
infant was

visit.

V.
Medical record data related to your tyegnancy aid delivery will be collected when you join the
study and 46 weeks after birth, This information will be kept locked and confidential at all
times and your name will not appear on the collected information. The data collected will
become part of the study results, but only in group form, never with any infOrmation that could
tie you to the study. When the study is concluded, this informatior. will be shi. cOded for your
orotection.

SE 2 C 2012
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Risks and Discomforts: There are no discomforts associated with this activity. Any risk of a
privacy violation is mitigated by strict confidentiality procedures.

BENEFITS
You andior your child may or may not receive a direct benefit as a result of participating in this
study. However, the results of this study will provide helpful information about how vitamin D
is passed to babies from breast milk.

COMPENSTATION
You will receive a gift card from Target Stores in the amount of $20 when we meet with you at
delivery and one in the amount of $30 when we meet with you at 46 weeks postpartum.
COSTS
You will not be responsible for the costs of the prenatal vitamins, any supplements received, or
any blood analysis for this study.
NEW FINDINGS
You will be notified of any new information that may affect your willingness to continue your
participation in this study.
ADVERSE REACTIONS
If you have an adverse reaction (get hurt or sick) as a direct result of taking part in this study,
immediate and appropriate medical treatment will be made available. However, you or your
insurance carrier will be responsible for all medical costs associated with any adverse reaction or
injury while taking part in this study. No compensation is available from study sponsors, except
as permitted by law.

WITHDRAWAL
You may choose to discontinue your participation in the study at anytime without penalty. If
you decide to withdraw from the study, we ask that you notify the principal investigator.
CONFIDENTIALITY
All information is kept confidential. You will be assigned an identification number that will be
used to code your research data for computer entry. Paper copies of your personal information
and medical data will be kept in a locked file, with access limited to approved staff members,
aadnars such as the 1* nners1t of”iorth Dakota Institutional Re Len Beard and I !SD4 auo±tors
4$o Health S stern s lnsouicral Re’ ,en Board aid other rtate a frcercl 2gereles as crc inca
0
rL a r- ‘or sacrd carcer f r ru Pr
h
seoratc ocreO C es
trc e
4 tes t nc ‘e -a ‘a asposeC ot jon
e cid r rteo fng tcrnr n
will be shredded. Any results from your participation in this project may be published in a
scientific journal or presented at professional conferences, but only in a Irirm not identifiable
with :vou
STATEMENT OF PRIVACY RIGHTS
Please see the Authorization for Access to Personal Health information form which must he
signed to participait a Ac study

SEP 202012
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ALTRU tALALTU
Sflovr

This research studY has been reviewed by the Altru Health System Institutional Review Board
(IRB) and by the University of North Dakota JRB for the purpose of protecting your safety and
tights. Both the Institutional Review Boards were instituted under Federal and State law to
review studies such as this one in order to protect research participants from: unnecessary risks,
risks that outweigh benefits, and procedures that are scientifically unnecessary.
QUESTIONS
You are free to ask questions at any time during the study. Contact the principal investigator,
Doria Thiele, CNM, APRN, IBCLC at 406-210-4890 for any information or if problems arise
during the study. She can be reached by mail at the College of Nursing. University of North
Dakota. 400 Oxford Street Stop 9025, Grand Forks, North Dakota, 58202-9025. You may also
contact Doria Thiele’s academic advisor, Dr. Cindy Anderson, at any time during the study. She
can be reached at 701-777-4354 or by mail at the above address. If you have any other questions
or concerns, please call the Office of Research Development and Compliance at the University
of North Dakota at 701-777-4279. Additionally, if you have any questions regarding your rights
as a research subject, you may contact the Altru Health System IRD at 701-780-1750.

ALTU ALT SYSTEM
STTUTJAL
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CONSENT
Your signature below indicates that you have read this form, have had the study explained, and
have had any questions answered to your satisfaction, that you now understand what will be
expected of you, that you agree to take part in this study, and that you authorize the use of your
personal health information and agree to take part in this study.
A copy of this signed Informed Consent Statement will be given to you

1 understand that my medical records and study records are confidential. However.
representatives of the study sponsor, the US. Food and Drug Administration (FDA), or the
Institutional Review Board (IRB) may need to inspect my medical and/or study records. By
signing this consent, I am allowing this inspection.

Your Signature

Date

Your Name Printed

Study Team Member

Date

Study Team Member
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Tisis research study has been reviewed by the AItru Health Spate in Institutional Review B••oa:..rd
(IRB) and by the U•niversity of North Dakota IRB for the purpose of protecting your safety and
rights. Both the Institutional Review Boards were Instituted under Federal and State law to
revIew studies such as this one in order to protect research participants from: unnecessary risks,
risks that autweigh benefits, and procedures that are scientifically unnecessary.
QUESTJONS
You are tree to ask questions at any time during the study. Contact the principal investigator,
Doria Thiele, CNM,.APRN, Ii3CLC at 406-210-4890 for any Information or 1fprohlems ari.ae
during the study. She can be reached by mail at the College of Nursing, University of North
Dakota, 400 Oxford Street 5.top 9021., Grand Forks, North Dakota, 58202-9025. You may also
contact Doria Thick’s academic advisor, Dr. Cindy Anderson, at any time during the study, She
can be reached at 701-777-4354 or by mail at the above address, If you have any other questions
or concerns, please call the Office of Research D-eveiopmenta:nd Compliance at tile ljniverslty
ci North Dakota at 701-777-4279. Additionally, if von have any questions reganding your rights.
as a research, suhcct, you may contact the Aitru Health System 1kB at 701—7801 750

tiasecwsny of 55.’fl k.:jlflta
Ftaaesrrch t)e:ssiloçasl:ant ii leeslrnanca
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CON SENT
Your signature belo indicates that you have read this form, hae had the study explained, and
have had any questions ansered to sour satisfaction, that you now understand what il1 be
expected of you, that you agree to take part in this study, and that you authorize the use of sour
personal health information and agree to take part in this study.
A copy of this signed Informed Consent Statement will be gien to ou

I understand that my medical records and study records are confidential. However,
representatives of the study sponsor, the US. Food and Drug Administration (FDA). or the
Institutional Reiew Board (IRB) ma need to inspect my medical andIor study records By
sigmng this consent, I am allowing this inspection.

Date

Your Signature

Your Name Printed

Study Team Member

Study Team Member

Date

—
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Maternal Vitamin D Supplementation to Correct Deficiency in Mothers and
Breastfed Infants
Authorization for Access to Personal Health Information
A federal government rule has been issued to protect the privacy rights of patients. The rule is
designed to protect the confidentiality of your personal health information. We are required by
these new regulations to obtain your authorization to share personal health information that may
reveal your identity.

What Information will be Used or Disclosed
For this research study. the health information to be used or disclosed includes information
contained in your existing medical records and new information created or collected during this
study Your records may include information about your physical examinations, medical history,
blood samples, and any other data collected or reviewed during the course of the study as
described in the consent form. Specifically, we will be collecting vitamin D levels, as well as
possible other related analysis, from obtained blood samples, information about the course of
your pregnancy and delivery, and information about how you feed your infant in the first 4-6
weeks after birth.
Purpose for Use or Disclosure
The purpose for use or disclosure of information gathered will be to develop a better
understanding of how vitamin D levels in the mother effect how much vitamin D her baby
receives through breast milk. This study will help measure the safety and effectiveness of
vitamin D supplementation for women and their breastfed babies.
Who May Use or Disclose Information
The persons and organizations that may use or disdose your individually identifiable health
information may include, approved staff members, auditors, such as the Altru or University of
North Dakota Institutional Review Board and USDA auditors, and other state or federal
agencies as provided by federal regulations.

Who May Receive Information
The persons and entities that may receive your personal health information may include: Doria
Thiele, CNM, APRN, Principal Investigator, Dr. Cindy Anderson, PhD, WHNP-BC, FAAN, Dr.
David Roth, Statistical Consultant, and personnel at the Grand Forks Human Nutrition Research
Center, The data sent by the principal investigator to the sponsor usually does not include your
name, address, or social security number. However, the sponsor might review or copy all of
your records to assure the quality of the study or for other uses allowed by law.
Every effort will be made to maintain confidentiality of information accessed However, absolute
confidentiality cannot be guaranteed. Once your personal health information is released it may
be re.disdosed, at which point your health information will no longer be protected by federal
pnvacy regulations
Thration
Th a

OT

Atitflonzation
ation is effective untli the end of this res

Right to Refuse, Withdraw or Cancel Authorization
You may refuse to sign this authorization. If you refuse to sign this authorization, you will not be
able to take part in this study. However, you will not be penalized or lose any benefits to which
you are othese entitled. You Wi cont!nue to receive t.eatment for your condition
ou nave the right to cancei this authorzaton or wthdraw from this study at any time with no
penalty if you choose to do so. you must notify The principai investgator n writing at Done
Thtele CNM, APRN, 1BCLC at College of Nursing. University of North Dakota, 400 Oxford
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Street Stop 9025, Grand Forks, North Dakota, 582029025. Data collected prior to cancellation
of this authorization may be used in order to preserve the scientific integrity of the study.
Patient Access to Records
You have the right to access your medical records at any time. However you will not be able to
access study specific information until the study is completed, at which time your right of access
will be restored
Privacy Authorization
I have read this Privacy Authorization and have had my questions answered to my satisfaction
at this time, I understand that by signing this consent, I authorize the release of my medical
records and health information related to this study. I authorize the use, disclosure, review
duplication, storage and data transfer of my medical records and study information I
understand this information may be obtained by the persons and organizations stated above I
will receive a copy of this signed authorization

Signature of Participant

Date

Name of Participant (Printed)

Date

Name of Legal Representative

Or
Signature of Legal Representative
(Printed)
Relationship to Participant
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Appendix E
Food Frequency Questionnaire
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Food Frequency Questionnaire

ID Number:

DateS

Instructions:
+ Mark each line food item iy oçç (whatever is the most accurate daily, weekly, or monthly)
+ If there are any foods/beverages you eat on a regular basis thai are not listed, please write them down in the space proided
after each table
Example:
each month
each eek
each da
Number of limes

1-3

IJ

1

2-4

-6

1

Milk (drank :wzce a day durrng past 3

2-3

4-5

6

X

Chocolate milk ‘did nor drin/ at a/I Junngpa’i 3 monrhri

X

During the last 3 months, how often did you eat or drink a ser lug of the foods or beverages listed here?
DAiRY PRODUCTS

each month

Number of times

0

each week

1-3

2-4

1

each day
5-6

1

2-3

4-5

6

Milk, 8 fluid ounces

Chocolate milk (hot or cold), 8 fluid ounces
Instant nonfat dry milk, 1
scup (powder)
Evaporated milk (nonfat),

2

cup

Cheese (plain or as part of a dish or sandwich), 1 ounce
Youurt, 1 cup
Ice cream, 1 cup
Butter, 1 teaspoon
Margarine. 1 teaspoon
What kind of milk do you usually drink’
Skim

1%

Whole

Soymilk

Other

Are there any other dairy products you ate/drank in the last 3 months not listed above’
lfyes. pleasename

—

FRUIT & FRUIT JUICES

Number of times

No

Yes

Ifyes, how often.

each month
0
1-3

each week
1

2-4

each day
5-6

1

2-3

61-

4-5

Orange juice, 8 fluid ounces
Orange juice (with Calcium & Vitamin D), 8 fluid ounces
Other 1000 o fruit juice, 8 fluid ounces
Lemonade, 8 fluid ounces
Fruit drinks (Kool-Aid, Hi-C, Gatorade). 8 fluid ounces
Apple or appiesauce.imedum

Banana. I medium

-t--

Orange o grapefruit I medium

Watermelon, 1 medium wedge
-

Strawberries i cup w,hole
Raisinso, ,)v
-

1-,e ft

\4

3
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Study 608 Food Frequency Questionnaire
VEGETABLES

Number of times

each month
0
13

each week
1

24

54

1

each day
44
23

64

Tomatoes or tomato juice, I medium
Green beans, 1 cup
Carrots, 1 cup
Corn, 1 cup
• Broccoli or cauliflower, 1 cup
Dried beans or peas, 1 cup prepared
Winter (orange) squash, 1 cup
Sweet potatoes or yams 1 medium
Spinach or other greens, 1 cup
Potatoes (baked boiled, or mashed). 1 cup
French fries or hash browns, 1 medium order
Vegetable soup. 1 cup
Lettuce salad, 1 14 cups
Salad dressing or mayonnaise, 2 tablespoons
No

Are there any other vegetables you ate in the last 3 months not listed abose?
If yes, how often

If yes, please name

each month

SNACKS, SV4 EETS, AND BEVERAGES
Number of times

0

Chips (potato, corn, etc), 1 ounce (about 15 chips)
Peanuts, 1 ounce
Mixed nuts, 1 ounce
Sunflower seeds, 1 ounce
Brownies or cookies, 1 piece (24nch square)
Pumpkin or sweet potato pie, I piece (‘ of 9-inch pie)
Other pie, 1 piece Q of 94nch pie)
Pudding

2

cup

Jell-I) gelatin
Ii

a

2

cup

aid

bar

u

c

0
R ar oda pop

lu d u

ci s

Sugar-free soda pop, 12 fluid ounces
Coffee or

Yes

ten, 8 fluid ounces
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14

each week
1

24

54

1

each day
4-5
24

6+

Study 608 Food Frequency Questionnaire
EGGS, MEATS. FISH, MAIN DISHES, ETC.
Number of6mes

1 each month
0

1-3

each day

each week
1

2-4

1

5-6

4-5

2-

Eggs. 2 large
Bacon or sausa2e. I piece
Peanut butter, 2 tablespoons
Hamburger (prepared any way). 3 ounces prepared
Chicken or turkey, 3 ounces prepared
Pork chops, roast pork or ribs, 3 ounces prepared

Steak or roast (beef, bison, venison), 3 ounces prepared
Salmon, 3 ounces prepared

Oilpacked canned tuna, 3 ounces prepared
Water-packed canned tuna, 3 ounces prepared
Fried fish or fish sticks, 3 ounces prepared
Baked/broiled fish (halibut, walleye, cod), 3 ounces prepared
Pickled herring, 2 pieces
Sardines, 2 pieces
Spaghetti or other pasta with sauce, 1 cup
Macaroni and cheese. 1 cup
Pizza, 2 small slices
Stew, 1 cup
No

Are there any other main dish items you ate in the last 3 months not listed above’
lfyes, please name_

Number of times

0

Oatmeal or other hot cereal, 1 cup prepared

Coldcereaklcup(1 ounce)
White bread or rolls, 1 slice
Whole wheat bread or rolls. I slice
Flour tortilla, I medium
(‘oibread or corn tom!i&imedium
cup

Wild rice, 1 cup
Popcorn, 2 cups popped
What kind of cold cereal do you usualk eat

di’

each week

each month

BREADS AND CEREALS

Yes

Ifves. how often

othei di ‘ack ccc

iame
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1-3

1

2-4

5-6

1

each day
4-5
2-3

J

6’-

Study 608 Food Frequency Questionnaire
+

9
Are there an other foods with added vitamin D that you ate drank in the last 3 months

+

If yes please name

Yes

o

If yes. how often

EMONTllS:
No

Yes

1

Do you take vitamins or minerals

2

if yes, check all nutrients andlor combinations (select individual vitamins,minerals if taken as single item per tablet capsule)
per Day Week Month (circle one)
per Day Week Month (circle one)
per Day Week / Month (circle one)
per Dii Week Month (circle one)
per Day Week Month (circle one)
per Day Week Month (circle one)
per Day Week Month (circle one)
per Day Week Month (circle one)
per Day Week Month (circle one)
per Day Week Month (circle one)
per Day / Week Month (circle one)
per Day Week Month (circle one)
per Day Week / Month (circle one)
per Day Week Month (circle one)
per Day Week / Month (circle one)
per Day / Week / Month (circle one)

How many
How many
How many
How many
How many
How mans
How many
How many
How many
How many.
How many
How many
How many
How many
How many
How many

Brand.
Antacids w Calcium
Prenatal Vitamins
Brand
Brand
Multiple Vitamins
4 iron
Brand
Multiple
Multiple Vitamins/Minerals Brand
Brand
WCornplex
Brand
Calcium \ itamin D
Vitamin A
Amount per tablet/capsule
Vitamin C
Amount per tablet/capsule
Amount per tablet/capsule.
Vitamin D
Vitamin 1/
Amount per tablet/capsule
Amount per tablet/capsule
Folic Acid
Calcium
Amount per tablet/capsule
Iron
kmount per tablet/capsule
Zinc
Amount per tablet/capsule
Other (please list)
Don’t Know
-

No

3

Do you take herbal/other nutrition supplements like Echinacea Fish oil, Fiber, etc

4

If yes, please list name, amount per item, and number taken per day, week or month for each

5

Do you follow a special diet’?

No

Yes

6

If yes, please check all that apply

Diabetic

Low sodium

Weight gain

Other diet (please name)

High protein

Weight loss

Vegetarian (Please circle the foods that you DO NOT eat)
Poultry
7

Red Meat

Nuts

Low cholesterol

Low fat

Dairy

Eggs

Pork

Yes

Fish

Seafood/Shellfish

Other foods (please list)
No known food allergies

Do you have any food allergies? (Please choose all that apply)
Dairy foods

“

Wheat

Eggs

Milk

Other (please name)

S

How many days a week do you usually eat a Morning meal

11

In your household who does most of the food preparation

160

Midda meal

Self

Spouse partner

bvening meal

Restaurant Cafeteria

Appendix F
Infant Intake Tool
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_________

ID#:

Age
Weeks
Example
Example
2
0

Age
Days
1
4

Vitamin D
Supplement
400 IU

None

None

Sirnilac Advance

Formula Intake
Brand Name

None
1 oz after nursing X 8 nursings
forthe day

1
2
3
4
S
6
7

1

2

3

4

S

Formula Intake
Number of Ounces Eaten

8
9
10
ii
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

36
37
38

43

44

162

=
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Appendix G
Record Retrieval Form
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SF
VP V

S
P3-t
r
9-

Outc r

Datv

€

*

I

FT—fuf for
NT-nrrar s.
PTesrfypr
ET-esr’yter

r
Snterhm
numb. o w

Gender

01—vsgrnal
02—op vaginal forceps or vacuum)
03-G-sectlon

ve

2)

OR

lbs los

Type of Delivery

Ej

/

00None noted
01Preeciampata
02 Gestedonal f4ypertention
03Placenta prewa
04PIacent& abrupbon
05=Pre-gestattonot dwbete Type
08=Pregeatatlon& dwbetes Type K
07Geatational dwbetea
OdePPH, requinng btrod transfuwon
09=PTL reqwnng treatment
10PPROM
99-Other

Maternal ComDlicatons

3)

2)

1)

Maternal
Description

Date of First Prenatal Visit:

o’umented 01—male
i umented
O2female

§jt8tlq ial AgeJgo

Gender

e9nancy Outco e

Ct av d r ,tatus

/

cIc’tion form for each participant enrolled in the study

& Detailed Past Obstetrical Histery

Instructions

On

____________

3)LLJ

I

I
mm lckllyy

DoWt Know
Refused to Answer
Does Not Apply

Code:I

Reason for death:

Date of Death:

Coding Key
7
-4 Temporarily Missing (not currently avaable)
-5 Multiple Responses (needs review)
-8
-8 Permanently Missing (not documented in chart) -9

01 —ardrovascular
02-Congenrtal Defect
O3Resprratory
04-Prematunty
05 SepsIs
06-Unknown
99—Other

_____________

lf LB& Child NOT Living

etalIlntant Complications NOTIv
or Deaf

I_I_I

2)

Code

1>LL

Fetalllnfant
Descrption

09-None noted
01 4ntraUtenne Growth Restnctlon
02 Small for Gestabonal Age
03 Large for Gestatronal Age
04-Respiratory Drstress Syndrome
05-Meconarm Aspiration
OSOther defect
07—Other genetic disease
08-Observe for sepsrv
09-Nypoglycemrs
99-Other

3)

2)1_Li

Code

Birth Weight

Maternal Age at Time of Delivery:

ID Number:

_________
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1

2
2
2
2

i
1
1

23

Other Specify

1

1

1

Fiepatitis C

2

hiatnc Disorder Specify

1

titisB

1pIeae spec#y

2
2

1
1

2

2

2

2

1

1

2

2

1

1

2

1

2(

1‘
12
13
14
15
16
17
19

10

rpease apec#y)

2

1
1

lar heart disease
t er S ructural heart disease
cry artery dsease/
jestwe heart failure
Nephropathy/Nephrotic syndrome!
Olomeruionephritis
Rena’ insufficiency! renal failure
Sickle cell anemia
Thrombocytopenia
Lupus erythematosus
Antiphospholipid antibody syndrome
Rheumatoid arthritis
Icerative colitis/Crohn’s disease
Malignancy Specify

8

2
2

1

iypothyroidism

6

2

1

2
2
2

1

1

hronic hypertension
1. iabetes meflitus (type 1 & 2)
)$rthyroidism

2

3
4

1

Seizure disorder

Absent

Asthma

Present

1

Medical Condition

(circle one for each)

2

S History of Medical conditions

__________________
____________

_________________________

j

1

1

1

1

1

1

1
1

1

1

1

1
1

1

1
1

I

1
1

1

1

1

Receiving
Medication

2

2

2

2
2

2
2

2

2

2

2

2

2

2
2

2

2
2

2
2

2

Not
Receiving
Medication
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C

ame

Code*

Mcdi ati r Vitamin, Vaccine
other

(please specify)

$pecify________________________

(please specify)

)eSpecify_____________

(please specify)

Prescdption Medication, Vitamins and Vaccines

25

Medical Condition

pecify_______________________

Tiimester

2

2

Absent

I

Postpartum

1

1

1

Receiving
Medication

2

2

Not
Receiving
Medication

Temporanly Missing (not currently available)
4 DoWt Know
4 Multiple Responses (needs review)
$ Relused to Answer
4= Permanently Missing (not documented n chart) 9 Does Not Apply

Coding Key

01 =Taken 02=Not taken

1

1

1

Present

(circle one for each)

167

o

4

3

2

Visit

[

F

\ \:
\-p rt.

Lk’

0!

1

I 0

I

“

Date

lbs

il

1(l= Aldornet

lo= Ace—Inhibitor
6) Other
antihperIen’o e

I64’ I3eta3locker

(3 Ca-Channel
ltlcker

I 62 lnheieloi

2’) Sleep Aide

2O=khwin

23’ )Priisterone

2t)Cd aeents

)=Uliemotherapeutics
22! 01)iuretics

• 2! )t)Hirth control pius

15’ t=Antips ehotics
I 9OAntivnsls

• 170Antiemeties

399( >thei \4edieaton

ulkiem acti C;

252 I h mid Replacenient

oeraetie,

l}i roid Agents
25 1 Antith rinds
\lult
lion
0-F ohite

\ 11,111110

5’)9( )ther

S4;>—6alciuni

52’

\ lidifllfl

I

Vitamins
(500 series)

Is

cha

Bys

2 Dia

Sys

2Dma

—

—

—

—

—

—

1 Sys__:

mm

Highest
Blood
Pressure

cm

Fundal
Height
Fetal
Movement
O0normal
01 decreased
02=absent

Fetal Heart
Rate

01 present
02=absent

Urine

Dipstick
Glucosuria
01 =Negative
O2Trace
03=> +1

Urine

Dipstick
Proteinuria
01 =Negative
02=Trace
03=+1 04=÷2
05=+3 06=+4

eat on all women enrolled in the study using medical records. Complete one row for

I!0 !H1!ULN

‘oor

Waght

he Prenatal Care

rnrn/ dd /yy
1

t

D Prenatal Care Visits

i

Mid 30on
1 )0 100 ene)

‘‘))

1

-__r

)thet

Specify

Other Condition

prenatal visit

I)

lnIIuenia
2; -1 lepatitr B

‘ Rubella
4(oVariee1Ia,oster immune
oloblmn ‘V/I

‘

j)

Vaccines
(()(J

Ii

Wa

--

4

168

6
2

Sys__

Dia

Da

I Sys

_______
_______

ZZZ_4ZZZ__ZZ

_____
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4

b

d
yy

Weight

Date

yQ

Da

Dm

Da

t3yb

—

y9

mm

—

—

Highest
Blood
Pressure

—

—

—

______

cm

Fundal
Height
Fetal
Movement
OOnormal
O1decreased
02=absent

Fetal Heart
Rate
O1present
O2absent

J

Speci

Other Condition

—4 Temporarily Mssrng (not currently available)
4 Dent Know
4 Multiple Responses (needs review)
$ Rekised to Answer
4 Permanently Missing (not documented in chart) 4 Does Not Apply

Coding Key

+1

O1Negative
02=Trace

O1=Negative
O2Trace
03=41 04+2
05+3 06+4
03

Urine
Dipstick
Glucosuria

Urine
Dipstick
Proteinuria

6

170
/
I

/

/

/

a

b

C

Date

H( IillgB

N qatve

I ecent Rh

RH Factor:

2.

P )SitrIe

Mothers Blood Type:

1.

LGenerat Prenatal Labs

esult
HCT %
HgB q/d

gve

*_________
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4

6

_____/

Urinalysis

G8S

_1__

___I__

dd / yy

Date

Date
dd /
=

If Other, speclfyy

**

Positive 02= Negative

Result(s)
4egative
Protein
0=Ketones
)4-Bacteria

01

Result

d.
—

_t
—

—

I
I
I

—

—

—

—
—

——

——

01 =Positive
02=Negative

Result

=
=

-7
-8
-9

—

——

——

Don’t Know
Refused to Answer
Does Not Apply

Other:

Other:

Other

1

I

—__________

If Positive, specify organism
01=GBS
02E Coil
03=Other
if Other specify
Other

Coding Key:
-4 = Temporarily Missing (not currently available>
-5 = Multiple Responses (needs review)
-6 Permanently Missing (not documented in chart)

_/

_/

c.
—

_I__I_

II

b

a.

mml dd I yy

Date

Urine culture:

00 = Absent
1+ 2+, 3+ or
4+, trace (5)

6.

_____________
_______________
_______________

8

172

8

Ne

Ft

i

Hepatt

)sitive
\Ieqative

esult

dlyy

Date
bilive

esult

HbeAg ((11€ t I antigen)
Anti HBc Igi I oil ore antibo
AntiHBs S I tibody)
Anti—Hbe e t d )
HBV DNA

tier hep B sero og

3 burface Antige

_____

——

(use codes below)

If others
hep B serology:

j

_I_!_

Result

—

C mg/dl
C mmoUL

0 mg/dl
C mrnol!L
C mgldl
C mmol/L

_!,,l_

l,,j

a

b

2 hr
C mg!dl
C mmo/L

1 hr

Blood Sugar Result

0 mgldt
0 mmo/L

Dmg!dI
D mmoUL

Random

C mg!dL
C mmo!L

Fasting

0 mgldl
0 mmolIL

Dmg/dI
D mmol!L

Dmg/dl
D mmol/L

0 mg/dL
0 mmoIIL

1 Hour

Blood Sugar Result
Fasting

——

**

—

01 Positive
02= Neaatve

0 mg!dI
C mmoUL

Date
mm! dd ! yy

12, GTT:

b

a

Date
mm! dd /

Diabetes screen:

C

a
b

Date
mm! dd !‘JY
__/I
_I_
I
I

10. Gonorrhea:

0 mg/dl
C mmot/L

C mg!dl
C mmol/L

3 hr

173

3

Twen y to

SFJ,i, a z

InsfrucUons
t

—I—

rid Iyy

Date

iour urine p otew

/

I

ddlyy

Date

eating:

ahzed Pre
If the numb
ows to ent

F Specialized testing

on all women enrolled prospectively into the study who have results of specialized testing in their charts All questions

Result
ng/24hr

Result

3,

ALT
(SGPT)

AST
(SGOT)

LDK

4. Pre-Eclampsia Labs:

t recent results chronologically

—

/

/

/

/

/

II

I

II

/

I

I

/
/

/

I

I

I

esuIt

IU

IU

‘U

ly

IU

lU

Units

2

c done of a type exceeds the number of rows provided, enter the results from the first prenatal lab tests on the first row

10

174

Hemoglobir

BUN

Uic Acd

I

I

I

I

1

aIdL

idL

1dL

IdL

-

rndL

m/dL

mIdL

mWdL

rn/dL

rnIdL

m/dL

—

24- hour
urine
protein

Urine
Prot!
Creat
Ratio

Platelets

I

I

I

I

-

/

/

/

,,

/

,

/1

/

‘

/

/

/

-—

/

rnm/dd/yy

Date

I

I

-

I

I

Result

Ratio
Result

* - -

-

—

—

—

-

mg124 hr

mg/24hr

mg/24 hr

mg124 hr

—

urine total protein_mgldL urine
creatinine random
mg/dL

—

—

urine total protein
mgldL urine
creatinine random
mg/dL

*

unne total protein
mg/dL urine
creatinine, random
mg/dL

—

KluL

KIuL

KIuL

urine total protein
mgldL urine
creatinine random
mgldL

-

11

175
—

i__

i__lw

- _I__!_

—

Date
m/ dd yy

ett bur eflance:

Specify

5 Othe L a Tests:

1
I
I

I
I
I

02= Abnormal

Resuft
01 =Normal

**

**

**

**

——

01= Reactive
02= Nonreactive, reassuring
03= Nonreactwe nonreassuring
requires further testing or deIvery

ResuLt

le Stress Tests (NSTs):

/

/

Date Done
m

176

Date

G. kiPabent Stay

—
*

—

—
—
—

2.Dia___

Sys

1 Sys__
2. Dia

1 Ss
2 Dia

I Sys___
2 Da

Highest
Blood Pressures
On MgSO
?
4

yes
no

no

yes

yes
no

no

yes

End time
End date:

Start time
If yes:
Start date:

End date
End time

Start date.

Start time

If yes:

End time

End date.

Ifyes:
Start date

Start time

End time

End date:

Start time.

Start date

If yes:

13

Appendix H
Postpartum Record Retrieval Form

177

178

o

medical c

I

de

TA
EP
MP W

S8=Sl)

v
p

Outcome

GA

GA:

Date

EDC

-

nn4kr yy

-

/

+
FT-4ufl terr
NTwteatcrc if
PThear)y p scm
ETesr)y tsr ucocici

On:

___________
_____

/
/

___

(cv

2)

*

—

r

OR

(bsloz

___I

• 02=op vaginal (forceps or vacuum)
03=C-section

01 =vagna

02=fenrale

01 =maie

Gender

m5
J_zr

1)

Type of Delivery
-

-

/

—

-

• 990ther

[lo=PRoM

OlPreeclampsia
a2- Gestational Kypertention
03Pfacenta previa
04Placental ebruption
O5Pre-gestattorial diabetes Type
OSoPre-gestatlonal diabetes Type (I
O7at3esationa( diabetes
08=PPH. requiring blood transfusion
09=PTL requiring treatment

00=None noted

Ttrni Complications

3)

21

1)

/

Maternal
Description

Date of First Prenatal Visit:

_iEZ1

I

Enter time n eok civ
I documented
If numbo of wev e
w ‘i-ccmented
enter

Gender

Time

P ognancy Outco a

Gravida Status

LMP

______

b t action form for each participant enrolled in the study

A. DetailedPastObstetricatHistory

C

Instructions

Reviewed by,

____________—

:

I

-

2)

1)

01 Cardiovascu1ar

99=Other

02Corrgenital Defect
Q3Respiratory
04-Prematunty
05-Sepsis
06-Unknown

I

I
rn,n/dd!yy

Dont Know
Refused to Answer
Does Not Apply

Code:

Reason for death:

Child NOT Living
(Reason for Death)

I_Li

Date of Death:

If LB & Child NOT LMn

CodIng Key.
-4 Temporarily Missing (not currently available)
-7
-5 = Multiple Responses (needs revIew)
-8
-6 Permanently Missing (not documented tn chart) -9

99=Other

09-Hypoglycemia

Ol-Intra-Uterine Growth Restriction
02- Small for Gestational Age
03- Large for Gestational Age
04-Respiratory Distress Syndrome
OS-Mecortium Aspiration
06=Other defect
07Other genetic disease
08-Observe for sepsis

OONone noted

3)

2)

‘)LLJ

Fetal/infant
Descrrption
Code

Fetatllnfant Complications

2)j_I_

1)Lj

Code

Birth Weight

Maternal Age at Time of Delivery:

ID Number:

_____________

179

it

ttQr5
-

aic

ii n

\a

S

“C

)phctt
t st wuncs

vu kants

\epresiants

\ni icoazulaiib

ho

Name

L\Uithsl2ertCnSises
161= Aldomet
l62” I abetolol
l6 (a-Channel
Blockers
164= Beta-Blockets
1t55 Ace4nhthttor
6)t)ther
antili per1emo e

Jsterois

—

260khogani
2’) Sleep Aide

Progesterone
.D4
=
0

220 Diuretics
23ca(I igcnt

3tt()I3trtli control plk
21 0Aheinotherapeutics

170 Antiemeties
I S ) Anups ChOtiC4
19)\ntivuals

IZIZ Z

Code*

Medication, Vitamin, Vaccine

Prescription Medication, Vitamins and Vaccines — Received Since Delivery

00- 0( series)

B.

t99 A lOser Medication

IrotdAts
25 1 =Antiths roids
os eractis ci
252lhroid Replacement
(under etive

—

ID Number:

(500 series)

Vitamins

ll It
s4 A aletuni
5 19 DII ci
S itamin

sitanuin
521 —Iron

10 Multi
T
5

J

other

+

1)

S SCCIIIC

globulin V/It i)
(,o() 4)tliei

,catei imriiune

o4tO ViuicelLi

(10 Inlluen,a
02° hepatitis B
6 ( il.6jl,eIla

accines
(6OO series)

2

180

00

00 senes)

MJiat ns
i

o igulant
Ic ss rots
ils mIs
Ia nines

ottcs

[D Matorn Diagnoses Sncc DeIivry

ype of Suge

—

I 70—Antiemetica
180 Auipsychotics
190—Antosrals
209041irth control pills
2 l90Cheniothcrapcutrcs
220d)iuretics
230(il agents
240—Pr gesterone
260—Rhogam
270= Sleep \ide
2SOStewas

11edicat1onsPrescribed

Days Hospitalized

161 Aldomet
162=1 abetoIol
163— (‘a4hanncl
I ilockers
164 BetroHiockers
l65’ elnbihitoi
169 Othei
antthypertensive

—

[CMatrnaI Surgenei/Ht pdahzations Smce Delivery

399 (Slier Medication

252 fliyroid Replacement
(under active)

(overactis c)

Thyroid Ag>
:51 Antiuiroida

Able to Breastfeed?

ID Number.

Iron
lolate
halcium
Other
vL9lmm

520
530
S40
599

viulnhln

510 Multi

Vitamins
series)
(500

4

1>

vaccine

610 lnflumnia
620 hepatitis 11
630 Rubella
640 VarieeI1a
Foster immune
dohnlni (V/Ri)
69 4 >thei

(600 series)

Vaccines

Expected Duration

I ong Term Implications

181

I lnftlntPecdingractKe%

c

Diagnosis

1 Infant Diagnos.i rnca Delivery
9
Hosp4

I
Able to Breastfeed

Fxpeted Duration

Infant has never received any formula
Infant received small amounts ( 3 oi) formula in the first week
Infant has received small amounts( 3 oz) of formula several times
Infant has received small amounts (. 3 oz) of formula weekly
Infant receives small amounts ( 3 oz) of formula a few times per week
Infant receives full feedings (:3 oz) of formula a few times per week
Infant receives full feedings ( 3 oi) of formula once a day
Infant receives full feedings ( 3 oz) of formula seeraI times a day
Infant receives only formula fcedings

Medications Prescribed?

ID Number:

4

Appendix I
Adverse Event Forms

182

51

I

Y

I

I

I

S
Si

L
hiS
)J4)
I
0I

4

Scotaitc
i vi micr oft

h

) ittrtonilR

i is

t)
1

Hoail

th
Or Septenibc 4
o ye wcte 10 ified bs Don Ihiele that o ie ci toe paiticipa its in he ud>
isa iospitaiiicd is night oi i kidi ey stile S i 1 o provided a wcent aitici p iN shod iv Dr
4 an flofa
louis iegardin tha tots and ciii no I Vhim nD upl ri tati n 1
corn nit cc, D
t (2ndr Andciso i w s in cont ct with one of th pail vipant care ii widen and
to nuisc pra t,tio u is is one inc med that ti s is a sociated is th icr paticiat on i the st d
a v ci and feels it was oi iv relattd to hei incicased i isk witi p egnanev

Oui imu cdii c feedback to Don wi tc a ccit in lip ssiil tie e ul d any in hosçit 1 lab
1 parii(ipant
)(fltiJ) I I tlowuiri r
[ihc wore diawn a ih°
ctuiies, In pMii(U a’ tt
paticnt’s nc pios dna aic iamiiinr witl nrcgnaney associated kidney stone and weic
un ‘o icerned bont hei partieipatioi in M I hicic s udy

The ieseaiche
s wcr° able to obtain the baselin vitan ni I) level Di the participant h was 74 5
1
iobL (kreater than or eqnal to 80 nmol I s coos, Icred snffieicnt by most coi tempoiary
itarnin D iescarchcis and Ms. 1 hide is u Ing that as her cot oh Di the study with 225 ninol/I
c thc co off tot n axanur lcvcl) Ihc pai icipa it
2viOH)D les ci isa cc tair I> not tc c high,
and we n t anticipitc that it will be raised above thc max nit m cnt off by hci on studs
iii

ieatrncnt

Oni ie nan ierd’ tic n to Ms. I hid was contin c with the stud) as pia icd hut additioi a
h oc wo kinvcstinatio i may be tm ntcd i rhs pati nt r other pa icnts t pciicr e i niai
crents

S ic rcl3

D

d
Iycc
I a Sn

i

183

*1

f-SE

‘ii

Ff3

‘MTIG

r,:u

vern

S

t

d P
0
a

3
r

i2

F
j;

Pitt.

STIC

S’

I

%t

a
0

it

F

a4

orr

1

i

a

€

-

S

-

_,—

a

—a

4-0
r

NI

L

4

R

r

V

as

‘S

or

r
-a

-a

af

3

IC

C,
--_

flc’T
—

a

--

rCPa

a

A

-

qf

Rt.at

%C

2

-

5V

a—

a

184

-

‘ci

A
L

I-

3d

a
a

t.

-.

a
V

SW
a
‘3

H

55
’
1
PRO

V

-

c—a

“

S

1± P’ PS

C

SE

-

-C

-

-‘3--

43

‘4O
A
T
E1

NtkE

E

‘-

PI

4

q

C

a
!

C”

4P’
14

‘c4?)AJ7O
4PED

rAFt

.n

PAFTh LEJ
C

4- aFiThS

-M

a

e

Sr

kI

Va’

r
4
u

,--y

ak
I

—

--

C

PSP

A

C

Si-C’

3

:ataS

—

C

-;

-C

3

T

185

r

C.

tAltru

un Boar

I ntitut

4dvcre L’ tnt Repnr

t

V

a

adverse eve

Detailed
_

at

<a

<
—

;

Ste

z

J

a<

t

3

Q
-

—c

t-

—I
4

*2

4—

*22

-

r
a-

Gutcane at acvrse eet

x

<a

a

4)

<a’s

a
-<‘C va

<

-

4L V

a
N

*2

Tie

o
0
4
D ?5

186

rr°n’

187
:Aq pEMOJddE•

puc 9Rfl339 uesq seq uode )Li5A5 es.isspe sqj

I

A1tru
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Institutional Review Board (IRB)

Adverse Event Report
Revised 5/10/il

All sencus adveie events, whether occurring at the local stutty site or at other stucty sites, ate to be reported to the Altru Health
System 1R8 using this fom7.
Ljamej4temalvitamfrt D

to correct dinmothersandbreasjnfants__

Date of Event 9/412012
Date Known to You: 9/412012
Name of Study Drug, Device or Procedure. (not study name) Vitamin D 3800 lU/Daily, Or, Placebo (400 IU daily from
-

Adverse Event #: 1
Initial Report (Yes or No): Yes
Follow-up report #
Detailed description of adverse event and action taken (use additional pages or attach additional documentation, if

necessary):

One of the study participants developed a kidney stone which necessitated an over-night stay in the hospital with ureter
stent placement. Kidney stones are relatively common in pregnancy. She has been in the study for I month and is now
33 weeks gestation. Upon learning of this incident, her primary care clinic was contacted and they reported they felt
it was
not study related, They also reported that no labs were done at the hospital as this is considered to be solely pregnancy
related. 1 then contacted the Data Safety Monitoring Board with the information and they are currently working on
reviewing the data and drafting a report. The participant’s baseline circulating vitamin 0 level (25[OH]D) was 745 nmol/L
(80 nrnol/L to 225 nmol/L is considered sufficientlnormal), so she did not enter the study with an unusually high
25[OHJD.
Outcome of adverse event: (Check all that apply)
Required Intervention

Life threatening

X

Other (Explain):

Hospitalization-initial or prolonged

Death
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Congenital anomalylbirth defect

Did this event occur in the above listed study?
Is this type of adverse event described in the consent form approved by this lRB?
Did this event occur to a subject enrolled in the study at Altru Health System?
If yes, was this event reported to:______ Study Sponsor
Co-Investigators

X

Yes
Yes
Yes

X

Relationship of the Event to any research treatment appears to be: (Sponsor assessment)
Unknown
Not related
Unlikely
Possibly
Probably
—

Relationship of the Event to any research treatment appears to be: (P1 assessment
Unknown
Not related
Unlikely
X
Possibly
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189

Date

H

References

ACOG Committee on Obstetric Practice. (2011). ACOG committee opinion no. 495:
Vitamin D: Screening and supplementation during pregnancy. Obstetrics and
Gynecology, 118(1), 197-198. doi:10.1097/AOG.0b013e318227f06b

Ahuja, J., Montville, J., Omolewa-Tomobi, G., Heendeniya, K., Martin, C., Steinfeldt, L.,
. . . Moshfegh, A. (2012). USDA food and nutrient database for dietary studies, 5.0.
(). Bethesda, MD: U.S. Department of Agriculture, Agricultural Research Service,
Food Surveys Research Group.

Akbar, N. A., & Zacharek, M. A. (2011). Vitamin D: Immunomodulation of asthma,
allergic rhinitis, and chronic rhinosinusitis. Current Opinion in Otolaryngology &
Head and Neck Surgery, 19(3), 224-228. doi:10.1097/MOO.0b013e3283465687

Ala-Houhala, M. (1985). 25-hydroxyvitamin D levels during breast-feeding with or
without maternal or infantile supplementation of vitamin D. Journal of Pediatric
Gastroenterology and Nutrition, 4(2), 220-226.

190

Ala-Houhala, M., Koskinen, T., Terho, A., Koivula, T., & Visakorpi, J. (1986). Maternal
compared with infant vitamin D supplementation. Archives of Disease in Childhood,
61(12), 1159-1163.

Arnson, Y., & Amital, H. (2011). Is vitamin D a new therapeutic agent in
autoinflammatory and pain syndromes? The Israel Medical Association Journal :
IMAJ, 13(4), 234-235.

Arnson, Y., Itzhaky, D., Mosseri, M., Barak, V., Tzur, B., Agmon-Levin, N., & Amital,
H. (2013). Vitamin D inflammatory cytokines and coronary events: A
comprehensive review. Clinical Reviews in Allergy & Immunology,
doi:10.1007/s12016-013-8356-0

Baccarelli, A., & Bollati, V. (2009). Epigenetics and environmental chemicals. Current
Opinion in Pediatrics, 21(2), 243-251.

Baker, A. M., Haeri, S., Camargo, C. A.,Jr, Espinola, J. A., & Stuebe, A. M. (2010). A
nested case-control study of midgestation vitamin D deficiency and risk of severe
preeclampsia. The Journal of Clinical Endocrinology and Metabolism, 95(11), 51055109. doi:10.1210/jc.2010-0996

Baker, A. M., Haeri, S., Camargo, C. A.,Jr, Stuebe, A. M., & Boggess, K. A. (2012).
First-trimester maternal vitamin D status and risk for gestational diabetes (GDM) a
nested case-control study. Diabetes/Metabolism Research and Reviews, 28(2), 164168. doi:10.1002/dmrr.1282; 10.1002/dmrr.1282
191

Balasubramanian, S. (2011). Vitamin D deficiency in breastfed infants & the need for
routine vitamin D supplementation. The Indian Journal of Medical Research,
133(3), 250-252.

Balasubramanian, S., & Ganesh, R. (2008). Vitamin D deficiency in exclusively breastfed infants. The Indian Journal of Medical Research, 127(3), 250-255.

Balasubramanian, S., Shivbalan, S., & Kumar, P. S. (2006). Hypocalcemia due to vitamin
D deficiency in exclusively breastfed infants. Indian Pediatrics, 43(3), 247-251.

Barker, D. J. (1994). Maternal and fetal origins of coronary heart disease. Journal of the
Royal College of Physicians of London, 28(6), 544-551.

Barker, D. J. (1995). The fetal and infant origins of disease. European Journal of Clinical
Investigation, 25(7), 457-463.

Barker, D. J. (1997). Fetal nutrition and cardiovascular disease in later life. British
Medical Bulletin, 53(1), 96-108.

Barker, D. J. (2000). In utero programming of cardiovascular disease. Theriogenology,
53(2), 555-574.

Barker, D. J., Eriksson, J. G., Forsen, T., & Osmond, C. (2002). Fetal origins of adult
disease: Strength of effects and biological basis. International Journal of
Epidemiology, 31(6), 1235-1239.

192

Barker, D. J., & Fall, C. H. (1993). Fetal and infant origins of cardiovascular disease.
Archives of Disease in Childhood, 68(6), 797-799.

Barker, T., Martins, T. B., Hill, H. R., Kjeldsberg, C. R., Dixon, B. M., Schneider, E. D.,
. . . Weaver, L. K. (2013). Circulating pro-inflammatory cytokines are elevated and
peak power output correlates with 25-hydroxyvitamin D in vitamin D insufficient
adults. European Journal of Applied Physiology, doi:10.1007/s00421-012-2582-7

Barnard, K., & Colon-Emeric, C. (2010). Extraskeletal effects of vitamin D in older
adults: Cardiovascular disease, mortality, mood, and cognition. The American
Journal of Geriatric Pharmacotherapy, 8(1), 4-33.
doi:10.1016/j.amjopharm.2010.02.004; 10.1016/j.amjopharm.2010.02.004

Barrera, D., Noyola-Martinez, N., Avila, E., Halhali, A., Larrea, F., & Diaz, L. (2012).
Calcitriol inhibits interleukin-10 expression in cultured human trophoblasts under
normal and inflammatory conditions. Cytokine, 57(3), 316-321.
doi:10.1016/j.cyto.2011.11.020; 10.1016/j.cyto.2011.11.020

Barrett, H., & McElduff, A. (2010). Vitamin D and pregnancy: An old problem revisited.
Best Practice & Research.Clinical Endocrinology & Metabolism, 24(4), 527-539.
doi:10.1016/j.beem.2010.05.010

193

Basile, L. A., Taylor, S. N., Wagner, C. L., Horst, R. L., & Hollis, B. W. (2006). The
effect of high-dose vitamin D supplementation on serum vitamin D levels and milk
calcium concentration in lactating women and their infants. Breastfeeding Medicine
: The Official Journal of the Academy of Breastfeeding Medicine, 1(1), 27-35.
doi:10.1089/bfm.2006.1.27

Basile, L. A., Taylor, S. N., Wagner, C. L., Quinones, L., & Hollis, B. W. (2007).
Neonatal vitamin D status at birth at latitude 32 degrees 72': Evidence of deficiency.
Journal of Perinatology : Official Journal of the California Perinatal Association,
27(9), 568-571. doi:10.1038/sj.jp.7211796

Bendall, A., de Costa, C., Woods, C., & Howat, P. (2012). Vitamin D levels in pregnant
women booking for antenatal care in far north queensland. The Australian & New
Zealand Journal of Obstetrics & Gynaecology, 52(4), 391-394. doi:10.1111/j.1479828X.2012.01423.x; 10.1111/j.1479-828X.2012.01423.x

Bischoff-Ferrari, H. A., Giovannucci, E., Willett, W. C., Dietrich, T., & Dawson-Hughes,
B. (2006). Estimation of optimal serum concentrations of 25-hydroxyvitamin D for
multiple health outcomes. The American Journal of Clinical Nutrition, 84(1), 18-28.

Bodnar, L. M., Catov, J. M., Simhan, H. N., Holick, M. F., Powers, R. W., & Roberts, J.
M. (2007). Maternal vitamin D deficiency increases the risk of preeclampsia. The
Journal of Clinical Endocrinology and Metabolism, 92(9), 3517-3522.
doi:10.1210/jc.2007-0718
194

Bodnar, L. M., & Simhan, H. N. (2010). Vitamin D may be a link to black-white
disparities in adverse birth outcomes. Obstetrical & Gynecological Survey, 65(4),
273-284. doi:10.1097/OGX.0b013e3181dbc55b

Bodnar, L. M., Simhan, H. N., Powers, R. W., Frank, M. P., Cooperstein, E., & Roberts,
J. M. (2007). High prevalence of vitamin D insufficiency in black and white
pregnant women residing in the northern united states and their neonates. The
Journal of Nutrition, 137(2), 447-452.

Bowyer, L., Catling-Paull, C., Diamond, T., Homer, C., Davis, G., & Craig, M. E.
(2009). Vitamin D, PTH and calcium levels in pregnant women and their neonates.
Clinical Endocrinology, 70(3), 372-377. doi:10.1111/j.1365-2265.2008.03316.x;
10.1111/j.1365-2265.2008.03316.x

Brannon, P. M. (2012). Vitamin D and adverse pregnancy outcomes: Beyond bone health
and growth. The Proceedings of the Nutrition Society, 71(2), 205-212.
doi:10.1017/S0029665111003399

Brooke, O. G., Brown, I. R., Bone, C. D., Carter, N. D., Cleeve, H. J., Maxwell, J. D., . . .
Winder, S. M. (1980). Vitamin D supplements in pregnant asian women: Effects on
calcium status and fetal growth. British Medical Journal, 280(6216), 751-754.

Brooke, O. G., Butters, F., & Wood, C. (1981). Intrauterine vitamin D nutrition and
postnatal growth in asian infants. British Medical Journal (Clinical Research Ed.),
283(6298), 1024.
195

Camadoo, L., Tibbott, R., & Isaza, F. (2007). Maternal vitamin D deficiency associated
with neonatal hypocalcaemic convulsions. Nutrition Journal, 6, 23.
doi:10.1186/1475-2891-6-23

Camargo, C. A.,Jr, Ingham, T., Wickens, K., Thadhani, R., Silvers, K. M., Epton, M. J., .
. . New Zealand Asthma and Allergy Cohort Study Group. (2011). Cord-blood 25hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma.
Pediatrics, 127(1), e180-7. doi:10.1542/peds.2010-0442

Centers for Disease Control and Prevention (CDC). (1999). Safer and healthier foods.
MMWR.Morbidity and Mortality Weekly Report, 48(40), 905-913.

Chen, P., Hu, P., Xie, D., Qin, Y., Wang, F., & Wang, H. (2010). Meta-analysis of
vitamin D, calcium and the prevention of breast cancer. Breast Cancer Research and
Treatment, 121(2), 469-477. doi:10.1007/s10549-009-0593-9; 10.1007/s10549-0090593-9

Christesen, H. T., Elvander, C., Lamont, R. F., & Jorgensen, J. S. (2012). The impact of
vitamin D in pregnancy on extraskeletal health in children: A systematic review.
Acta Obstetricia Et Gynecologica Scandinavica, 91(12), 1368-1380.
doi:10.1111/aogs.12006; 10.1111/aogs.12006

196

Clifton-Bligh, R. J., McElduff, P., & McElduff, A. (2008). Maternal vitamin D
deficiency, ethnicity and gestational diabetes. Diabetic Medicine : A Journal of the
British Diabetic Association, 25(6), 678-684. doi:10.1111/j.14645491.2008.02422.x; 10.1111/j.1464-5491.2008.02422.x

Collins-Fulea, C., Klima, K., & Wegienka, G. R. (2012). Prevalence of low vitamin D
levels in an urban midwestern obstetric practice. Journal of Midwifery & Women's
Health, 57(5), 439-444. doi:10.1111/j.1542-2011.2012.00167.x; 10.1111/j.15422011.2012.00167.x

Cooper, J. D., Smyth, D. J., Walker, N. M., Stevens, H., Burren, O. S., Wallace, C., . . .
Todd, J. A. (2011). Inherited variation in vitamin D genes is associated with
predisposition to autoimmune disease type 1 diabetes. Diabetes, 60(5), 1624-1631.
doi:10.2337/db10-1656

Cosgrove, L., & Dietrich, A. (1985). Nutritional rickets in breast-fed infants. The Journal
of Family Practice, 21(3), 205-209.

Cota, B., & Allen, P. (2010). The developmental origins of health and disease hypothesis.
Pediatric Nursing, 36(3), 157-166.

Datta, S., Alfaham, M., Davies, D. P., Dunstan, F., Woodhead, S., Evans, J., & Richards,
B. (2002). Vitamin D deficiency in pregnant women from a non-european ethnic
minority population--an interventional study. BJOG : An International Journal of
Obstetrics and Gynaecology, 109(8), 905-908.
197

Dawodu, A., Saadi, H. F., Bekdache, G., Javed, Y., Altaye, M., & Hollis, B. W. (2013).
Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a
population with endemic vitamin D deficiency. The Journal of Clinical
Endocrinology and Metabolism, doi:10.1210/jc.2013-1154

Dawodu, A., & Wagner, C. L. (2007). Mother-child vitamin D deficiency: An
international perspective. Archives of Disease in Childhood, 92(9), 737-740.
doi:10.1136/adc.2007.122689

Delvin, E. E., Salle, B. L., Glorieux, F. H., Adeleine, P., & David, L. S. (1986). Vitamin
D supplementation during pregnancy: Effect on neonatal calcium homeostasis. The
Journal of Pediatrics, 109(2), 328-334.

Denney, J. M., Nelson, E. L., Wadhwa, P. D., Waters, T. P., Mathew, L., Chung, E. K., . .
. Culhane, J. F. (2011). Longitudinal modulation of immune system cytokine profile
during pregnancy. Cytokine, 53(2), 170-177. doi:10.1016/j.cyto.2010.11.005;
10.1016/j.cyto.2010.11.005

De-Regil, L. M., Palacios, C., Ansary, A., Kulier, R., & Pena-Rosas, J. P. (2012).
Vitamin D supplementation for women during pregnancy. Cochrane Database of
Systematic Reviews (Online), 2, CD008873. doi:10.1002/14651858.CD008873.pub2

198

Di Rosa, M., Malaguarnera, G., De Gregorio, C., Palumbo, M., Nunnari, G., &
Malaguarnera, L. (2012). Immuno-modulatory effects of vitamin D3 in human
monocyte and macrophages. Cellular Immunology, 280(1), 36-43.
doi:10.1016/j.cellimm.2012.10.009; 10.1016/j.cellimm.2012.10.009

Dietary reference intakes: Guiding principles for nutrition labeling and fortification.
(2004). Nutrition Reviews, 62(2), 73-79.

Dror, D. K., King, J. C., Durand, D. J., & Allen, L. H. (2011a). Association of modifiable
and nonmodifiable factors with vitamin D status in pregnant women and neonates in
oakland, CA. Journal of the American Dietetic Association, 111(1), 111-116.
doi:10.1016/j.jada.2010.10.002

Dror, D. K., King, J. C., Durand, D. J., & Allen, L. H. (2011b). Association of modifiable
and nonmodifiable factors with vitamin D status in pregnant women and neonates in
oakland, CA. Journal of the American Dietetic Association, 111(1), 111-116.
doi:10.1016/j.jada.2010.10.002

Eichholzer, M., Platz, E. A., Bienstock, J. L., Monsegue, D., Akereyeni, F., Hollis, B. W.,
. . . Rohrmann, S. (2013). Racial variation in vitamin D cord blood concentration in
white and black male neonates. Cancer Causes & Control : CCC, 24(1), 91-98.
doi:10.1007/s10552-012-0093-9; 10.1007/s10552-012-0093-9

199

Eliades, M., & Pittas, A. G. (2009). Vitamin D and type 2 diabetes. Clinical Reviews in
Bone and Mineral Metabolism, 7, 185-198. doi:10.1007/s12018-009-9041-y

Ellis, J. A., Munro, J. E., & Ponsonby, A. L. (2010). Possible environmental determinants
of juvenile idiopathic arthritis. Rheumatology (Oxford, England), 49(3), 411-425.
doi:10.1093/rheumatology/kep383

Epstein, S. (2006). The problem of low levels of vitamin D and osteoporosis: Use of
combination therapy with alendronic acid and colecalciferol (vitamin D3). Drugs &
Aging, 23(8), 617-625.

Erkkola, M., Kaila, M., Nwaru, B. I., Kronberg-Kippila, C., Ahonen, S., Nevalainen, J., .
. . Virtanen, S. M. (2009). Maternal vitamin D intake during pregnancy is inversely
associated with asthma and allergic rhinitis in 5-year-old children. Clinical and
Experimental Allergy : Journal of the British Society for Allergy and Clinical
Immunology, 39(6), 875-882. doi:10.1111/j.1365-2222.2009.03234.x

Erkkola, M., Nwaru, B. I., & Viljakainen, H. T. (2011). Maternal vitamin D during
pregnancy and its relation to immune-mediated diseases in the offspring. Vitamins
and Hormones, 86, 239-260. doi:10.1016/B978-0-12-386960-9.00010-1

FAO/WHO. (2004). <br />Vitamin and mineral requirements in human nutrition : Report
of a joint FAO/WHO expert consultation, bangkok, thailand, 21–30 september 1998.
Joint FAO/WHO Expert Consultation on Human Vitamin and Mineral
Requirements,
200

Feneis, J. F., & Arora, R. R. (2010). Role of vitamin D in blood pressure homeostasis.
American Journal of Therapeutics, 17(6), e221-9.
doi:10.1097/MJT.0b013e3181d16999; 10.1097/MJT.0b013e3181d16999

Fernandes de Abreu, D. A., Landel, V., & Feron, F. (2011). Seasonal, gestational and
postnatal influences on multiple sclerosis: The beneficial role of a vitamin D
supplementation during early life. Journal of the Neurological Sciences, 311(1-2),
64-68. doi:10.1016/j.jns.2011.08.044; 10.1016/j.jns.2011.08.044

Garland, C. F., Comstock, G. W., Garland, F. C., Helsing, K. J., Shaw, E. K., & Gorham,
E. D. (1989). Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective
study. Lancet, 2(8673), 1176-1178.

Garland, C. F., Grant, W. B., Boucher, B. J., Cross, H. S., Garland, F. C., Gillie, O., . . .
Zittermann, A. (2009). Open letter to IARC director christopher P. wild-re: IARC
working group report 5: Vitamin D and cancer. Dermato-Endocrinology, 1(2), 119120.

Garland, F. C., Garland, C. F., Gorham, E. D., & Young, J. F. (1990). Geographic
variation in breast cancer mortality in the united states: A hypothesis involving
exposure to solar radiation. Preventive Medicine, 19(6), 614-622.

201

Ginde, A. A., Liu, M. C., & Camargo, C. A.,Jr. (2009). Demographic differences and
trends of vitamin D insufficiency in the US population, 1988-2004. Archives of
Internal Medicine, 169(6), 626-632. doi:10.1001/archinternmed.2008.604;
10.1001/archinternmed.2008.604

Gloth, F. M.,3rd, Gundberg, C. M., Hollis, B. W., Haddad, J. G.,Jr, & Tobin, J. D.
(1995). Vitamin D deficiency in homebound elderly persons. JAMA : The Journal of
the American Medical Association, 274(21), 1683-1686.

Gloth, F. M.,3rd, Tobin, J. D., Sherman, S. S., & Hollis, B. W. (1991). Is the
recommended daily allowance for vitamin D too low for the homebound elderly?
Journal of the American Geriatrics Society, 39(2), 137-141.

Grant, W. B. (2011a). An estimate of the global reduction in mortality rates through
doubling vitamin D levels. European Journal of Clinical Nutrition, 65(9), 10161026. doi:10.1038/ejcn.2011.68; 10.1038/ejcn.2011.68

Grant, W. B. (2011b). Is the institute of medicine report on calcium and vitamin D good
science? Biological Research for Nursing, 13(2), 117-119.
doi:10.1177/1099800410396947

Gravina, S., & Vijg, J. (2010). Epigenetic factors in aging and longevity. Pflugers Archiv
: European Journal of Physiology, 459(2), 247-258. doi:10.1007/s00424-009-07307; 10.1007/s00424-009-0730-7

202

Greer, F. R. (2008). 25-hydroxyvitamin D: Functional outcomes in infants and young
children. The American Journal of Clinical Nutrition, 88(2), 529S-533S.

Greer, F. R., Hollis, B. W., Cripps, D. J., & Tsang, R. C. (1984). Effects of maternal
ultraviolet B irradiation on vitamin D content of human milk. The Journal of
Pediatrics, 105(3), 431-433.

Greer, F. R., Hollis, B. W., & Napoli, J. L. (1984). High concentrations of vitamin D2 in
human milk associated with pharmacologic doses of vitamin D2. The Journal of
Pediatrics, 105(1), 61-64.

Haddad, J. G., Matsuoka, L. Y., Hollis, B. W., Hu, Y. Z., & Wortsman, J. (1993). Human
plasma transport of vitamin D after its endogenous synthesis. The Journal of Clinical
Investigation, 91(6), 2552-2555. doi:10.1172/JCI116492

Halicioglu, O., Sutcuoglu, S., Koc, F., Yildiz, O., Akman, S. A., & Aksit, S. (2012).
Vitamin D status of exclusively breastfed 4-month-old infants supplemented during
different seasons. Pediatrics, 130(4), e921-7. doi:10.1542/peds.2012-0017;
10.1542/peds.2012-0017

Hanwell, H. E., & Banwell, B. (2011). Assessment of evidence for a protective role of
vitamin D in multiple sclerosis. Biochimica Et Biophysica Acta, 1812(2), 202-212.
doi:10.1016/j.bbadis.2010.07.017

203

Harrison, H. E. (1975). Vitamin D malnutrition. Progress in Food & Nutrition Science,
1(5), 349-357.

Haugen, M., Brantsaeter, A. L., Trogstad, L., Alexander, J., Roth, C., Magnus, P., &
Meltzer, H. M. (2009). Vitamin D supplementation and reduced risk of preeclampsia
in nulliparous women. Epidemiology (Cambridge, Mass.), 20(5), 720-726.
doi:10.1097/EDE.0b013e3181a70f08

Heaney, R. P., Davies, K. M., Chen, T. C., Holick, M. F., & Barger-Lux, M. J. (2003).
Human serum 25-hydroxycholecalciferol response to extended oral dosing with
cholecalciferol. The American Journal of Clinical Nutrition, 77(1), 204-210.

Heaney, R. P., & Holick, M. F. (2011). Why the IOM recommendations for vitamin D
are deficient. Journal of Bone and Mineral Research : The Official Journal of the
American Society for Bone and Mineral Research, 26(3), 455-457.
doi:10.1002/jbmr.328; 10.1002/jbmr.328

Heaney, R. P., Recker, R. R., Grote, J., Horst, R. L., & Armas, L. A. (2011). Vitamin
D(3) is more potent than vitamin D(2) in humans. The Journal of Clinical
Endocrinology and Metabolism, 96(3), E447-52. doi:10.1210/jc.2010-2230

Holick, M. F. (2005). The vitamin D epidemic and its health consequences. The Journal
of Nutrition, 135(11), 2739S-48S.

204

Holick, M. F. (2006). The role of vitamin D for bone health and fracture prevention.
Current Osteoporosis Reports, 4(3), 96-102.

Holick, M. F. (2011). Vitamin D: Evolutionary, physiological and health perspectives.
Current Drug Targets, 12(1), 4-18.

Hollis, B. W. (1983). Individual quantitation of vitamin D2, vitamin D3, 25hydroxyvitamin D2, and 25-hydroxyvitamin D3 in human milk. Analytical
Biochemistry, 131(1), 211-219.

Hollis, B. W. (2005). Circulating 25-hydroxyvitamin D levels indicative of vitamin D
sufficiency: Implications for establishing a new effective dietary intake
recommendation for vitamin D. The Journal of Nutrition, 135(2), 317-322.

Hollis, B. W. (2007). Vitamin D requirement during pregnancy and lactation. Journal of
Bone and Mineral Research : The Official Journal of the American Society for Bone
and Mineral Research, 22 Suppl 2, V39-44. doi:10.1359/jbmr.07s215

Hollis, B. W. (2008). Assessment of vitamin D status and definition of a normal
circulating range of 25-hydroxyvitamin D. Current Opinion in Endocrinology,
Diabetes, and Obesity, 15(6), 489-494. doi:10.1097/MED.0b013e328317ca6c

Hollis, B. W. (2009). Nutrition: US recommendations fail to correct vitamin D
deficiency. Nature Reviews.Endocrinology, 5(10), 534-536.
doi:10.1038/nrendo.2009.178
205

Hollis, B. W. (2012). Assessment and interpretation of circulating 25-hydroxyvitamin D
and 1,25-dihydroxyvitamin D in the clinical environment. Rheumatic Diseases
Clinics of North America, 38(1), 29-44. doi:10.1016/j.rdc.2012.03.005;
10.1016/j.rdc.2012.03.005

Hollis, B. W., Johnson, D., Hulsey, T. C., Ebeling, M., & Wagner, C. L. (2011). Vitamin
D supplementation during pregnancy: Double-blind, randomized clinical trial of
safety and effectiveness. Journal of Bone and Mineral Research : The Official
Journal of the American Society for Bone and Mineral Research, 26(10), 2341-2357.
doi:10.1002/jbmr.463; 10.1002/jbmr.463

Hollis, B. W., Pittard, W. B.,3rd, & Reinhardt, T. A. (1986). Relationships among
vitamin D, 25-hydroxyvitamin D, and vitamin D-binding protein concentrations in
the plasma and milk of human subjects. The Journal of Clinical Endocrinology and
Metabolism, 62(1), 41-44.

Hollis, B. W., Roos, B. A., Draper, H. H., & Lambert, P. W. (1981). Vitamin D and its
metabolites in human and bovine milk. The Journal of Nutrition, 111(7), 1240-1248.

Hollis, B. W., Roos, B. A., & Lambert, P. W. (1982). Vitamin D compounds in human
and bovine milk. Advances in Nutritional Research, 4, 59-75.

Hollis, B. W., & Wagner, C. L. (2004a). Assessment of dietary vitamin D requirements
during pregnancy and lactation. The American Journal of Clinical Nutrition, 79(5),
717-726.
206

Hollis, B. W., & Wagner, C. L. (2004b). Vitamin D requirements during lactation: Highdose maternal supplementation as therapy to prevent hypovitaminosis D for both the
mother and the nursing infant. The American Journal of Clinical Nutrition, 80(6
Suppl), 1752S-8S.

Hollis, B. W., & Wagner, C. L. (2006). Nutritional vitamin D status during pregnancy:
Reasons for concern. CMAJ : Canadian Medical Association Journal = Journal De
L'Association Medicale Canadienne, 174(9), 1287-1290. doi:10.1503/cmaj.060149

Hollis, B. W., & Wagner, C. L. (2011). The vitamin D requirement during human
lactation: The facts and IOM's 'utter' failure. Public Health Nutrition, 14(4), 748749. doi:10.1017/S1368980011000309

Holmes, V. A., Barnes, M. S., Alexander, H. D., McFaul, P., & Wallace, J. M. (2009).
Vitamin D deficiency and insufficiency in pregnant women: A longitudinal study.
The British Journal of Nutrition, 102(6), 876-881. doi:10.1017/S0007114509297236

Hypponen, E., Laara, E., Reunanen, A., Jarvelin, M. R., & Virtanen, S. M. (2001). Intake
of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet, 358(9292),
1500-1503. doi:10.1016/S0140-6736(01)06580-1

Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin
D and Calcium. (2011).

207

Jamali, Z., Asadikaram, G., Mahmoodi, M., Sayadi, A., Jamalizadeh, A., SalehMoghadam, M., . . . Arababadi, M. K. (2013). Vitamin D status in female students
and its relation to calcium metabolism markers, lifestyles, and polymorphism in
vitamin D receptor. Clinical Laboratory, 59(3-4), 407-413.

Kaludjerovic, J., & Vieth, R. (2010). Relationship between vitamin D during perinatal
development and health. Journal of Midwifery & Women's Health, 55(6), 550-560.
doi:10.1016/j.jmwh.2010.02.016

Kamen, D. L., Cooper, G. S., Bouali, H., Shaftman, S. R., Hollis, B. W., & Gilkeson, G.
S. (2006). Vitamin D deficiency in systemic lupus erythematosus. Autoimmunity
Reviews, 5(2), 114-117. doi:10.1016/j.autrev.2005.05.009

Karatekin, G., Kaya, A., Salihoglu, O., Balci, H., & Nuhoglu, A. (2009). Association of
subclinical vitamin D deficiency in newborns with acute lower respiratory infection
and their mothers. European Journal of Clinical Nutrition, 63(4), 473-477.
doi:10.1038/sj.ejcn.1602960

Kimball, S. M., & Vieth, R. (2007). A comparison of automated methods for the
quantitation of serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. Clinical
Biochemistry, 40(16-17), 1305-1310. doi:10.1016/j.clinbiochem.2007.07.015

Kovacs, C. S. (2008). Vitamin D in pregnancy and lactation: Maternal, fetal, and neonatal
outcomes from human and animal studies. The American Journal of Clinical
Nutrition, 88(2), 520S-528S.
208

Kunz, C., Niesen, M., von Lilienfeld-Toal, H., & Burmeister, W. (1984). Vitamin D, 25hydroxy-vitamin D and 1,25-dihydroxy-vitamin D in cow's milk, infant formulas and
breast milk during different stages of lactation. International Journal for Vitamin
and Nutrition Research.Internationale Zeitschrift Fur Vitamin- Und
Ernahrungsforschung.Journal International De Vitaminologie Et De Nutrition,
54(2-3), 141-148.

Lagishetty, V., Liu, N. Q., & Hewison, M. (2011). Vitamin D metabolism and innate
immunity. Molecular and Cellular Endocrinology, 347(1-2), 97-105.
doi:10.1016/j.mce.2011.04.015

Lappe, J. M. (2011). The role of vitamin D in human health: A paradigm shift. Journal of
Evidence-Based Complementary & Alternative Medicine, 16(1), 58-72.
doi:10.1177/1533210110392952

Lee, J. M., Smith, J. R., Philipp, B. L., Chen, T. C., Mathieu, J., & Holick, M. F. (2007).
Vitamin D deficiency in a healthy group of mothers and newborn infants. Clinical
Pediatrics, 46(1), 42-44. doi:10.1177/0009922806289311

Li, W., Green, T. J., Innis, S. M., Barr, S. I., Whiting, S. J., Shand, A., & von Dadelszen,
P. (2011). Suboptimal vitamin D levels in pregnant women despite supplement use.
Canadian Journal of Public Health.Revue Canadienne De Sante Publique, 102(4),
308-312.

209

Li, Y. C. (2003). Vitamin D regulation of the renin-angiotensin system. Journal of
Cellular Biochemistry, 88(2), 327-331. doi:10.1002/jcb.10343

Lips, P., Wiersinga, A., van Ginkel, F. C., Jongen, M. J., Netelenbos, J. C., Hackeng, W.
H., . . . van der Vijgh, W. J. (1988). The effect of vitamin D supplementation on
vitamin D status and parathyroid function in elderly subjects. The Journal of Clinical
Endocrinology and Metabolism, 67(4), 644-650.

Lucas, R. M., Ponsonby, A. L., Pasco, J. A., & Morley, R. (2008). Future health
implications of prenatal and early-life vitamin D status. Nutrition Reviews, 66(12),
710-720. doi:10.1111/j.1753-4887.2008.00126.x; 10.1111/j.17534887.2008.00126.x

Madden, K., Feldman, H. A., Smith, E. M., Gordon, C. M., Keisling, S. M., Sullivan, R.
M., . . . Randolph, A. G. (2012). Vitamin D deficiency in critically ill children.
Pediatrics, 130(3), 421-428. doi:10.1542/peds.2011-3328; 10.1542/peds.2011-3328

Maghbooli, Z., Hossein-Nezhad, A., Karimi, F., Shafaei, A. R., & Larijani, B. (2008).
Correlation between vitamin D3 deficiency and insulin resistance in pregnancy.
Diabetes/Metabolism Research and Reviews, 24(1), 27-32. doi:10.1002/dmrr.737

Mahomed, K., & Gulmezoglu, A. M. (2011). WITHDRAWN: Vitamin D
supplementation in pregnancy. Cochrane Database of Systematic Reviews (Online),
(2):CD000228. doi(2), CD000228. doi:10.1002/14651858.CD000228.pub2;
10.1002/14651858.CD000228.pub2
210

Mallet, E., Gugi, B., Brunelle, P., Henocq, A., Basuyau, J. P., & Lemeur, H. (1986).
Vitamin D supplementation in pregnancy: A controlled trial of two methods.
Obstetrics and Gynecology, 68(3), 300-304.

Marjamaki, L., Niinisto, S., Kenward, M. G., Uusitalo, L., Uusitalo, U., Ovaskainen, M.
L., . . . Virtanen, S. M. (2010). Maternal intake of vitamin D during pregnancy and
risk of advanced beta cell autoimmunity and type 1 diabetes in offspring.
Diabetologia, 53(8), 1599-1607. doi:10.1007/s00125-010-1734-8

Marya, R. K., Rathee, S., Lata, V., & Mudgil, S. (1981). Effects of vitamin D
supplementation in pregnancy. Gynecologic and Obstetric Investigation, 12(3), 155161.

Matsuoka, L. Y., Wortsman, J., Haddad, J. G., & Hollis, B. W. (1989). In vivo threshold
for cutaneous synthesis of vitamin D3. The Journal of Laboratory and Clinical
Medicine, 114(3), 301-305.

Maxwell, J. D., Ang, L., Brooke, O. G., & Brown, I. R. (1981). Vitamin D supplements
enhance weight gain and nutritional status in pregnant asians. British Journal of
Obstetrics and Gynaecology, 88(10), 987-991.

McCollum, J. D., Simmonds, N., Becket, J. E., & Shipley, P. G. (1922). Studies on
experimental rickets. XXI. an experimental demonstration of the existence of a
vitamin, which promotes calcium deposition. Journal of Biological Chemistry,
53(8), 219-312.
211

McEwen, M., & Wills, E. M. (2010). Theoretical basis for nursing (Third ed.).
Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins.

McGrath, J. (2001). Does 'imprinting' with low prenatal vitamin D contribute to the risk
of various adult disorders? Medical Hypotheses, 56(3), 367-371.

McGrath, J. J., Burne, T. H., Feron, F., Mackay-Sim, A., & Eyles, D. W. (2010).
Developmental vitamin D deficiency and risk of schizophrenia: A 10-year update.
Schizophrenia Bulletin, 36(6), 1073-1078. doi:10.1093/schbul/sbq101

Merewood, A., Mehta, S. D., Chen, T. C., Bauchner, H., & Holick, M. F. (2009).
Association between vitamin D deficiency and primary cesarean section. The
Journal of Clinical Endocrinology and Metabolism, 94(3), 940-945.
doi:10.1210/jc.2008-1217

Merewood, A., Mehta, S. D., Grossman, X., Chen, T. C., Mathieu, J., Holick, M. F., &
Bauchner, H. (2012). Vitamin D status among 4-month-old infants in new england:
A prospective cohort study. Journal of Human Lactation : Official Journal of
International Lactation Consultant Association, 28(2), 159-166.
doi:10.1177/0890334411434802; 10.1177/0890334411434802

Merewood, A., Mehta, S. D., Grossman, X., Chen, T. C., Mathieu, J. S., Holick, M. F., &
Bauchner, H. (2010). Widespread vitamin D deficiency in urban massachusetts
newborns and their mothers. Pediatrics, 125(4), 640-647. doi:10.1542/peds.20092158
212

Miyake, Y., Sasaki, S., Tanaka, K., & Hirota, Y. (2010). Dairy food, calcium and vitamin
D intake in pregnancy, and wheeze and eczema in infants. The European
Respiratory Journal : Official Journal of the European Society for Clinical
Respiratory Physiology, 35(6), 1228-1234. doi:10.1183/09031936.00100609

Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., . .
. Altman, D. G. (2010). CONSORT 2010 explanation and elaboration: Updated
guidelines for reporting parallel group randomised trials. BMJ (Clinical Research
Ed.), 340, c869. doi:10.1136/bmj.c869

Mulligan, M. L., Felton, S. K., Riek, A. E., & Bernal-Mizrachi, C. (2010). Implications
of vitamin D deficiency in pregnancy and lactation. American Journal of Obstetrics
and Gynecology, 202(5), 429.e1-429.e9. doi:10.1016/j.ajog.2009.09.002

Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006). Serum
25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA : The Journal of
the American Medical Association, 296(23), 2832-2838.
doi:10.1001/jama.296.23.2832

Ng, K., Wolpin, B. M., Meyerhardt, J. A., Wu, K., Chan, A. T., Hollis, B. W., . . . Fuchs,
C. S. (2009). Prospective study of predictors of vitamin D status and survival in
patients with colorectal cancer. British Journal of Cancer, 101(6), 916-923.
doi:10.1038/sj.bjc.6605262

213

Novakovic, B., Galati, J. C., Chen, A., Morley, R., Craig, J. M., & Saffery, R. (2012).
Maternal vitamin D predominates over genetic factors in determining neonatal
circulating vitamin D concentrations. The American Journal of Clinical Nutrition,
96(1), 188-195. doi:10.3945/ajcn.112.035683; 10.3945/ajcn.112.035683

Orwoll, E., Riddle, M., & Prince, M. (1994). Effects of vitamin D on insulin and
glucagon secretion in non-insulin-dependent diabetes mellitus. The American
Journal of Clinical Nutrition, 59(5), 1083-1087.

Palm, M., Axelsson, O., Wernroth, L., Larsson, A., & Basu, S. (2013). Involvement of
inflammation in normal pregnancy. Acta Obstetricia Et Gynecologica Scandinavica,
92(5), 601-605. doi:10.1111/aogs.12093; 10.1111/aogs.12093

Pereira, F., Barbachano, A., Singh, P. K., Campbell, M. J., Munoz, A., & Larriba, M. J.
(2012). Vitamin D has wide regulatory effects on histone demethylase genes. Cell
Cycle (Georgetown, Tex.), 11(6), 1081-1089. doi:10.4161/cc.11.6.19508;
10.4161/cc.11.6.19508

Pludowski, P., Holick, M. F., Pilz, S., Wagner, C. L., Hollis, B. W., Grant, W. B., . . .
Soni, M. (2013). Vitamin D effects on musculoskeletal health, immunity,
autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and
mortality-A review of recent evidence. Autoimmunity Reviews,
doi:10.1016/j.autrev.2013.02.004; 10.1016/j.autrev.2013.02.004

214

Ponnapakkam, T., Bradford, E., & Gensure, R. (2010). A treatment trial of vitamin D
supplementation in breast-fed infants: Universal supplementation is not necessary
for rickets prevention in southern louisiana. Clinical Pediatrics, 49(11), 1053-1060.
doi:10.1177/0009922810376320

Rajakumar, K. (2003). Vitamin D, cod-liver oil, sunlight, and rickets: A historical
perspective. Pediatrics, 112(2), e132-5.

Riordan, J., & Countryman, B. A. (1980). Basics of breastfeeding. part iii: The biological
specificity of breast milk. JOGN Nursing; Journal of Obstetric, Gynecologic, and
Neonatal Nursing, 9(5), 273-277.

Robinson, C. J., Alanis, M. C., Wagner, C. L., Hollis, B. W., & Johnson, D. D. (2010).
Plasma 25-hydroxyvitamin D levels in early-onset severe preeclampsia. American
Journal of Obstetrics and Gynecology, 203(4), 366.e1-366.e6.
doi:10.1016/j.ajog.2010.06.036

Roth, D. E. (2011). Vitamin D supplementation during pregnancy: Safety considerations
in the design and interpretation of clinical trials. Journal of Perinatology : Official
Journal of the California Perinatal Association, 31(7), 449-459.
doi:10.1038/jp.2010.203; 10.1038/jp.2010.203

215

Saadi, H. F., Dawodu, A., Afandi, B., Zayed, R., Benedict, S., Nagelkerke, N., & Hollis,
B. W. (2009). Effect of combined maternal and infant vitamin D supplementation on
vitamin D status of exclusively breastfed infants. Maternal & Child Nutrition, 5(1),
25-32. doi:10.1111/j.1740-8709.2008.00145.x

Salama, M. M., & El-Sakka, A. S. (2010). Hypocalcemic seizures in breastfed infants
with rickets secondary to severe maternal vitamin D deficiency. Pakistan Journal of
Biological Sciences: PJBS, 13(9), 437-442.

Seckmeyer, G., Schrempf, M., Wieczorek, A., Riechelmann, S., Graw, K., Seckmeyer,
S., & Zankl, M. (2013). A novel method to calculate solar UV exposure relevant to
vitamin D production in humans. Photochemistry and Photobiology,
doi:10.1111/php.12074; 10.1111/php.12074

Senti, J., Thiele, D. K., & Anderson, C. M. (2012). Maternal vitamin D status as a critical
determinant in gestational diabetes. Journal of Obstetric, Gynecologic, and Neonatal
Nursing : JOGNN / NAACOG, 41(3), 328-338. doi:10.1111/j.15526909.2012.01366.x; 10.1111/j.1552-6909.2012.01366.x

Sharma, A., Satyam, A., & Sharma, J. B. (2007). Leptin, IL-10 and inflammatory
markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and
healthy non-pregnant women. American Journal of Reproductive Immunology (New
York, N.Y.: 1989), 58(1), 21-30. doi:10.1111/j.1600-0897.2007.00486.x

216

Soheilykhah, S., Mojibian, M., Rashidi, M., Rahimi-Saghand, S., & Jafari, F. (2010).
Maternal vitamin D status in gestational diabetes mellitus. Nutrition in Clinical
Practice : Official Publication of the American Society for Parenteral and Enteral
Nutrition, 25(5), 524-527. doi:10.1177/0884533610379851

Specker, B. L., Tsang, R. C., & Hollis, B. W. (1985). Effect of race and diet on humanmilk vitamin D and 25-hydroxyvitamin D. American Journal of Diseases of
Children (1960), 139(11), 1134-1137.

Suitor, C. J., Gardner, J., & Willett, W. C. (1989). A comparison of food frequency and
diet recall methods in studies of nutrient intake of low-income pregnant women.
Journal of the American Dietetic Association, 89(12), 1786-1794.

Swensen, A. R., Harnack, L. J., & Ross, J. A. (2001). Nutritional assessment of pregnant
women enrolled in the special supplemental program for women, infants, and
children (WIC). Journal of the American Dietetic Association, 101(8), 903-908.
doi:10.1016/S0002-8223(01)00221-8

Tande, D., Ralph, J., Johnson, L., Scheett, A., Hoverson, B., & Anderson, C. (2012). First
trimester dietary intake, biochemical measures, and subsequent gestational
hypertension among nulliparous women. Journal of Midwifery & Women's Health,
doi:10.1111/jmwh.12007

217

Taylor, S. N., Wagner, C. L., & Hollis, B. W. (2006). Maternal or neonatal vitamin D
supplementation during lactation: What is the better option? Annual Review of
Nutrition, doi:10.1146/annurev.nutr.27.061406.093815

Teaema, F. H., & Al Ansari, K. (2010). Nineteen cases of symptomatic neonatal
hypocalcemia secondary to vitamin D deficiency: A 2-year study. Journal of
Tropical Pediatrics, 56(2), 108-110. doi:10.1093/tropej/fmp063

Thandrayen, K., & Pettifor, J. M. (2012). Maternal vitamin D status: Implications for the
development of infantile nutritional rickets. Rheumatic Diseases Clinics of North
America, 38(1), 61-79. doi:10.1016/j.rdc.2012.03.007

Thiele, D. K., Senti, J. L., & Anderson, C. M. (2013). Maternal vitamin D
supplementation to meet the needs of the breastfed infant: A systematic review.
Journal of Human Lactation : Official Journal of International Lactation Consultant
Association, 29(2), 163-170. doi:10.1177/0890334413477916

Thomson, K., Morley, R., Grover, S. R., & Zacharin, M. R. (2004). Postnatal evaluation
of vitamin D and bone health in women who were vitamin D-deficient in pregnancy,
and in their infants. The Medical Journal of Australia, 181(9), 486-488.

218

Thota, C., Farmer, T., Garfield, R. E., Menon, R., & Al-Hendy, A. (2013). Vitamin D
elicits anti-inflammatory response, inhibits contractile-associated proteins, and
modulates toll-like receptors in human myometrial cells. Reproductive Sciences
(Thousand Oaks, Calif.), 20(4), 463-475. doi:10.1177/1933719112459225;
10.1177/1933719112459225

Tiosano, D., Wildbaum, G., Gepstein, V., Verbitsky, O., Weisman, Y., Karin, N., &
Eztioni, A. (2013). The role of vitamin d receptor in innate and adaptive immunity:
A study in hereditary vitamin d-resistant rickets patients. The Journal of Clinical
Endocrinology and Metabolism, 98(4), 1685-1693. doi:10.1210/jc.2012-3858;
10.1210/jc.2012-3858

Touvier, M., Chan, D. S., Lau, R., Aune, D., Vieira, R., Greenwood, D. C., . . . Norat, T.
(2011). Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D
receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiology,
Biomarkers & Prevention : A Publication of the American Association for Cancer
Research, Cosponsored by the American Society of Preventive Oncology, 20(5),
1003-1016. doi:10.1158/1055-9965.EPI-10-1141; 10.1158/1055-9965.EPI-10-1141

U.S. department of agriculture, agricultural research service. 2011. USDA national
nutrient database for standard reference, release 24. (2011). Retrieved February 1st,
2013, from http://www.ars.usda.gov/ba/bhnrc/ndl

219

Utrillas, M. P., Marin, M. J., Esteve, A. R., Estelles, V., Gandia, S., Nunez, J. A., &
Martinez-Lozano, J. A. (2013). Ten years of measured UV index from the spanish
UVB radiometric network. Journal of Photochemistry and Photobiology.B, Biology,
125C, 1-7. doi:10.1016/j.jphotobiol.2013.04.005; 10.1016/j.jphotobiol.2013.04.005

Vaidya, A., & Forman, J. P. (2010). Vitamin D and hypertension: Current evidence and
future directions. Hypertension, 56(5), 774-779.
doi:10.1161/HYPERTENSIONAHA.109.140160;
10.1161/HYPERTENSIONAHA.109.140160

Vaidya, A., Sun, B., Larson, C., Forman, J. P., & Williams, J. S. (2012). Vitamin D3
therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a
converting enzyme inhibitor in obese hypertensives: An interventional study. The
Journal of Clinical Endocrinology and Metabolism, 97(7), 2456-2465.
doi:10.1210/jc.2012-1156; 10.1210/jc.2012-1156

Vaidya, A., & Williams, J. S. (2012). The relationship between vitamin D and the reninangiotensin system in the pathophysiology of hypertension, kidney disease, and
diabetes. Metabolism: Clinical and Experimental, 61(4), 450-458.
doi:10.1016/j.metabol.2011.09.007; 10.1016/j.metabol.2011.09.007

Vieth, R., Chan, P. C., & MacFarlane, G. D. (2001). Efficacy and safety of vitamin D3
intake exceeding the lowest observed adverse effect level. The American Journal of
Clinical Nutrition, 73(2), 288-294.
220

Vieth, R., Ladak, Y., & Walfish, P. G. (2003). Age-related changes in the 25hydroxyvitamin D versus parathyroid hormone relationship suggest a different
reason why older adults require more vitamin D. The Journal of Clinical
Endocrinology and Metabolism, 88(1), 185-191.

Viljakainen, H. T., Saarnio, E., Hytinantti, T., Miettinen, M., Surcel, H., Makitie, O., . . .
Lamberg-Allardt, C. (2010). Maternal vitamin D status determines bone variables in
the newborn. The Journal of Clinical Endocrinology and Metabolism, 95(4), 17491757. doi:10.1210/jc.2009-1391

Wagner, C. L., & Hollis, B. W. (2011). Beyond PTH: Assessing vitamin D status during
early pregnancy. Clinical Endocrinology, 75(3), 285-286. doi:10.1111/j.13652265.2011.04164.x; 10.1111/j.1365-2265.2011.04164.x

Wagner, C. L., Howard, C., Hulsey, T. C., Lawrence, R. A., Taylor, S. N., Will, H., . . .
Hollis, B. W. (2010). Circulating 25-hydroxyvitamin d levels in fully breastfed
infants on oral vitamin d supplementation. International Journal of Endocrinology,
2010, 235035. doi:10.1155/2010/235035

Wagner, C. L., Hulsey, T. C., Fanning, D., Ebeling, M., & Hollis, B. W. (2006). Highdose vitamin D3 supplementation in a cohort of breastfeeding mothers and their
infants: A 6-month follow-up pilot study. Breastfeeding Medicine : The Official
Journal of the Academy of Breastfeeding Medicine, 1(2), 59-70.
doi:10.1089/bfm.2006.1.59
221

Wagner, C. L., McNeil, R., Hamilton, S. A., Winkler, J., Rodriguez Cook, C., Warner,
G., . . . Hollis, B. W. (2013a). A randomized trial of vitamin D supplementation in 2
community health center networks in south carolina. American Journal of Obstetrics
and Gynecology, 208(2), 137.e1-137.13. doi:10.1016/j.ajog.2012.10.888;
10.1016/j.ajog.2012.10.888

Wagner, C. L., McNeil, R. B., Johnson, D. D., Hulsey, T. C., Ebeling, M., Robinson, C., .
. . Hollis, B. W. (2013b). Health characteristics and outcomes of two randomized
vitamin D supplementation trials during pregnancy: A combined analysis. The
Journal of Steroid Biochemistry and Molecular Biology,
doi:10.1016/j.jsbmb.2013.01.002; 10.1016/j.jsbmb.2013.01.002

Wagner, C. L., Taylor, S. N., & Hollis, B. W. (2008). Does vitamin D make the world go
'round'? Breastfeeding Medicine : The Official Journal of the Academy of
Breastfeeding Medicine, 3(4), 239-250. doi:10.1089/bfm.2008.9984

Wagner, C. L., Taylor, S. N., Johnson, D. D., & Hollis, B. W. (2012). The role of vitamin
D in pregnancy and lactation: Emerging concepts. Women's Health (London,
England), 8(3), 323-340. doi:10.2217/whe.12.17

Walker, V. P., Zhang, X., Rastegar, I., Liu, P. T., Hollis, B. W., Adams, J. S., & Modlin,
R. L. (2011). Cord blood vitamin D status impacts innate immune responses. The
Journal of Clinical Endocrinology and Metabolism, doi:10.1210/jc.2010-1559

222

Wallace, A. M., Gibson, S., de la Hunty, A., Lamberg-Allardt, C., & Ashwell, M. (2010).
Measurement of 25-hydroxyvitamin D in the clinical laboratory: Current procedures,
performance characteristics and limitations. Steroids, 75(7), 477-488.
doi:10.1016/j.steroids.2010.02.012; 10.1016/j.steroids.2010.02.012

Wang, J., Yang, F., Mao, M., Liu, D. H., Yang, H. M., & Yang, S. F. (2010). High
prevalence of vitamin D and calcium deficiency among pregnant women and their
newborns in chengdu, china. World Journal of Pediatrics : WJP, 6(3), 265-267.
doi:10.1007/s12519-010-0224-x; 10.1007/s12519-010-0224-x

Waterhouse, J. C., Perez, T. H., & Albert, P. J. (2009). Reversing bacteria-induced
vitamin D receptor dysfunction is key to autoimmune disease. Annals of the New
York Academy of Sciences, 1173, 757-765. doi:10.1111/j.1749-6632.2009.04637.x

Weiss, S. T., & Litonjua, A. A. (2011). Vitamin D insufficiency. The New England
Journal of Medicine, 364(14), 1379; author reply 1380.
doi:10.1056/NEJMc1101911#SA3

Young, L. E. (2001). Imprinting of genes and the barker hypothesis. Twin Research : The
Official Journal of the International Society for Twin Studies, 4(5), 307-317.
doi:10.1375/1369052012632

Yu, C. K., Sykes, L., Sethi, M., Teoh, T. G., & Robinson, S. (2009). Vitamin D
deficiency and supplementation during pregnancy. Clinical Endocrinology, 70(5),
685-690. doi:10.1111/j.1365-2265.2008.03403.x
223

Yuen, A. W., & Jablonski, N. G. (2010). Vitamin D: In the evolution of human skin
colour. Medical Hypotheses, 74(1), 39-44. doi:10.1016/j.mehy.2009.08.007;
10.1016/j.mehy.2009.08.007

Zhang, C., Qiu, C., Hu, F. B., David, R. M., van Dam, R. M., Bralley, A., & Williams,
M. A. (2008). Maternal plasma 25-hydroxyvitamin D concentrations and the risk for
gestational diabetes mellitus. PloS One, 3(11), e3753.
doi:10.1371/journal.pone.0003753; 10.1371/journal.pone.0003753

Zhu, H., Wang, X., Shi, H., Su, S., Harshfield, G. A., Gutin, B., . . . Dong, Y. (2013). A
genome-wide methylation study of severe vitamin D deficiency in african american
adolescents. The Journal of Pediatrics, 162(5), 1004-1009.e1.
doi:10.1016/j.jpeds.2012.10.059; 10.1016/j.jpeds.2012.10.059

224

